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SUMMARY
Summary
Pancreatic ductal adenocarcinoma (PDAC) represents the fourth common cause
of cancer-related deaths worldwide. Most PDACs are diagnosed at advanced
stage when distant metastasis already emerged. Even patients successfully under-
going complete resection of the primary tumor usually develop distant metastasis
shortly after surgery. PDAC metastases mostly form in the liver, whereas recent
studies suggest that dissemination of pancreatic ductal epithelial cells (PDECs)
to this site may already occur prior to primary tumor formation. Yet, it remains
widely unclear how the hepatic microenvironment and its condition impact on
metastatic outgrowth of disseminated PDECs. Therefore, this study aimed at
elucidating the impact of a physiological liver microenvironment, characterized
by hepatic stellate cells (HSCs) and an inflammatory hepatic microenvironment,
featuring high abundance of hepatic myofibroblasts (HMFs), on growth behavior
of premalignant and malignant PDECs.
Characterization of liver metastases in PDAC bearing mice unveiled the emer-
gence of micrometastases with low amounts of proliferating tumor cells in HSCs-
rich microenvironments, whereas macrometastases with significantly higher quan-
tities of proliferating tumor cells were detected in HMFs-rich areas. To examine
if inflammatory conditions in the liver promote growth of disseminated PDAC
cells, a syngeneic mouse model was deployed for which aging was selected as in-
flammatory stimulus. Two weeks after orthotopic injection of R254 PDAC cells,
aged mice exposed significantly higher amounts of proliferating disseminated tu-
mor cells (DTCs) in the liver than young mice whereas primary tumor size of
both groups was comparable. Gene expression analysis of liver tissues showed
higher expression of HMFs-related genes including vascular endothelial growth
factor (VEGF) in aged mice while young animals showed higher expression of
functional homologues of human interleukin-8 (IL-8). Importantly, four weeks
after tumor cell injection, micrometastases were exclusively detected in livers of
aged mice.
To examine underlying mechanisms of these findings, an indirect coculture sys-
tem was utilized in which premalignant H6c7-kras cells or malignant Panc1 cells
were cultured in presence of HSCs or HMFs. In line with in vivo findings, pres-
ence of HSCs resulted in a significantly lower amount of proliferative H6c7-kras
and Panc1 cells compared to HMFs coculture. Interestingly, HSCs coculture in-
duced a quiescence-associated phenotype (QAP) in both PDEC lines, character-
ized by flattened and enlarged morphology, absence of Ki67, low phosphorylated
(p)-ERK/p-p38 ratio, accompanied by higher p21 protein levels and senescence-
associated β-galactosidase activity than HMFs cocultured PDECs. Of note,
HSCs-mediated growth arrest could be identified as a state of dormancy. When
I
SUMMARY
cultivating HSCs cocultured Panc1 cells in presence of HMFs for further 6 days,
a significant amount of Panc1 cells with QAP features regained proliferative ac-
tivity. This effect was less pronounced in H6c7-kras cells, indicating a lower
propensity of premalignant PDECs to escape dormancy. Importantly, IL-8 was
identified as inducer of HSCs-mediated QAP, whereas VEGF could be identified
as a factor by which HMFs promote growth and revert dormancy in PDECs.
Taken together, this work shows a striking impact of the hepatic microenviron-
ment and its condition on the growth behavior of premalignant and malignant
PDECs, thereby identifying HSCs and HMFs as components of a dormancy per-
missive or restrictive hepatic microenvironment, respectively. Moreover, this is
the first study providing ample evidence that aging-related inflammation of the
liver acts to promote metastatic outgrowth of dormant pancreatic DTCs.
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Zusammenfassung
Das duktale Adenokarzinom des Pankreas (PDAC) stellt die viertha¨ufigste Ur-
sache krebsbedingter Todesursachen weltweit dar. Das PDAC wird meist in fort-
geschrittenem Stadium diagnostiziert, wenn bereits Fernmetastasen entstanden
sind. Sogar solche Patienten bei denen der Prima¨rtumor vollsta¨ndig reseziert wer-
den kann, entwickeln gewo¨hnlich Fernmetastasen kurze Zeit nach dem Eingriff.
PDAC-Metastasen bilden sich zumeist in der Leber, wobei neuere Studien da-
rauf hinweisen, dass die Disseminierung von pankreatischen Duktusepithelzellen
(PDEZ) in die Leber der vollsta¨ndigen Entwicklung des Prima¨rtumors vorausge-
hen kann. Jedoch ist bislang kaum bekannt, wie die hepatische Mikroumgebung
und ihr Zustand das Auswachsen von disseminierten PDEZ zu Metastasen bee-
influssen ko¨nnen. Das Ziel dieser Studie war es daher, den Einfluss einer phys-
iologischen Leberumgebung, charakterisiert durch hepatische Sternzellen (HSZ),
und einer entzu¨ndlichen Mikroumgebung, charakterisiert durch hepatische Myofi-
broblasten (HMF), auf das Wachstumsverhalten von pra¨malignen und malignen
PDEZ aufzukla¨ren.
Die Charakterisierung von Lebermetastasen in einem endogenen PDAC-Maus-
modell deckte das Aufkommen von Mikrometastasen mit einer geringen Anzahl
an proliferierenden Tumorzellen in HSZ-reichen Mikroumgebungen auf, wa¨hrend
Makrometastasen mit einer signifikant ho¨heren Anzahl an proliferierenden Tu-
morzellen in HMF-reichen Mikroumgebungen festgestellt wurden. Um zu unter-
suchen, ob inflammatorische Bedingungen in der Leber das Wachstum dissemi-
nierter PDAC-Zellen fo¨rdern, wurde ein syngenes Mausmodell angewendet, fu¨r
welches Altern als Entzu¨ndungs-stimulus gewa¨hlt wurde. Zwei Wochen nach der
orthotopen Injektion von R254-PDAC-Zellen zeigten gealterte Ma¨use eine sig-
nifikant ho¨here Anzahl an proliferierenden disseminierten Tumorzellen (DTZ) in
der Leber als junge Ma¨use, wobei Prima¨rtumoren vergleichbare Gro¨ßen aufwiesen.
Genexpressionsanalysen von Lebergeweben zeigten eine deutlich ho¨here Expres-
sion von HMF-assoziierten Genen, einschließlich Vascular Endothelial Growth
Factor (VEGF ) in gealterten Ma¨usen, wa¨hrend junge Ma¨use eine ho¨here Expres-
sion der funktionellen Homologe des humanen Interleukin-8 (IL-8 ) aufwiesen.
Hervorzuheben ist, dass vier Wochen nach Tumorzell-Injektion Mikrometastasen
ausschließlich in a¨lteren Ma¨usen detektiert wurden. Um die diesen Befunden
unterliegenden Mechanismen aufzukla¨ren, wurde ein indirektes Kokultur-System
angewendet, in welchem pra¨maligne H6c7-kras-Zellen oder maligne Panc1-Zellen
in Gegenwart von HSZ oder HMF kultiviert wurden. In Einklang mit den in
vivo Befunden resultierte die Gegenwart von HSZ in einer signifikant niedrigeren
Anzahl an proliferierenden H6c7-kras- und Panc1-Zellen. HSZ induzierten einen
Quieszenz-assoziierten Pha¨notyp (QAP) in beiden PDEZ-Linien. Dieser zeich-
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nete sich durch eine abgeflachte und vergro¨ßerte Morphologie, die Abwesen-
heit von Ki67, einem niedrigen Verha¨ltnis von phosphoryliertem (p-)ERK zu
p-p38, begleitet von einer ho¨heren p21 Proteinmenge und Seneszenz-assoziierter
β-Galactosidase-Aktivita¨t als in HMF-kokultivierten PDEZ aus. Zudem kon-
nte dieser HSZ-vermittelte Wachstumsarrest als Zustand von Tumorzelldormanz
identifiziert werden. Die Untersuchung HSZ-kokultivierter Panc1-Zellen, die an-
schließend in Gegenwart von HMF kultiviert wurden, zeigte die Wiedererlangung
proliferativer Aktivita¨t in einem deutlichen Anteil an Panc1-Zellen mit QAP-
Eigenschaften. Dieser Effekt war weniger stark ausgepra¨gt in H6c7-kras-Zellen,
was eine geringere Tendenz von pra¨malignen PDEZ, den Dormanz-Zustand zu
verlassen, anzeigt. IL-8 konnte als Induktor des HSZ-vermittelten QAP bes-
timmt werden, wa¨hrend VEGF als Faktor identifiziert wurde, u¨ber den HMF das
Wachstum und die Reversion von Dormanz in PDEZ fo¨rdern.
Zusammengenommen zeigen die Ergebnisse dieser Arbeit einen beachtlichen Ein-
fluss der hepatischen Mikroumgebung und ihres Zustandes auf das Wachstumsver-
halten von pra¨malignen und malignen PDEZ und identifizieren HSZ und HMF
als Komponenten einer Dormanz-permissiven bzw. -restriktiven Leberumgebung.
Dies ist die erste Studie, die zeigt, dass altersbedingte Entzu¨ndung in der Leber
das Auswachsen ruhender pankreatischer DTZ begu¨nstigt.
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1. Introduction
1.1. The pancreatic ductal adenocarcinoma
(PDAC)
1.1.1. Epidemiology and etiology
The pancreatic ductal adenocarcinoma (PDAC) is characterized by an aggressive
biology and a particularly poor prognosis. About 18.600 new cases of PDAC were
predicted for the year 2016 in Germany [1]. Despite its low incidence of 14.3 per
100.000 male inhabitants and 11.3 per 100.000 female inhabitants PDAC is ranked
the fourth leading cause of cancer-related deaths in Germany and the most fatal
malignancy of the gastrointestinal tract [1, 2]. PDAC has a 5 year survival rate of
solely 8 % and a 10 year survival rate of 7 % whereas most patients will succumb
to the disease within the first 12 months after prognosis [1, 3]. Accordingly,
the count of new cases of PDAC nearly equals the number of PDAC-related
deaths. Whereas significant effort has been invested in the exploration of PDAC
in the last decades, no evident progress regarding the curability of this disease
has been made. A recent report accordingly predicted that by 2030 PDAC will
be the second leading cause of cancer-related deaths worldwide [4]. PDAC is a
disease of elderly patients. The median age upon diagnosis is 71 for male and 75
for female patients while the lifetime risk to develop PDAC is 1.49 % [5]. PDAC
makes itself felt by unspecific symptoms, which mostly emerge in the late stage of
carcinogenesis. Upon diagnosis 80 % of PDAC patients present with an advanced
stage of the disease, commonly when metastatic spread has already occurred. In
this case, a curative therapy is no longer feasible and patients will be subjected
to palliative care [6]. To date, full resection of the tumor represents the only
curative therapy option for PDAC patients in Germany [6]. Perfidiously, even
patients who successfully undergo complete tumor resection without detectable
PDAC cells in the tumor margin (R0) commonly develop local recurrences or
metastases within months after surgical intervention [7, 8]. In the consequence,
80 % of PDAC patients being treated after curative therapy schemes will also die
within the first 2 years after diagnosis [9, 10]
To date only a few risk factors for PDAC development are ensured. Most of these
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factors are attributable to lifestyle and hence represent modifiable risk factors.
Foremost smoking accounts for 20 % - 35 % of PDAC cases and increases the
disease risk about 2.2-fold [11, 12]. The risk to develop PDAC is still modestly
elevated even 10 years after smoking cessation [11]. Excessive alcoholic abuse is
recognized as a further lifestyle factor promoting the development of PDAC. An
increased and dose dependent disease risk was assessed for the consumption of
more than three drinks a day [13]. Furthermore, alcohol and its metabolites were
shown to exhibit direct carcinogenic potential and represent the main factors to
drive pancreatitis [14]. Accordingly, chronic pancreatitis, among other sustained
inflammatory conditions, is assumed to pave the ground for PDAC development
[15]. Moreover, a correlation between diabetes mellitus type 1 and type 2 and
PDAC carcinogenesis has been reported [16, 17]. Further studies accordingly
suggest that dietary factors and obesity increase the PDAC disease risk. For
instance, a prospective study with adult U.S. citizens associated a body mass
index (BMI) higher than 40 kg/m2 with a relative disease risk of 1.49 for men
and 2.76 for women [18].
About 10 % of all PDAC cases are based on a hereditary background. Various
genetic conditions have been linked to PDAC carcinogenesis, among them Peutz-
Jeghers syndrome, hereditary pancreatitis and cystic fibrosis. The penetration of
these predispositions is commonly high and raises the risk to develop PDAC by
2-fold to 132-fold [5, 19, 20]. A better understanding of the causes and risks that
promote the development of PDAC is needed to improve patient prognosis. To
date, only a conscious lifestyle or a lifestyle change regarding the above mentioned
factors are considered to lower the chance of developing PDAC. Next to regular
physical activity, fat-reduced nutrition and the consumption of fruits, vegetables
and whole grains represent accepted beneficial lifestyle components [21, 22].
1.1.2. Pathology
The pancreas is a glandular organ compartmentalized into an exocrine and en-
docrine gland [23]. The exocrine serous tissue produces bicarbonate-rich digestive
juice which is drained into the duodenum via acinus ducts [24]. The endocrine
pancreas is formed by islets of Langerhans. Latter ones produce glucagon, insulin,
somatostatin, pancreatic polypeptide and ghrelin which are directly released into
the blood circulation [25]. Both parts of the pancreas can give rise to tumors. Tu-
mors of the exocrine pancreas tissue represent 95 % of all cancers of the pancreas.
Among these, PDAC exposes the highest prevalence and accounts for 90 % of all
cases [9]. Other malignancies of the exocrine pancreas like the mucinous cystade-
nocarcinoma or the acinar adenocarcinoma as well as tumors of the endocrine
pancreas expose a superior prognosis to PDAC due to the earlier emergence of
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symptoms and better therapy response [26, 27].
The PDAC is assumed to emerge by stepwise progression from precursor lesions
like the intraductal papillary mucinous neoplasia (IPMN), mucinous cystic neo-
plasia (MCN) or pancreatic intraepithelial neoplasia (PanIN) [28]. More recently,
the acinoductal compartment has been established as a potential origin of PDAC
[29]. Acinoductal structures may undergo acinar to ductal metaplasia (ADM)
and subsequently develop to tubular complexes (TC) and atypical flat lesions
(AFL). This process may lead to PanIN formation or represent and independent
progenitor of PDAC [30]. Among the potential precursor lesions of PDAC the
highest significance is accredited to PanINs. These represent asymptomatic le-
sions composed of mucinous columnar and cuboidal cells. They are categorized
into different stages according to the degree of hyperplasia and dysplasia [31]. In
contrast to the physiological pancreas duct which exhibits a monolayered, highly
prismatic and polarized epithelium, PanIN-1 lesions expose low grade mucinous
dysplasia (PanIN-1a) or papillary duct structures (PanIN-1b) with a basal polar-
ization of nuclei [32]. PanIN-2 lesions are characterized by nuclear pleomorphism
and high amounts of papillae [33]. Finally, PanIN-3 lesions show a high grade of
dysplasia and hyperplasia while epithelial cells in contrast to carcinoma maintain
their contact to the basement membrane and are non-invasive. They are hence
referred to as carcinoma in situ [32].
The multistep progression from a healthy pancreatic ductal epithelium to PDAC
via PanIN lesions is hallmarked by common genetic and epigenetic alterations.
Most abundant and detected in about 95 % of all PDAC cases is the KRASG12D
point mutation [34, 35]. This mutation is already detectable in most PanIN-1 le-
sions [36]. The gene product of the KRAS proto-oncogene interacts with several
signaling molecules with implications in cellular proliferation, survival, differen-
tiation and migration [37]. KRAS mutations are hence recognized as the main
driver mutations of PanIN initiation and progression [36]. Further common mu-
tations detectable already at the early PanIN stage are P16/CDKN2A, GNAS
and BRAF [36]. Later mutational events in the pathogenesis of PDAC are loss of
function of TP53 and SMAD4 which are reported to occur at the PanIN-3 stage
[38]. Mutations in TP53 are found in 75 % of all PDAC [39]. The most common
mutational events accompanying PanIN progression are depicted in Figure 1.1.
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Figure 1.1.: Development of primary PDAC. A normal pancreas duct develops to PDAC via stepwise
progression of pancreatic intraepithelial neoplastia (PanIN) lesions. PanIN progression is accompanied by
the frequent accumulation of mutations. Upper panel: Hematoxilin eosin (HE) stainings of pancreas sections
(adapted from Han and Hoff, 2013). Lower panel: The four most common driver mutations of PDAC.
A distinctive pathologic hallmark of PDAC is its pronounced desmoplastic reac-
tion. Unlike most other cancer entities, PDAC tumors comprise a vast amount
of non-neoplastic cells and corresponding extracellular matrix (ECM). The ac-
tivated profound tumor stroma of PDAC can make up to 80 % of the entire
tumor volume [40]. A plethora of different non-neoplastic cells contribute to the
desmoplastic reaction. Immune cells like mast cells, macrophages, lymphocytes
and plasma cells as well as adipocytes and endothelial cells can be found in the
PDAC stroma [41–43]. Cancer-associated fibroblasts (CAFs) represent the pre-
dominant cellular component of the PDAC stroma. These emerge from pancreatic
stellate cells (PSC) and represent the source of the majority of ECM molecules
in the tumor mass. Hence, increasing amounts of type I, type III and type V
collagen (col) and fibronectin can be detected during PDAC progression [42, 44].
Furthermore, PSCs and CAFs produce various cytokines, chemokines and growth
factors which support primary tumor progression [45]. The recruitment and ac-
tivation of PSCs was shown to occur already at the PanIN stage [46]. While a
tumor promoting impact of the PDAC stroma was considered as ensured, recent
studies challenged this dogma and claimed that the stroma may act to restrain
tumor progression [47, 48]. In fact, compelling evidence for either mode of ac-
tion of the tumor stroma was brought forward. On the one hand various studies
accordingly support the view that the desmoplastic reaction represents the basis
for the profound chemoresistance of PDAC [49, 50]. On the other hand it was
recently shown that depletion of CAFs can result in more dedifferentiated and
aggressive PDAC tumors [47, 48].
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1.1.3. Therapy and clinical challenges
Various clinical factors contribute to the aggravated treatability and correspond-
ing dismal prognosis of PDAC. Foremost the late occurrence of symptoms and
their ambiguity narrow the timeframe for a potential curative clinical intervention
[5]. Moreover, due to its posterior position in the abdomen the pancreas itself is
difficult to access by most imaging modalities [6]. Common imaging techniques
like sonography, computed tomography or magnetic resonance imaging (MRI)
are only feasible to detect primary tumors which exceed a certain size [51]. Fur-
thermore, the close proximity of the pancreas to truncus coeliacus, duodenum,
common bile duct, arteria mesenterica superior and hepatic portal vein render
the resection of PDAC a most challenging and time consuming surgical interven-
tion [6, 9]. Concurrently, invasion of local lymph nodes is commonly observed in
PDAC [52]. As a result of the entirety of these clinical factors, a successful R0
resection is only achieved in about 30 – 50 % of operated PDAC patients [53].
Compared to R0 resection, R1 resection status represents a negative prognostic
factor and commonly leads to local recurrence [54]. However, as mentioned above,
even patients who underwent R0 resection present with a local relapse and/or liver
metastases within the first months after surgery [7, 8, 53]. A further challenge
oncologists have to face is PDAC’s profound chemoresistance [6]. In fact, the
spectrum of potential adjuvant and neo-adjuvant chemotherapy approaches to
prolong PDAC patient survival is nearly exhausted. In the curative and pallia-
tive setting gemcitabine is the common drug of choice and increases the overall
survival to about 6 months [55]. More recently, the addition of nab-paclitaxel to
gemcitabine treatment has been approved as beneficial and was shown to lead to
an increased overall survival of 8.5 months compared to gemcitabine monotherapy
[56]. Patients in palliative care can be treated after the polychemotherapeutical
FOLFIRINOX therapy scheme. This comprises folinic acid, 5-fluoruracil (5-FU),
irinotecan as well as oxaliplatin and leads to an overall survival of 11 months.
However, albeit enhanced progression free survival this treatment exhibits a con-
siderable toxicity profile and is only applicable to patients in an adequate general
condition [57]. Finally, even the curative approach, encompassing surgical resec-
tion and adjuvant gemcitabine treatment, achieves an overall survival of 12-19
months [58]. Hence, novel curative and palliative therapy approaches as well as
more sensitive detection techniques are urgently needed to oppose the aggressive
nature of PDAC. In the last years, the tumor stroma shifted into the focus of at-
tention of PDAC research as it comprises several potential targets of therapeutical
intervention [59].
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1.2. Metastasis
The vast majority of cancer patients does not die in the wake of the primary
tumor but metastatic disease [60]. Yet, current therapy options are not fitted
to particularly target PDAC metastases whereas the resistance mechanisms of
primary and secondary lesions to chemotherapy may differ fundamentally. To
achieve success in the treatment of metastatic disease, a better understanding of
the various steps of metastatic progression is urgently demanded.
1.2.1. The invasion-metastasis cascade in carcinoma
A tumor cell has to acquire certain genetic alterations and morphologic features
to successfully leave the primary organ and form a metastatic lesion at the sec-
ondary site. The microenvironment and the condition of the neoplastic cell itself
determine the success of this process [61].
Figure 1.2.: The invasion-metastasis cascade of malignant carcinoma. A primary tumor forms
(1) and cells from this tumor invade the local tissue (2). Some cells manage to intravasate into newly
formed blood vessels and to survive as circulating tumor cell (CTC) in the blood circulation (3). At the
distant organ, some cells adhere to the endothelial surface and extravasate into the organ (4). Disseminated
tumor cells (DTCs) form a micrometastasis which later on outgrows to an overt and clinically detectable
metastasis (5).
As the first step of malignant progression, neoplastic cells need to acquire inva-
sive features enabling them to perforate the basement membrane and penetrate
the surrounding tissue [62]. In order to evade the primary context, invasive cells
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must intravasate into the blood circulation or infest the lymphatic system [63].
Neoplastic cells are then transported to distant organs as single or clustered cir-
culating tumor cells (CTCs) and subsequently extravasate at the secondary site
[63]. Cells which successfully migrated into a distant compartment or organ
are termed disseminated tumor cells (DTCs). If single DTCs or DTC clusters
possess an adequate equipment to survive and proliferate in the secondary mi-
croenvironment they may outgrow to overt metastases [61]. A graphic scheme of
the invasion-metastasis cascade of carcinoma is depicted in Figure 1.2.
The basement membrane represents an organised scaffold that separates epithe-
lia and endothelia from the underlying connective tissue [62]. Neoplastic cells
express various proteases like metalloproteases (MMPs) which facilitate the pen-
etration of this scaffold and digestion of the dense ECM of the microenvironment
[64]. Moreover, epithelial to mesenchymal transition (EMT) is considered an im-
portant prerequisite in this context [65]. During EMT, epithelial cells lose their
polarity and acquire a motile mesenchymal phenotype. This process is promoted
by transcription factors like Slug, Snail, Twist and ZEB-1 which initiate the down-
regulation of epithelial molecules, e.g. E-cadherin, occludin and cytokeratins and
upregulation of mesenchymal markers like vimentin [66]. In the consequence, the
intercellular contact is disrupted and cells may leave the epithelial context to
invade the surrounding tissue. The microenvironment plays a crucial role in the
induction of EMT in neoplastic cells as stromal cells may release EMT promot-
ing factors. For example macrophages, myofibroblasts and other stromal cells are
reported sources of tumor necrosis factor-α (TNF -α) and transforming growth
factor-β (TGF-β), both of which are potent inducers of EMT processes [67–69].
In this fashion, a desmoplastic stroma encompassing a primary lesion may further
boost the invasive behavior and aggressiveness of cells which successfully left their
epithelial context. Moreover, the process of EMT has been linked to the acquisi-
tion of cancer stemness features. This includes an enhanced self-renewal capacity
and the initiation of survival pathways which are mandatory to overcome apop-
tosis cues elicited by immune cells [70]. The major route of metastatic spread is
the haematogenous circulation [71]. The intravasation of neoplastic cells into the
circulation is supported by angiogenesis processes accompanying primary tumor
progression [71]. In contrast to normal vessels, those emerging during angiogen-
esis expose a diffuse growth and morphology and exhibit increased permeability
which facilitates the entry of invasive cells into the circulation [72]. However,
once entered the bloodstream CTCs need to evade prevailing shear forces and
the elimination by immune cells. By the expression of tissue factor (TF) which
acts as an initiator of platelet coagulation, CTCs gain a significant advantage for
survival. The TF-mediated accumulation of platelets around the CTC protects
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the cell of physical stress and concurrently impedes CTC lysis by NK cells [73, 74].
Once arrived at the secondary organ, CTCs must attach to the luminal side of
vascular endothelial cells and breach the sub-epithelial ECM [75]. The extrava-
sation of CTCs is facilitated by platelet-mediated upregulation of CCL2 which
promotes monocyte recruitment and vascular permeability [76]. Furthermore, re-
cent in vitro and in vivo studies suggest that the reversion of EMT and newly
acquisition of an epithelial phenotype during mesenchymal to epithelial transition
(MET) may increase the chance for carcinoma cells to successfully seed in the sec-
ondary organ [77]. Finally, cells which successfully disseminated need to establish
a growth promoting niche to eventually outgrow to clinical relevant metastases.
It his hence assumed that pre-existing inflammatory conditions in the secondary
environment increase the likelihood of successful metastatic progression. How-
ever, which cell entities of the secondary microenvironment are involved in this
process and the mechanisms by which they impact on DTCs is poorly understood.
1.2.2. Limiting steps in the metastatic cascade
The various steps a neoplastic cell has to take in order to evade the primary
epithelium and to colonize a distant organ represent stochastic events and are all
connected with a significant risk of elimination [78]. The initial loss of contact to
the basement membrane represents one of the first apoptotic stimuli a neoplastic
cell has to overcome [79]. In the blood circulation, CTCs are constantly exposed
to numerous immune regulatory components and distinct physical stress cues [71].
A high proportion of CTCs falls a victim to apoptosis while being trapped in the
branches of the secondary vasculature since CTCs have a diameter which is 3 to
4 times larger than the pores of capillaries in distant organs [80]. Importantly,
most of the cells which manage to seed the secondary organ are poorly adapted
to the prevalent conditions in the microenvironment they encounter and are con-
sequently growth arrested [81]. In a pioneering mouse study the highest number
of tumor cells failed to initiate growth after successful dissemination to the sec-
ondary organ [82]. Further clinical data suggest that the process of colonization
may occur with a notable delay since breast cancer patients develop metastases
up to decades after initial treatment even in the absence of a detectable primary
tumor [83]. These data indicate that colonization of the secondary organ may
indeed represent the most rate-limiting step in the metastatic cascade. Overall,
cancer metastasis is a highly inefficient process. Mathematical modelling of the
metastatic cascade predicted that less than 0.01 % of CTCs shed into the cir-
culation effectively form a clinical relevant metastatic lesion [84, 85]. However,
parameters leading to this low value may fundamentally differ between differ-
ent cancer entities since some cancer entities like lung cancer or PDAC expose a
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particular rapid occurrence of metastasis after initial diagnosis [86].
1.2.3. Metastasis in PDAC
Gaining a profound understanding of the metastatic progression of PDAC is of
particular significance as the presence of metastases by the time of diagnosis im-
pedes a curative therapy attempt. The hallmark genetic alterations of PDAC may
represent distinct components of the disease’s metastatic propensity as mutations
in KRAS, P16/CDKN2A, TP53 and SMAD4 have been implicated in metastatic
processes in PDAC mouse models as well as patient samples, respectively [60].
Historically, the prevalent opinion on PDAC metastasis was that neoplastic cells
demand the entirety of these mutations to escape the primary context and dis-
seminate to distant organs. Tumor cell dissemination and metastasis formation
were accordingly recognized as late events in the evolution of PDAC and other
cancer entities. In fact, Yachida et al. could show that the development from a
normal cell to a neoplastic cell with metastatic capacity takes nearly 20 years and
that metastasis occurs in the last 3 years before patient’s decease [87]. However,
more recent reports argue that PDAC dissemination may occur concomitantly
to primary tumor progression when only few genetic alterations have been ac-
quired [88]. This hypothesis is partially based on the clinical observation that
the majority of PDAC patients who undergo surgical resection and show no signs
of metastasis succumb to metastatic disease within 5 years [8]. Further support
for this hypothesis was recently brought forward by Rhim et al. who provided
experimental evidence for the early dissemination of pancreatic ductal epithelial
cells (PDECs). Using fluorescence based lineage tracing they detected PDECs
in the circulation and livers of mice carrying pancreas duct specific KRAS and
TP53 mutations (KPC) that harbored only PanIN lesions. These cells exposed
a mesenchymal phenotype and markers of cancer-initiating cells. Importantly,
circulating PDECs isolated from KRAS mutated mice (KC) exposed poor colony
formation capacity in vitro indicating that further intrinsic alterations or envi-
ronmental cues are necessary for successful colonization [89]. Interestingly, the
same group was able to detect circulating PDECs in blood samples of patients
with pancreatic cystic lesions strongly indicating clinical relevance of early dis-
semination of PDECs from precancerous lesions [90]. The current view on the
invasion and metastasis cascade of PDAC under particular consideration of the
early dissemination model is schematically depicted in Figure 1.3.
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Figure 1.3.: The invasion-metastasis cascade in PDAC. Pancreatic ductal epithelial cells (PDECs)
first invade the surrounding connective tissue. PDECs may derive from an established primary tumor or,
as more recent reports suggest, also from precancerous lesions like PanIN [89, 90]. In this case, epithelial-
to-mesenchymal transition may precede the complete acquisition of PDAC hallmark mutations. After
intravasation, premalignant PDECs from PanIN lesions or malignant PDAC cells may similarly be found
in the circulation as circulating PDECs. After reaching the liver, disseminated PDECs are confronted
with conditions of the secondary foreign microenvironment that may determine if these cells may go into
apoptosis, become growth arrested or outgrow to overt metastases.
1.3. Role of the cellular hepatic microenvironment
in PDAC metastasis
PDAC cells comprise the propensity to metastasize to various organs including
the peritoneum, lungs, bones and lymph nodes [91]. However 80 % of PDAC
patients develop metastases in the liver rendering it the predominant site of
metastatic spread in PDAC [92]. A particular understanding of the organ as
well as the interplay of cell types it encompasses with DTCs is mandatory to
identify potential novel targets for therapeutical intervention [93]. The liver is
the central metabolic organ in vertebrates. It is located in the right epigas-
trium in close proximity to pancreas, bile, stomach, duodenum and colon [94].
Its central physiologic tasks are the detoxification of detrimental compounds and
metabolites as well as the production of bile. Furthermore, the liver is criti-
cally involved in the biosynthesis of amino acids and clotting factors as well as
the storage of glycogen [95]. The organ’s haemal supply is provided by hepatic
sinusoids which distribute blood inflowing from the vena portae (75 %) and ar-
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teria hepatica propria (25 %) whereas both vessels represent potential entrance
routes for CTCs [93]. It is hence assumed that the liver is predominantly seeded
by PDECs due to its direct circulatory conjunction with the pancreas via the
vena portae [96]. However, the poor efficiency of metastatic processes described
above strongly indicates that additional cellular adaption processes are required
to effectively colonize the hepatic microenvironment [96]. In 1889, Stephen Paget
formulated the ’seed and soil theory’ claiming that a DTC of a certain tumor
entity (’seed’) demands the interplay with a particular secondary environment
(’soil’) for successful metastatic colonization [97]. This theory, describing a pro-
cess also referred to as tumor cell homing was validated by various studies which
demonstrated that DTCs of different cancer entities selectively seed in specific
target organs [97, 98]. Hence, the unique composition of the liver may represent
a particular sanctuary for DTCs of pancreas duct origin. The predominant cell
type endemic to the liver is the parenchymatic hepatocyte occupying about 80 %
of the organ’s volume [99]. Non-parenchymatic cells represent 40 % of the hepatic
cell repertoire [99]. Among non-parenchymatic cells Kupffer cells are the most
abundant ones. They represent a specialized type of macrophages which differ-
entiate in the liver and are detectable along the sinusoidal walls [100]. Kupffer
cells are among other functions responsible for the phagocytosis of e.g. bacteria
and aged erythrocytes in the hepatic blood circulation [101]. A particular role
in the context of inflammation assume hepatic stellate cells (HSCs) which rep-
resent the second most abundant non-parenchymatic cell entity in the liver. In
a physiological liver, quiescent HSCs represent 5 % - 8 % of the cellular hepatic
composition and reside in the space of Disse [102]. HSCs are characterized by the
occurrence of the intermediate filament desmin and the deposition of cytoplasmic
droplets storing vitamin A in form of retinoic esters [102]. They expose a slow
cycling phenotype and slight cytokine secretion [103]. Furthermore, HSCs may
directly contribute to immune responses as they are reported to exhibit an antigen
presenting capacity [104]. Albeit their low abundance, HSCs represent the key
effector cell entity of inflammatory processes and other function impairing stim-
uli in the liver [103]. After perceiving activation cues like inflammation, injury,
infection or chemotherapy, HSCs cease the storage of retinoic acids and transdif-
ferentiate into hepatic myofibroblasts (HMFs*) [103, 105]. HMFs expose a high
abundance of α-smooth muscle actin (α-SMA) and release a plethora of growth
factors, including TGF-β, platelet derived growth factor (PDGF), vascular en-
dothelial growth factor (VEGF) and stromal derived factor-1 (SDF-1) [105–107].
*In the literature the nomenclature for hepatic stellate cells at different degrees of transd-
ifferentiation is used inconsistently. In this thesis, the term hepatic stellate cells (HSCs) rep-
resents the stage of quiescence or early activation while the designation hepatic myofibroblasts
(HMFs) is used to describe HSCs at an advanced state of activation.
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Moreover, HMFs are the main source of ECM molecules like type I and type III
collagens [103, 108]. As such, HMFs on the one hand determine and preserve the
architecture of the organ upon injury whereas on the other hand their dysregu-
lated propagation may lead to chronic fibrosis and cancer progression. Figure
1.4 schematically demonstrates the localization and transdifferentiation of HSCs
in the space of Disse [109].
Figure 1.4.: The activation of hepatic stellate cells (HSCs). HSCs are located in the space of Disse
and represent a quiescent cell population. Upon activation stimuli like e.g. inflammation or injury, HSCs
cease their lipid storing function and transdifferentiate into hepatic myofibroblasts (HMFs). Latter ones
release a plethora of extracellular matrix molecules and determine the architecture of the liver (adapted
from [109]).
Importantly, it has lately been shown that HMFs are critically involved in homing
processes of PDAC cells to the liver and the formation of a growth and survival
promoting microenvironment, termed a pre-metastatic niche [110, 111]. How-
ever the entire spectrum of HSC activation cues and the fashion by which HMFs
contribute to liver metastasis in PDAC and other types of cancer are yet insuffi-
ciently investigated. Moreover, it is not known which cells in the liver contribute
to the poor efficiency of metastases and determine if DTCs may outgrow to overt
metastases or remain in a growth arrested condition.
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1.4. The different shapes of growth arrest
The dysregulation of growth control is a key feature of cancer cells. The acqui-
sition of replicative immortality, the ability to evade growth suppressors and the
sustainment of proliferative signaling are accordingly recognized as hallmarks of
cancer [112]. Most chemotherapeutical agents are hence designed to target highly
proliferative cells [113]. Concomitantly, eradicating non-proliferative tumor cells
is mandatory to prevent tumor recurrence and to fully cure cancer diseases. This
is since some tumor cells may persist in the organism after treatment in a state
of growth arrest. As such tumor cells are not affected by most chemotherapeutic
agents and may hence be the source of relapse after treatment [114]. Various re-
ports support the view that DTCs acquire a state of growth arrest when having
infiltrated distant organs as they lack adequate adhesion and growth signaling
[115, 116]. The ability of neoplastic cells to enter and escape cellular growth
arrest may hence represent a crucial step in metastatic evolution [117]. However,
the detection of growth arrested tumor cells is particularly challenging as these
are clinically unobtrusive [118]. Furthermore, the acquisition of growth arrest in
neoplastic cells can manifest in different shapes and phenotypes which may, how-
ever, encompass distinct relevance for cancer progression and recurrence [119].
Thus, understanding and characterizing the different mechanisms of growth ar-
rest in cancer cells and PDECs specifically is mandatory to identify novel markers
for their detection in order to prevent tumor relapse and metastatic progression.
1.4.1. Quiescence
Cellular quiescence is defined as a state in which cells are non-dividing but uphold
their proliferative potential [120]. Quiescent cells are captured in the G0-phase
and are hence situated outside the cell cycle which applies to most cells of adult
mammalian organisms [121]. In comparison to G1 cells, G0 cells may re-enter the
S-phase with a distinct lag of variable duration [122]. Quiescence mechanisms
are mandatory for the physiological function of various tissues. For example,
immune competent cell populations like lymphocytes demand a tight regulation
of the balance between quiescence and proliferation to ensure a spatiotemporally
controlled immune response [123]. Furthermore, quiescent cells are provided with
the ability to survive stress and detrimental cues which is of particular importance
for long-living cells like stem cells. When situated in a quiescent state, cells cease
various basic cellular processes like metabolism and are generally refractory to
differentiation cues [124]. Quiescence in vitro is acquired when cells lack mitotic
signals, normally received by e.g serum growth factors and nutrients [125] It
was hence long time assumed that quiescence represents a passive state whereas
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the more recent view sees quiescence as a condition that is actively maintained
by various cell entities via induction of corresponding signaling pathways [122].
Among these particular significance is attributed to the retinoblastoma (Rb)-
E2F pathway. Proteins of the Rb family including Rb, p130 and p107 promote
quiescence by binding and repressing E2F transcription factors which regulate a
plethora of genes involved in DNA replication and cell cycle progression [122, 126,
127]. The Rb-E2F pathway is mutated in most, possibly in all cancer cells [128].
It is considered a bistable switch determining if quiescent cells overcome the
rescue-point (R-point) which sentinels the cell’s entry into the cell cycle [129].
A further critical regulator of cellular quiescence is p53 which was shown to
maintain quiescence in fibroblasts and hematopoietic stem cells via promotion of
its downstream targets Gfi-1 and Necdin [130, 131]. Of note, p53 also regulates
the cyclin dependent kinase (CDK) inhibitor p21. Latter protein is found in
higher abundances in quiescent cells and is also an integral component of the
Rb-E2F pathway [132]. It could be shown that normal fibroblasts induced to
quiescence fail to enter growth arrest when p21 is compromised [133]. The lack of
proliferative signaling in quiescent cells can be utilized to detect these in vitro and
in vivo. For this purpose, bromodeoxyuridine (BrdU) labelling as well as Ki67
stainings can be employed [134]. Moreover, the upregulation of above-mentioned
signaling molecules like p53 and p21 can be documented via immuno-histological
and cytological stainings as well as western blot analysis.
1.4.2. Senescence
Historically, cellular senescence was demarcated from quiescence by a final loss
of proliferative potential [125]. Senescent cells, in contrast to quiescent cells, are
captured while being situated inside the G1 or G2 phase of the cell cycle and
remain metabolically active [125]. Cellular senescence occurs when cells receive
growth promoting signals while their proliferation is halted [125]. It is consid-
ered a critical protective mechanism to ensure tissue function and to separate out
dysfunctional, aging and stressed cells [135, 136]. Consequently, senescent cells
can be observed in patient tissues after treatment with chemotherapeutic agents
or radiation [137]. The initial observation of cellular senescence traces back to
Leonard Hayflick who described in 1961 that the number of deviations a cell may
undergo in culture is confined and that cells are irreversibly growth arrested after
exceeding this limit (Hayflick limit) [138]. This mechanism of senescence induc-
tion is termed replicative senescence. It is a consequence of the DNA polymerase’s
disability to replicate the lagging strand of the DNA at the 3’ end which results
in shortening of telomeres at a rate of 100 – 120 nucleotides per cycle [139, 140].
Once telomeres reach a critical length, a DNA damage response (DDR) is induced
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[141]. The DDR manifests in the emergence of histone y-H2AX foci as well as
activation of the kinases ATM and ATR [142, 143]. Furthermore, this process is
highly dependent on p53 and p21 which are downstream targets of ATM and ATR
[135, 144]. P21 activation leads to the inhibition of CDK2 which in turn results in
a cease of Rb-mediated proliferation cues and subsequent growth arrest [144, 145].
If the DDR trespasses a certain threshold, it will not lead to DNA damage repair
but either to apoptosis or senescence [136]. Senescence can also occur as a result of
cellular stress cues albeit functional telomeres and persistent telomerase activity.
Potent triggers of the so called stress-induced senescence (SIS) can be epigenetic
stress and reactive oxygen species (ROS) but also the loss of tumor suppres-
sors and activation of oncogenes [144, 146]. In contrast to replicative senescence,
SIS is achieved via ARF or p16 signaling. The ARF kinase fulfills its function
via the p53-p21 axis similar to ATM and ATR while p16-mediated senescence
is achieved via CDK4/6- and Rb-inhibition [144, 147, 148]. Oncogene induced
senescence (OIS) represents a subform of SIS in which the KRAS oncogene plays
a particular role. Mutations in the KRAS gene like the KRASG12D mutation
can on the one hand cause enhanced proliferation but also hyperreplication and
consequent growth arrest due to replicative and oxidative stress [144, 149]. OIS
hence represents a further crucial checkpoint neoplastic cells need to escape in
order to successfully form a tumor. It was recently demonstrated that mutant
p53 promotes the overcoming of KRAS -mediated OIS in premalignant PDECs
and fosters their malignant progression [150].
Senescent cells expose a particular phenotype including a flattened and enlarged
morphology with a diminished nucleoplasmatic ratio in vitro and are often mult-
inucleated [151]. Irrespective of the senescence induction cue a common feature
of senescent cells is the release of various pro- and anti-inflammatory cytokines.
This senescence-associated secretory phenotype (SASP) is a consequence of the
DDR and encompasses factors like Interleukin (IL)-6, IL-8, IL-1 as well as various
chemokines of the CXCL and CCL families [152]. The SASP can be utilized as
surrogate marker for the detection of senescent cells in vivo and in vitro. The
common increase in p16/CDKN2a, p21 and p53 may also help to identify senes-
cent cells [136]. Yet, the most accepted marker for the detection of senescent
cells is an increased activity of acid β-Galactosidase [153]. Acid β-Galactosidase
is located in the lysosome, which experiences a marked increase during senescence
induction, and can be detected at high levels in senescent cells at pH 6.0. It is
hence termed senescence-associated β-galactosidase (SABG). However, the con-
comitant detection of SABG and other senescence markers like heterochromartin
foci or γ-H2AX is recommended to precisely characterize senescent cells [136].
The predominant view that senescence represents an irreversible growth arrest
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has been challenged by different observations published in the last years. For
example, the inhibition of p53 or the mTOR-pathway was able to restore the
proliferative capacity of cells which exposed a senescent phenotype [154, 155].
Furthermore, some breast cancer patients harbored SABG and p16 positive cells
after receiving neoadjuvant therapy indicating that senescent cells could represent
a source of tumor relapse in vivo [135].
1.4.3. Dormancy
In general, the biological term dormancy describes a condition in which an or-
ganism or a cell temporarily ceases its physiological functions and growth. It can
be observed in various biological systems e.g. in plant seeds that fail to germi-
nate or in animals as a delay of development also termed diapause [156, 157].
However, dormancy has particular implications in cancer. In this context, the
term dormancy is mostly used to describe a period following treatment during
which patients remain asymptomatic before they expose local tumor recurrence
and/or metastasis [158]. Cancer dormancy encompasses the absence or cessa-
tion of growth on two levels: The level of a tumor cell population (tumor mass
dormancy) or on the cellular level (cellular dormancy). Tumor mass dormancy
covers mechanisms that restrain the propagation of a tumor cell population. Such
populations may contain proliferative cells but do not expose spatial expansion
due to the concomitant elimination of a corresponding amount of cells [118].
One mechanism counteracting growth may be active immune surveillance by in-
nate and adaptive immune effector mechanisms resulting in immune-mediated
dormancy [119]. Moreover, growing tumors rely on the recruitment of vessels
to ensure nutrient and oxygen supply. If proangiogenic factors like VEGF and
antiangiogenic factors like thrombospondin (TSP) balance each other, tumors
are caught in angiogenic dormancy [159]. Similar to cellular quiescence cellular
dormancy describes cells which exist in a reversible G0 -G1 arrest and expose
diminished metabolic activity. Additionally, the definition of cellular dormancy
includes that in contrast to quiescence a certain trigger stimulus is required to
revert it [119]. The induction of dormancy can be a result of disturbed growth fac-
tor and adhesion signaling. Two pioneering studies by Aguirre-Ghiso and Liu et
al. showed that disruption of EGFR-mediated urokinase plasminogen activator
receptor (uPAR) signaling causes diminished ERK activation and proliferation
and a dormant phenotype in head and neck squamous carcinoma (HNSC) cells
[115, 160]. These findings were supported by more recent studies which showed
that restoration of VCAM-1 adhesion signaling represents a potent trigger to
counteract the dormant phenotype of breast cancer cells [119, 161]. Aguirre-
Ghiso et al. were able to show that the ratio of phosphorylated (p-) ERK and
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p-p38 helps to identify cells and tumors in a state of dormancy. In their hands,
sustained ERK activity favored a proliferative phenotype in cells of different can-
cer entities whereas a low p-ERK/p-p38 signaling ratio correlated with cellular
dormancy [160]. Furthermore, ERK signaling is negatively regulated by p-p38
and hence inhibition of p38 in dormant cells is sufficient to bring back prolif-
erative activity of some cancer cells [162]. Meanwhile, few stimuli which may
act to revert tumor mass dormancy and cellular dormancy could be identified.
Sustained proangiogenic VEGF signaling helps to induce the angiogenic switch
which promotes blood supply of tumorous lesions thereby restraining angiogenic
dormancy [163]. Furthermore, diminished TGF-β signaling was reported to pro-
mote reactivation of dormant metastatic breast cancer cells [164].
Tumor mass dormancy and cancer cell dormancy are considered the basis for
different important clinical observations like minimum residual disease (MRD)
[114]. MRD occurs when a therapeutical intervention fails to fully eradicate all
cells of a tumor. As a consequence, some cells may survive in the patient’s or-
gans and eventually give rise to tumor relapse after concluded treatment [114].
This is also relevant for PDAC where remaining vital tumor cells are commonly
observed in the bone marrow, lymph nodes, blood and peritoneum [165]. Lin et
al. recently delivered experimental evidence that the dysregulation of the c-Myc
oncogene may be critically involved in the induction and maintenance of this pro-
cess [166]. Due to the rapid disease process of PDAC dormancy processes appear
less important than in other cancer entities like e.g. breast or prostate cancer
where recurrence could be observed years or sometimes even decades after treat-
ment [167]. Yet, the concept of dormancy could help to explain the emergence of
metastases shortly after therapy despite full removal of the primary tumor [8]. Of
note, the early dissemination model proposed for some cancer entities including
PDAC only gains clinical relevance when assuming that early DTCs may survive
in distant organs for longer periods [117, 167]. Hence, the concept of early dis-
semination is probable to strongly depend on dormancy processes.
Yet, it is not fully understood whether cellular dormancy indeed represents a
distinct phenotype and mechanism independent of cellular quiescence and senes-
cence. As noted above, all three mechanisms of growth arrest are achieved by
similar key molecules and pathways. Accordingly, their phenotypic and morpho-
logic features overlap. Whereas irreversible senescence is not likely to represent a
mechanism underlying tumor recurrence and metastatic spread, reversible senes-
cence may be a mechanistic fit for the latter processes. Since cellular senescence
comprises the pro-inflammatory SASP as additional feature it may be relevant for
the detection and eradication of tumor cells which kind of growth arrest underlies
MRD and occult metastasis.
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Role of the microenvironment in the induction and reversion of dormancy
The observation that adhesion and growth factor signaling influence the dormant
phenotype of neoplastic cells implies that additional to cell intrinsic factors the
microenvironment represents a crucial determinant for the acquisition and main-
tenance of a dormant phenotype in neoplastic cells [168]. Some organs comprise a
relatively high ability to support the growth of DTCs and are hence classified as
‘dormancy permissive’ microenvironments [119]. The bone marrow is considered
a dormancy permissive environment as it exhibits high amounts of factors like
growth arrest specific protein 6 (GAS 6), bone morphogenetic proteins 4 and 7
(BMP4 and BMP7) as well as TGF-β2, all of which were shown to induce cellu-
lar dormancy in different cancer entities [169–172]. In accordance with the seed
and soil hypothesis, some organs provide conditions which promote the escape
from dormancy and are hence termed ‘dormancy restrictive’ [119]. Bragado et
al. were able to show that the relatively low levels of TGF-β2 in the lungs allow
for dormancy escape and metastasis formation of HNSC DTCs in a p38 depen-
dent manner [171]. Importantly, the induction and reversion of dormancy may
also rely on inflammatory processes. Utilizing an experimental model of breast
cancer metastasis, Barkan et al. showed that inflammation of pulmonary tissue,
manifesting in enhanced collagen-1 release, may drive DTCs to escape cellular
dormancy [173, 174].
1.5. Aim of the study
Despite extensive research efforts undertaken in the last decades and significant
progress in the understanding of the pathological events underlying its develop-
ment, PDAC remains a widely incurable malignancy. This is mainly owed to
the frequent occurrence of metastatic disease which commonly manifests prior to
diagnosis or even subsequent to successful resection of the primary tumor [6–8].
Since the liver is colonized in 80 % of all PDAC patients, understanding of mech-
anisms which underlie the outgrowth of disseminated PDECs in the liver may
reveal promising novel targets for PDAC treatment [92]. However, the patho-
logical events promoting PDAC liver metastasis as well as their chronology are
poorly understood. The link between primary PDAC progression and inflamma-
tion is to date well established and the tumor stroma is shifting into the centre
of attention of PDAC therapy research [175]. However, the poor availability of
patient material aggravates the characterization of PDAC liver metastasis, par-
ticularly in the early course of metastatic disease [6]. Hence, it remains widely
unclear how inflammatory cues in the hepatic microenvironment may impact on
the accretion and progression of disseminated PDECs. Studies from HNSC and
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mammary carcinoma support the view that inflammatory conditions in the sec-
ondary organ promote the escape of DTCs from growth arrest and foster their
outgrowth to metastases [171, 173]. It was therefore hypothesized that the con-
dition of the hepatic microenvironment – physiological versus inflamed – may
critically determine the fate and proliferative behavior of disseminated PDECs.
In the liver, HSCs and thereof transdifferentiated HMFs are the main effector cell
population of inflammatory processes [105]. Accordingly, inflamed livers expose a
high amount of HMFs (cf. Chapter 1.3). Hence, in this study HSCs and HMFs
were regarded as representative of a physiological or inflamed liver microenviron-
ment, respectively.
Figure 1.5.: Working hypothesis. HSCs are a characteristic of a physiological liver whereas an inflamed
liver is characterized by higher amounts of HMFs. It was recently reported that besides malignant PDAC
cells, also premalignant PDECs may disseminate to the liver [89]. It was hence hypothesized that the
condition of the liver – physiological versus inflamed – determines the likelihood of succesfull outgrowth of
dissemintated PDECs from PanINs or PDAC to overt metastases.
In a first step, it was sought to characterize PDAC metastases with particular
regard to tumor cell proliferation and the abundance of HSC and HMF in the
direct microenvironment. For this approach, liver sections of the well-established
KPC mouse model of PDAC were analyzed for tumor cell proliferation and stro-
mal composition via immunohistological methods [176].
Aging is an accepted risk factor for PDAC onset [5]. It was previously shown that
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aging is associated with various systemic alterations including cellular senescence
and altered intercellular communication which manifest in a state of subclini-
cal inflammation also referred to as smouldering inflammation or ‘inflammag-
ing’ [177]. Accordingly, some studies report that HMFs emerge concomitantly
with proceeding age [103]. It was hence hypothesized that inflammaging fosters
the outgrowth of metastases in the liver. To study the impact of aging-related
smouldering inflammation on the proliferation of disseminated PDECs, a syn-
geneic mouse model was used. Therefore, C57Bl/J mice 8 weeks or 52 of age
were injected orthotopically with KPC derived PDAC cells. These animals were
analyzed regarding primary and secondary tumor progression via in vivo imaging
modalities and ex vivo via immunohistological stainings.
In vitro coculture systems were demonstrated to be useful tools for examining
the mutual impact of stromal cells and tumor cells and to determine underlying
mechanisms of intercellular communication [178, 179]. In previous own work,
an indirect coculture system could be established which is feasible to examine
the impact of HSCs and HMFs on PDECs [180, 181]. This model relies on the
murine cell line M1-4HSC which exhibits various features of HSCs, including
desmin-positivity and TGF-β responsivity [182]. Under substantial administra-
tion of exogenous TGF-β, M1-4HSC acquire an HMFs-like phenotype, termed
M-HT, which manifests in a spindle-shaped morphology and diminished amounts
of intracellular desmin [182]. Hence, the M1-4HSC cell line was utilized repre-
sentative of HSCs and M-HT cells were applied representative of HMFs to model
a physiological or an inflamed hepatic microenvironment, respectively. Repre-
sentative of disseminated PDECs deriving from PanIN lesions the premalignant
PDEC line H6c7-kras was used whereas the malignant cell line Panc1 was utilized
to model DTCs from established PDAC. The indirect coculture of M1-4HSC or
M-HT with premalignant and malignant PDECs ought to provide indications for
the behavior of DTCs in the liver. Overall, this work aimed at gaining a better
understanding of the mechanisms underlying the outgrowth of liver metastasis in
PDAC.
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2.1. Laboratory devices
Device Manufacturer
Centrifuges
Heraeus Fresco 17 Thermo Scientific, Schwerte, DE
Heraeus Multifuge 3 S-R Thermo Scientific, Schwerte, DE
Heraeus Multifuge X1 Thermo Scientific, Schwerte, DE
Heraeus Pico 17 Thermo Scientific, Schwerte, DE
Rotina 420 R Hettich, Tuttlingen, DE
Sprout mini centrifuge Heathrow Scientific, Vernon Hills, US
Incubators
BBD 6220 CO2 incubator Thermo Scientific, Schwerte, DE
GyroTwister 3D shaker Labnet, Woodbridge, US
HERA Cell 240 incubator Thermo Scientific, Schwerte, DE
PMS 1000 Microplate Shaker Grant bio, Essex, UK
QBA1 table incubator Grant, Cambridge, UK
Stuart SRT9 roll mixer Bibby Scientific Ltd., Stone, UK
WNB 7-45 water bath Memmert, Schwabach, DE
WTC ED-53 incubator Binder, Tuttlingen, DE
Measuring Devices
Fusion SL detection system Vilber Lourmat, Eberhardzell, DE
LightCycler 480 II Roche, Basel, CH
Infinite® 200 PRO, plate reader Tecan, Crailsheim, DE
NanoQuant Plate Tecan, Crailsheim, DE
NightOWL LB 983 Berthold Technol., Bad Wildbad, DE
Neubauer counting chamber Marienfeld, Lauda-Koenigshofen, DE
pH 7110 pH-meter inoLab, Weilheim, DE
Vevo770® FujiFilm VisualSonics, Toronto, CAN
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Histology devices
FS20 MultiGourmet Braun, Aschaffenburg, DE
HM430 Microtome Thermo Fisher, Darmstadt, DE
Heating Plate 100 °C Ju¨rgens, Bremen, DE
Paraffin stretch bath Medax, Neumu¨nster, DE
TES 99 Paraffin embedding sys-
tem
Medite, Burgdorf, DE
Microscopes
AE2000 Motic, Wetzlar, DE
Axiovert 25 Zeiss, Jena, DE
Axio Scope-A1 Zeiss, Jena, DE
BZ-9000 II Keyence, Osaka JPN
Evos XL Core Cell Imaging
System
AMG, Bothell, US
Other devices
ARPEGE 110 nitrogen tank AirLiquide, Paris, FR
CS-300V Power supply Cleaver Scientific, West Sussex, UK
Freezer Liebherr, Ochsenhausen, DE
Fridge Liebherr, Ochsenhausen, DE
HERAfreeze Basic freezer Thermo Scientific, Schwerte, DE
Laboport vacuum pump KNF Neuberger, Freiburg, DE
MILLI-Q Reagent Water System Merck Millipore, Billerica, US
MR Hei-Mix S magnetic
stirrer
Heidolph Instruments,
Schwabach, DE
OmniPAGE VS10D gel
chamber
Cleaver Scientific, West Sussex, UK
SD20 Semi Dry Maxi transfer
chamber
Cleaver Scientific, West Sussex, UK
Sonicator Sonoplus Bandelin, Berlin, DE
Sunrise remote control Tecan, Crailsheim, DE
Vortex Genius 3 vortex
shaker
IKA-Werke, Staufen, DE
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Pipettes
Finnpipette F1 0.2-2 µl Thermo Scientific, Schwerte, DE
Finnpipette F1 1-10 µl Thermo Scientific, Schwerte, DE
Finnpipette F1 2-20 µl Thermo Scientific, Schwerte, DE
Finnpipette F1 20-200 µl Thermo Scientific, Schwerte, DE
Finnpipette F1 100-1000 µl Thermo Scientific, Schwerte, DE
Macro pipette controller Brand, Wertheim, DE
Pipetboy acu Integra Biosciences, Fernwald, DE
Sterile benches
HERA Safe Thermo Scientific, Schwerte, DE
HERA Safe KS Thermo Scientific, Schwerte, DE
Scales
Precisa BJ 2100D Precisa Gravimetrics, Dietikon, CH
Precisa XB120A Precisa Gravimetrics, Dietikon, CH
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2.2. Consumables
Consumable Manufacturer
0.1 - 10 µl, 10 - 200 µl,
100 - 1000 µl pipette tips
Sarstedt, Nuembrecht, DE
1.25 mL, 5.0 mL Ritips Ritter, Schwabmuenchen, DE
1.5 mL, 2 mL Eppendorf tubes Eppendorf, Hamburg, DE
15 mL, 50 mL centrifuge tubes Sarstedt, Nuembrecht, DE
18 mm coverslips Menzel, Braunschweig, DE
5 mL, 10 mL, 50 mL serological
pipettes
greiner bio-one, Frickenhausen, DE
6-/12-/96-well flat-bottom
plates
greiner bio-one, Frickenhausen, DE
6-/12-well transwell inserts, pore
size 0.4 µm
greiner bio-one, Frickenhausen, DE
75 cm2 cell culture flasks greiner bio-one, Frickenhausen, DE
96-well PCR plates, white Roche, Basel, CH
Cell Scraper 25 cm Sarstedt, Nuembrecht, DE
CryoPure tube, 1.0 mL, white Sarstedt, Nuembrecht, DE
Micro-Touch nitrile examination
gloves
Ansell, Muenchen, DE
Nalgene rapid-flow sterile dispos-
able filter with SFCA
membrane (pore size 0.2 µm)
Thermo Scientific, Schwerte, DE
Nunc® CryoTube® 1.8 ml Sigma Aldrich, Muenchen, DE
Parafilm M sealing film Brand, Wertheim, DE
RA Lamb Coverglass and Cover-
slip Staining Rack
Thermo Scientific, Schwerte, DE
SuperFrost object slide 76 x 26
mm
Menzel, Braunschweig, DE
Transfer pipettes 3.5 ml Sarstedt, Nuembrecht, DE
WatchMaker Forcep No. 6 Thermo Scientific, Schwerte, DE
Westran polyvinylidene
fluoride (PVDF) membrane
0.45 µm
Th.Geyer GmbH, Renningen, DE
Whatmann-3MM filter paper FE Healthcare, Buckinghamshire, UK
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2.3. Kit systems
Kit Manufacturer
Bio-Plex® Pro Assay Bio-Rad Laboratories, Muenchen, DE
DCTM Protein Assay Bio-Rad Laboratories, Muenchen, DE
Lab VisionTM MultiVision Poly-
mer Detection System
Thermo Fisher, Darmstadt, DE
MycoAlertTM Mycoplasma De-
tection Kit
Lonza Group, Basel, CH
NucleoSpin RNA/Protein Macherey-Nagel, Du¨ren, DE
RevertAid First Strand cDNA
Synthesis Kit
Thermo Scientific, Schwerte, DE
Senescence β-Galactosidase
Staining Kit
New England Biolabs GmbH,
Frankfurt(Main), DE
2.4. Software
Software Manufacturer
Axiovision 4.6 Carl Zeiss AG, Jena, DE
BIOREVO Keyence, Osaka, JPN
Citavi Swiss Academic Software
GmbH, Wa¨denswil, CH
Fireworks CS6 Adobe
FUSION-CAPT 16.06 Vilber Lourmat, Eberhardzell, DE
ImageJ 1.47v Wayne Rasband, National Institute
of Health, Bethesda, Maryland, US
LightCycler480 Software Roche, Basel, CH
i-controlTMMicroplate Reader
Software
Tecan, Crailsheim, DE
Microsoft Excel 2010 Microsoft Corporation, Redmond, US
SigmaPlot 12.5 Systat Software Inc., Chicago, US
Vevo® software FujiFilm VisualSonics, Toronto, CAN
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2.5. Chemicals, buffers and reagents
2.5.1. Chemicals
Chemical Manufacturer
2-mercaptoethanol Sigma-Aldrich, Muenchen, DE
6-aminocaproic acid Sigma-Aldrich, Muenchen, DE
Accutase solution EMD Millipore Corporation,
Temecula, California, US
Acetic acid, 10 % Carl Roth GmbH, Karlsruhe, DE
AEC substrate-Chromogen
Ready-to-Use
Dako Diagnostika, Hamburg, DE
All-trans-Retinoic acid (ATRA) Sigma Aldrich, Muenchen, DE
AMD3100 (Plerixafor) Kindly provided by PD Dr. Kirsten
Hattermann-Koch, Kiel, DE
Ammonium persulfate (APS) Merck Millipore, Darmstadt, DE
Bovine pituitary extract
(BPE)
Life Technologies, Darmstadt, DE
Bovine serum albumin (BSA),
fraction V
Biomol, Hamburg, DE
Bromphenol blue ACS Reag., Ph
Eur
Merck Millipore, Darmstadt, DE
Clarity Western ECL substrate Bio-Rad Laboratories, Muenchen, DE
Dithiothreitol (DTT) Sigma-Aldrich, Muenchen, DE
Dulbecco’s Modified Eagle
Medium (DMEM)
PAA, Pasching, AT
EnVision + system-HRP labelled
polymer anti-mouse
Dako Diagnostika, Hamburg, DE
Ethanol Merck Millipore, Darmstadt, DE
Fetal calf serum (FCS) Biochrom, Berlin, DE
FluorSaveTM Reagent Merck Millipore, Darmstadt, DE
Glycerol Sigma-Aldrich, Muenchen, DE
Hydrogen peroxide 30 % Th.Geyer GmbH, Renningen, DE
Keratinocyte serum-free medium Life Technologies, Darmstadt, DE
L-glutamine (L-Gln) PAA, Pasching, AT
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LightCycler480 SYBR Green I
Master
Roche, Basel, Switzerland
Mayer’s Haemalaun Applichem, Darmstadt, DE
Methanol Th.Geyer GmbH, Renningen, DE
Milk powder Carl Roth GmbH, Karlsruhe, DE
PageRuler prestained protein lad-
der
Thermo Scientific, Schwerte, DE
Paraformaldehyde (PFA) 4.5 %
(w/v)
BUEFA Chemikalien GmbH Co. KG,
Hude, DE
Penicillin-streptomycin
(Pen/Strep)
PAA, Pasching, AT
Phosphate buffered saline (PBS) PAA, Pasching, AT
Ponceau S Carl Roth GmbH, Karlsruhe, DE
Richard-Allan ScientificTM
Mounting Medium
Thermo Scientific, Schwerte, DE
Roswell Park Memorial Institute
(RPMI) 1640 medium
Biochrom, Berlin, DE
Rotiphorese gel 40 acrylamide/
bisacrylamide 40 % solution
Carl Roth GmbH, Karlsruhe, DE
Sodium chloride Carl Roth GmbH, Karlsruhe, DE
Sodium dodecyl sulfate (SDS)
ultra-pure
Carl Roth GmbH, Karlsruhe, DE
Sodium orthovanadate Santa Cruz Biotech., Heidelberg, DE
Sodium pyruvate 100 mM Biochrom, Berlin, DE
SteCM Medium provitro AG, Berlin, DE
Sudan Black B Sigma-Aldrich, Muenchen, DE
Tris base Carl Roth GmbH, Karlsruhe, DE
Triton X-100 Sigma-Aldrich, Muenchen, DE
Trypan blue solution Fluka 0.4 % Sigma-Aldrich, Muenchen, DE
Trypsin-EDTA PAA, Pasching, AT
Tween 20 Serva, Heidelberg, DE
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2.5.2. Buffers and formulations
Western blotting
Blot buffer A 300 mM Tris base
20 % (v/v) methanol
pH 11
Blot buffer B 25 mM Tris base
20 % (v/v) methanol
pH 10.6
Blot buffer C 25 mM Tris base
20 % (v/v) methanol
40 mM aminocaproid acid
pH 10.6
Blotto 50 g/l milk powder
in TBS-T (1x)
Laemmli buffer (2x) 128 mM Tris base
4.6 % (w/v) SDS
10 % (v/v) glycerol
1 mM sodium orthovanadate
pH 7.6
Loading Dye (4x) 50 ml Laemmli buffer (2x)
0.005 % (w/v) bromphenol blue
2.5 % (v/v) 2-mercaptoethanol
Separation gel buffer 1.5 M Tris base
0,4 % (w/v) SDS
pH 8,8
Stacking gel buffer 0.5 M Tris base
0.4 % (w/v) SDS
pH 6,8
TBS (10x) 20 mM Tris base
140 mM sodium chloride
pH 7.6
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TBS-Tween (TBS-T) 1798 ml ddH2O
200 ml TBS (10x)
1000 l Tween 20
Western blot running buffer 5000 mL ddH2O
25 mM Tris base
192 mM glycin
0.1 % (w/v) SDS
2.6. Material for in vivo experiments
2.6.1. Tools and consumables
Article Manufacturer
Insulin syringe U-40, 1 ml,
29,5 GA/0,33 x 12,7 mm
Becton Dickinson, USA
Bepanthen® Bayer Vital, Leverkusen DE
Gauze compress 10 ∗ 10 cm Hartmann, Heidenheim, DE
Gauze compress 6 ∗ 6 cm NOBA Verbandmaterial, Wetter, DE
Kodan® Schu¨lke & Mayr GmbH,
Norderstedt, DE
Micro needleholder after Mu¨ller
FM 061 R
Aesculap, Tuttlingen, DE
Micro tweezers with 1 x 2 teeth
after Mu¨ller FM034R
Aesculap, Tuttlingen, DE
Micro tweezers with ring (diame-
ter 1.2 mm)
Aesculap, Tuttlingen, DE
Veet depilation creme Reckitt Benckiser, Slough, UK
Vicryl 6-0 Ethicon Inc., Somerville, USA
Scissors, fine, straight, BC 060 R Aesculap, Tuttlingen, DE
sterile cotton buds Beese, Barsbu¨ttel, DE
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2.6.2. Injection solutions for in vivo experiments
Solution Manufacturer
Glucose 5% B.Braun solution Braun, Melsungen, DE
Anexate® (Flumazenil, 0,1 mg/ml) Roche, Grenzach-Wyhen, DE
Antisedan® (Atipamezol, 5 mg/ml) Pfizer, Karlsruhe, DE
D-Luciferin Firefly (XR-1001) Xenogen Corp., Alameda, USA
Dormitor® (Medetomidin, 1 mg/ml) Pfizer, Karlsruhe, DE
Fentanyl® (0,05 mg/ml) Janssen-Cilag, Neuss, DE
Isotonic sodiumchloride sol. 0,9 % Braun, Melsungen, DE
Midazolam® (1 mg/ml) Roche, Grenzach-Wyhen, DE
Naloxon® (0,4 mg/ml) CuraMed, Karlsruhe, DE
Temgesic® (0,3 mg/ml) Reckitt Benckiser, Slough, UK
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2.7. Cell biological material
2.7.1. Cell lines
Cell line Information / Source
A) Premalignant pancreatic ductal epithelial cells
H6c7eR-Kr
(referred to as H6c7-kras)
HPDE cell line immortalized with
HPV16-E6E7 genes and transduced
with the viral vector
pBabepuro-K-RasG12V [183]
PDAC relevant mutations: KRAS
B) Malignant pancreatic ductal epithelial cells
R254
PDAC cell line isolated from a pan-
creas of a KPC mouse carrying an
fLuc/GFP-reporter cassette [184]
PDAC relevant mutations:
KRAS, P16/CDKN2A, TP53
Panc1
Cell line generated from a 56-year-old
male with an adenocarcinoma in the
head of the pancreas [185]
PDAC relevant mutations:
KRAS, P16/CDKN2A, TP53
C) Hepatic stromal cells
M1-4HSC
HSCs line isolated from p19ARF null
mice in an early activation stage [182]
M-HT
M1-4HSC cells that have transdifferen-
tiated into myofibroblasts after mini-
mum 3 weeks exposure to 1 ng/ml ex-
ogenous TGF-β1 [182]
HHSteC
Human hepatic stellate cells isolated
from the liver of a 3 years old male in-
fant (SC-5300; provitro AG,
Berlin, DE)
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2.7.2. Culture media and additives
Cell line culture media
Routine cell culture
R254
DMEM High Glucose
(10 % (v/v) FCS, 1 %(v/v) L-Gln,
1 % (v/v) Pen/Strep)
H6c7-kras
50 % (v/v) keratinocyte-serumfree-
medium
(50 µg/ml bovine pituitary extract,
5 ng/ml EGF, 1 µg/ml puromycin),
50 % (v/v) RPMI 1640
(10 % (v/v) FCS, 1 % (v/v) L-Gln)
Panc1
RPMI 1640
(10 % (v/v) FCS, 1 %(v/v) L-Gln,
1 % (v/v) NaPyr)
M1-4HSC
MI-Medium
(DMEM High Glucose
10 % (v/v) FCS, 1 % (v/v) NaPyr,
1 % (v/v) Glut, 1 % (v/v) Pen/Strep)
M-HT MI-Medium (1 ng/ml TGF-β1)
HHSteC
SteC-Medium
(2% FCS + SteC-Medium supplements)
Coculture and blocking experiments
H6c7-kras
co
M1-4HSC
M-HT
HHSteC-HSC
RPMI 1640
(10 % (v/v) FCS, 1 % (v/v) L-Gln
Panc1
co
M1-4HSC
M-HT
HHSteC-HMF
1:1 RPMI 1640 : DMEM High Glucose
(10 % (v/v) FCS, 1 % (v/v) L-Gln)
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2.8. PCR-Primer
Gene 5’ - 3’ Sequence Annealing temp.
Purchased from Eurofins genomics
m β-Actin fw-AAGAGCTATGAGCTGCCT
rv-TACGGATGT CAACGTCAC
58 °C
m FGF2 fw-AGAGCGACCCACACGTCAAAC
rv-CCAACTGGAGTATTTCCGTGACC
58 °C
m/h GAPDH fw-TCCATGACAACTTTGGTATCGTGG
rv-GACGCCTGCTTCACCACCTTCT
58 °C
m TGF-β1 fw-GCTGAACCAAGGAGACGGAA
rv-AGAAGTTGGCATGGTAGCCC
58 °C
m VEGF-A fw-ACTGGACCCTGGCTTTACTG
rv-TCTGCTCTCCTTCTGTCGTG
58 °C
Purchased from realtimeprimers.com
m α-SMA fw-ATGCAGAAGGAGATCACAGC
rv-CAGCTTCGTCGTATTCCTGT
58 °C
m Col-1A1 fw-ATGATGCTAACGTGGTTCGT
rv-TGGTTAGGGTCGATCCAGTA
58 °C
m Desmin fw-CAGGAGATGGAATACCG
rv-GGCCATCTCATCCTTTAGGT
58 °C
m IL-6 fw-TAGTCCTTCCTACCCCAATTTCC
rv-TTGGTCCTTAGCCACTCCTTC
58 °C
m KC fw-CCAGAGCTTGAAGGTGTTGC
rv-TCTGAACCAAGGGAGCTTCA
58 °C
m LIX fw-CAGAAGGAGGTCTGTCTGGA
rv-TGGTTTCCCTTTTCTCATCA
58 °C
m MIP-2 fw-CAGACTCCAGCCACACTTCA
rv-TTCAGGGTCAAGGCAAACTT
58 °C
m TNF-α fw-CCCACTCTGACCCCTTTACT
rv-TTTGAGTCCTTGATGGTGGT
58 °C
Purchased from Biometra
m IL-1β fw-ATCCTCTGTGACTCATGGGATG
rv-GATCCACACTCTCCAGCTGCA
55 °C
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2.9. Biochemical Material
2.9.1. Antibodies
Primary antibodies
Specificity
(Clone)
Host
Isotype
Stock
Concentration
Dilution /
Application
Manufacturer
α-Smooth
muscle actin
(1A4)
mouse
IgG1
2-6 mg/ml 1:200 (IHC-p,
IF)
1:2000 (WB)
Sigma Aldrich,
Munich, DE
Desmin
(D93F5)
rabbit
IgG
- 1:1000 (WB)
1:50 (IHC-p,
IF)
Cell Signaling,
Frankfurt, DE
Ki67
(B56)
mouse
IgG1
0.5 mg/ml 1:200 (IHC-p)
1:100 (IHF)
1:250 (ICC)
BD Biosciences,
Heidelberg, DE
Cytokeratin-19
(10712-1-AP)
rabbit
IgG
100 µg/ml 1:200 (IHC-p) Proteintech EU,
Manchester, UK
GFP Tag
(A-11122)
rabbit
IgG
2 mg/ml 1:100 (IHF) Thermo Fisher,
Darmstadt, DE
HSP90
(H-114)
rabbit
IgG
200 µg/ml 1:2000 (WB) Santa Cruz, Hei-
delberg, DE
p21
(187)
mouse
IgG1
200 µg/ml 1:250 (WB) Cell Signaling,
Frankfurt, DE
p38 MAPK rabbit
IgG
27 µg/ml 1:1000 (WB) Cell Signalling,
Frankfurt, DE
p44/42
ERK1/2
rabbit
IgG
7.6 µg/ml 1:1000 (WB) Cell Signalling,
Frankfurt, DE
phospho-p38
MAPK (D3F9)
rabbit
IgG
78 µg/ml 1:1000 (WB) Cell Signalling,
Frankfurt, DE
phospho-
p44/42
ERK1/2
rabbit
IgG
150 µg/ml 1:1000 (WB) Cell Signalling,
Frankfurt, DE
COL1A1
(C-18)-R
rabbit
IgG
200 µg/ml 1:1000 (WB) Santa Cruz, Hei-
delberg, DE
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Isotype control antibodies
Name Host /
Isotype
Stock
Concentration
Dilution /
Application
Manufacturer
Isotype
(MAB002)
mouse
IgG1
0.5 mg/ml - R&D Systems,
Abingdon, UK
Normal Rabbit
IgG Control
rabbit
IgG1
1.0 mg/ml - R&D Systems,
Abingdon, UK
Secondary antibodies
Name Host /
Isotype
Stock
Concentration
Dilution /
Application
Manufacturer
mouse IgG
H&L
horse 170 µg/ml 1:2000 (WB) Cell Signalling,
Frankfurt, DE
rabbit IgG
H&L
goat 83 µg/ml 1:2000 (WB) Cell Signalling,
Frankfurt, DE
mouse IgG
H&L Alexa
fluor® 488
goat
IgG
2 mg/ml 1:400 (IHF) Life Technolo-
gies, Darmstadt,
DE
rabbit IgG
H&L
DyLight®
594
goat
IgG
2 mg/ml 1:400 (IHF) Thermo Fisher,
Darmstadt, DE
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Blocking antibodies
Antibody Target Final
Concentration
Manufacturer
Tocilizumab h IL-6R 10 µg/ml kindly provided by Prof.
Dr. Stefan Rose-John,
Kiel, DE
sgp130Fc IL-6/IL-6R-
complex
10 µg/ml kindly provided by
Conaris Research Insti-
tute AG, Kiel, DE
MAB208 h IL-8
(CXCL8)
2.5 µg/ml R&D Systems,
Abingdon, UK
Bevacizumab h VEGF-A 10 µg/ml Roche, Basel, CH
Aflibercept h/m VEGF-
A/B + PGF
10 µg/ml provided by Prof. Dr.
Alexa Klettner, Kiel, DE
Control antibodies
Antibody Isotype
control for
Final
Concentration
Manufacturer
Rituximab Tocilizumab
Bevacizumab
Aflibercept
10 µg/ml kindly provided by Prof.
Matthias Peipp, Kiel, DE
control Fc sgp130Fc 10 µg/ml kindly provided by
Conaris Research Insti-
tute AG, Kiel, DE
Isotype
(MAB002)
MAB208 2.5 µg/ml R&D Systems, Abing-
don, UK
2.9.2. Growth factors and cytokines
Factor Manufacturer
human Epidermal growth factor BioLegend, Fell, DE
human Transforming growth factor-β1 BioLegend, Fell, DE
human Stromal Derived Factor-1α PeproTech, Hamburg, DE
human Interleukin-6 BioLegend, Fell, DE
murine Interleukin-6 BioLegend, Fell, DE
human Interleukin-8 BioLegend, Fell, DE
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3.1. In situ characterization of liver metastases in
an endogenous PDAC mouse model
For the initial screening of liver metastases in a stroma-related context, liv-
ers of the established KPC mouse model (Pdx1-Cre; LSL-KrasG12D/+; LSL-
Trp53R172H/+) [176] were examined (Figure 3.1). Formalin-fixed paraffin-embedded
(FFPE) liver tissues were kindly provided by Prof. Dr. Dieter Saur and Prof. Dr.
Gu¨nter Schneider (II. Medizinische Klinik und Poliklinik, Klinikum Rechts der
Isar, Technical University Munich, Munich, Germany). Corresponding animal
experiments were executed in compliance with European guidelines for care and
use of laboratory animals and approved by local authorities (Az. 55.2-1-54-2532-
31-11).
Figure 3.1.: Experimental setup for the characterization of liver metastases in an endogenous
PDAC mouse model
3.1.1. Immunohistochemistry
FFPE liver tissue blocks were cut into serial sections of 3 µm slices and dried
overnight in an incubator at 37 °C. Tissue specimens were deparaffinized and re-
hydrated with xylene and graded ethanol baths in slide staining dishes containing
200 ml of the particular solution. Tissue slices were incubated in xylene twice for
10 min, respectively, following two incubation steps for 10 min in 100% ethanol.
Five min incubation in 95% ethanol including 1.5% H2O2 were affiliated in or-
der to quench the activity of endogenous peroxidases. Then, tissue sections were
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transferred into 70% ethanol, following incubations in 50% ethanol and ddH2O for
2 minutes (min), respectively. The rehydration of tissue sections was completed
by a 5 min washing step in PBS. Next, tissue sections were subjected to antigen
retrieval, which was performed at pH 6.0 for 20 min at subboiling temperature.
Sections were cooled at room temperature (RT) for another 20 min and washed
three times in PBS and a subsequent blocking step was performed. Therefore, sec-
tions were transferred into a wet chamber and 100 µl of a 4% BSA/PBS solution
with 0.3% Triton X-100 were pipetted onto the specimens before being covered
with parafilm in order to provide equal distribution of the blocking solution. In
the following, tissue sections were incubated overnight in primary antibody so-
lution in a wet chamber. Primary antibody solutions contained either rabbit
anti-mouse-cytokeratin-19 (CK-19) antibodies mixed with mouse anti-mouse-α-
smooth muscle actin (α-SMA) antibodies or rabbit anti-mouse-desmin antibodies
mixed with mouse anti-mouse-Ki67 antibodies diluted in 100 µl 1% BSA in PBS
solution with 0.3% Triton X-100, respectively. Detection of antibody-binding was
performed with the Lab VisionTM MultiVision Polymer Detection System accord-
ing to the manufacturer’s instructions. Tissue slices were therefore washed three
times in TBS-T + 0.3% Triton X-100 before one drop MultiVision Polymer Cock-
tail: anti-mouse/HRP + anti-rabbit/AP was added to the sections, which were
then incubated for 1 h at RT. Specimens were again washed 3 times in TBS-T
+ 0.3% Triton X-100 and chemical detection of HRP- or AP-antibody-complexes
was affiliated. For this purpose, 100 µl of freshly prepared LVblue solution were
pipetted onto the tissue slices and covered with parafilm for 10 min, followed
by three further washing steps in TBS-T + 0.3% Triton X-100. Subsequently,
100 µl of freshly prepared LVred solution were added to the slides for 10 min
under parafilm. Tissue sections were washed with ddH2O twice and afterwards
dried at RT. Finally, stained tissue sections were mounted with xylene-substitute
mounting medium provided in the kit.
For detailed morphologic analysis of tissue sections, haematoxylin and eosin (HE)
stainings were done on corresponding serial sections to visualize cell nuclei and
cytoplasm. Following deparaffinization and rehydration, tissue specimens were
therefore incubated for 10 seconds in haematoxylin solution and subsequently
rinsed in tab water for 5 min. Sections were then incubated in eosin for 5 min
and again rinsed in tab water for another 5 min. A dehydration via respective 2
min incubation steps in 50% ethanol, 70% ethanol and 100% ethanol was affili-
ated for long-term maintenance of staining intensity and sections were mounted
with Richard-Allan ScientificTM Mounting Medium.
Stained sections were evaluated using a Zeiss Axiovert 25 microscope equipped
with an Axiocam-503 color (Zeiss). The specificity of all stainings was verified
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performing parallel negative control stainings with corresponding IgG-control an-
tibodies. Identified liver metastases were verified by Prof. Dr. Christoph Ro¨cken
(Institute of Pathology; UKSH Campus Kiel; Kiel, Germany) on a sample basis.
The sizes of detected metastases were determined using the proprietary measuring
tool of the Zeiss AxioVision software. Ki67 scoring of CK-19-positive cells/areas
was done according to a pathologically validated 5-tiered scoring system adapted
from [186](Table 3.1).
For stroma characterization, the CK-19-positive area plus 2 cell diameter was
defined as region of interest. α-SMA- and desmin-immunostaining was assessed
using a 4 tiered scoring system (Table 3.1)
Table 3.1.: Scoring system for PDEC-proliferation and surrounding stroma
PDEC-proliferation scoring (Number of Ki67-positive cells)
Score 0 Score 1 Score 2 Score 3 Score 4
negative <10 % 10 - 50 % 50 - 99% 100 %
Stroma scoring (Intensity of α-SMA or desmin staining)
Score 0 Score 1 Score 2 Score 3
no staining weak staining intermediate
staining
strong
staining
3.2. Analysis of pancreatic and hepatic tumor
growth in an age-related syngeneic PDAC
mouse model
3.2.1. Animal care and tumor cell application
To determine the impact of inflammation on PDEC proliferation in an aging-
related in vivo inflammation model, C57BL/6J wild type mice, either 8 weeks
or 52 weeks of age, were obtained from Charles River Germany (Sulzfeld, Ger-
many). Animal experiments and care were carried out in accordance with Eu-
ropean guidelines for care and use of laboratory animals and approved by local
authorities (V242-77326/2015 (123-10/11). Mice were allowed to acclimatize and
kept in a sterile S1-environment in the central animal husbandry of UKSH Cam-
pus Kiel (Kiel, Germany) at 22°C ± 2°C and 55 ± 10% relative humidity in
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adherence to a 12 h light- and dark rhythm. Bedding, food and water were
autoclaved in order to achieve specific pathogen-free conditions in accordance
with FELASA-guidelines. All animals were exclusively fed with chlorophyll-free
food to minimize tissue autofluorescence, which compromises bioluminesence de-
tection. Mice were kept in Macrolon®-cages type III with filtertops in Lamina-
Flow-cabinets in groups of up to 5 animals. For both age groups, Twenty animals
were used per age group and 10 mice per age group were sacrificed after 2 weeks
and 4 weeks, respectively (Figure 3.2).
Figure 3.2.: Experimental setup for the analysis of pancreatic and hepatic tumor growth in
an age-related syngeneic PDAC mouse model.
For the preparation of tumor cells, 3∗104 R254 cells (cf. Chapter 2.7.1),
cultured and detached as described in Chapter 3.3.1 were suspended in
25 µl DMEM supplied with 10% FCS and placed on ice until application.
Abdominal surgery was performed as described previously [187] by Prof. Dr.
Jan-Hendrik Egberts, Dr. Charlotte Hauser and Dr. Jan-Paul Gundlach
(Department of General, Visceral-, Thoracic-, Transplantation- and Pediatric
Surgery, UKSH Campus Kiel, Kiel, Germany). For this purpose, mice re-
ceived general anaesthesia via intra-peritoneal injection of 5 µl/kg bodyweight
(BW) combination-narcosis composed of Midazolam (5 mg/kg BW), Fentanyl
(0.05 mg/kg BW) and Dormitor (0.5 mg/kg BW), which were mixed under
sterile conditions. The absence of paw withdrawal reflexes was verified and
animals were weighed before mouse abdomina were sterilized and shaved.
A median-laparotomy was performed, the pancreas identified and 25 µl of
R254 cell suspension were injected into the pancreas head. The abdominal
wall was immediately closed using Vicryl 6-0 suture. As control treatments,
one animal per group received an injection of 25 µl cell-free medium while a
second animal was completely excluded from the surgical intervention. To avoid
cooling, animals were placed on a heating mat during the time of surgery. The
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anesthesia was antagonized via subcutaneous injection of a mixed combination
of Anexate (0.1 mg/ml BW), Naloxon (0.4 mg/ml BW) and Antisedan (5 mg/ml
BW). The animal recovery was carefully supervised with red light rewarming
and supported with subcutaneous injection of Temgesic (0.1 mg/kg BW) and
Glucose 5% B.Braun solution (0.025 mg/kg BW). All animals survived the
respective treatment.
3.2.2. Determination of PDAC growth via ultrasound imaging
In vivo monitoring of primary and secondary tumor growth as well as the collec-
tion of tissues was carried out 2 weeks and 4 weeks post-operation. For this ap-
proach, operated animals as well as respective control animals were anesthetized
as described above and abdominal hair was removed with depilation creme. Be-
fore, during and between examination events, animals were placed on heating
mats to avoid cooling. After preparation, mice underwent abdominal ultrasound
screening using a Vevo770® high-resolution in vivo micro-imaging system which
exhibits a resolution of 30 µm. An RMV706 ultrasound transducer (20 - 60 MHz)
was used and signals recorded in sagittal and transversal direction. After 3-
dimensional image acquisition via the Vevo®-Software, volumetric analysis of
tumors was performed applying the ellipsoid-formula:
tumor volume (mm3) = tumor length (mm) ∗ tumor width (mm) ∗ tumor depth (mm)
2
Ultrasound examinations as well as primary tumor size measurements were car-
ried out by Dr. Olga Will (Molecular Imaging North Competence Center, Clinic
of Radiology and Neuroradiology, CAU and UKSH Campus Kiel, Kiel, Germany)
3.2.3. Determination of PDAC growth via detection of
bioluminescence
The expression of luciferase reporter-constructs by R254 cells allows for spe-
cific identification of tumors in mice via detection of bioluminescence signals.
Furthermore, the utilization of luciferase expressing cells delivers a control for
successful tumor cell accretion since only vital cells express luciferase and are
therefore able to process and activate exogenously supplied luciferin-substrate.
Luciferase-activity was measured in a NightOWL LB 983 in vivo Imaging Sys-
tem. For this procedure, animals received an intraperitoneal injection of 10 µl/kg
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BW a D-Luciferin Firefly solution. After 15 min, mice were transferred into the
NightOWL LB 983 imaging device and a picture was taken to document the posi-
tion of the animal. Subsequently, the bioluminescence signal was measured with
a 550 nm excitation filter and a 605 nm emission filter with the exposure time set
to 3 seconds. Signals were measured in photons per second (ph/s) and quantified
using the proprietary WinLight 32-Software®. The examination and analysis of
in vivo bioluminscence imaging was supervised by Dr. Sanjay Tiwari (Molecu-
lar Imaging North Competence Center, Clinic of Radiology and Neuroradiology,
CAU and UKSH Campus Kiel, Kiel, Germany).
3.2.4. Tissue collection and storage
Following in vivo imaging, mice were euthanised and fixed on polystyrene-panels
in supine position. Abdomina were then opened along the linea alba and pan-
creata as well as livers were carefully removed. In the following, organs were
bisected.
One half of the organ was transferred into a 1.8 ml Nunc® CryoTube®, snap-
frozen in liquid nitrogen and stored at -80°C for PCR-based analysis. The other
half of the respective tissue specimen was fixed in 4.5% PBS-buffered formalin
before it was dehydrated and transferred into a paraffin-block for immunohisto-
logical analysis. The dehydration and paraffinization procedure was carried out
at the Institute of Pathology, UKSH Campus Kiel (Kiel, Germany).
3.2.5. Immunofluorescence
Besides an fLuc-gene cassette, the reporter-construct of R254 cells also contains
an enhanced green fluorescent protein (EGFP)-gene cassette allowing specific
detection of R254 cells in tissues via antibody based visualization of expressed
GFP-Tags. For this approach, FFPE liver tissue blocks were cut into serial sec-
tions of 3 µm, which until incubation in primary antibody solution underwent
preparation steps as described in Chapter 3.1.1. The incubation in primary
antibody solution was carried out overnight at 4°C in a humidified chamber. The
applied solution consisted of rabbit anti-GFP-Tag antibodies mixed with mouse
anti-mouse-Ki67 antibodies diluted in 100 µl 1% BSA/PBS solution with 0.3%
Triton X-100. Following this step, tissue sections were washed in PBS with 0.3%
Triton X-100 three times and incubated in 70% ethanol supplied with 0.1% Sudan
Black-B for 20 min. Sudan Black-B was used to diminish tissue autofluorescence
which is particularly pronounced in FFPE liver tissues. After three further wash-
ing steps in PBS +0.3% Triton X-100, tissue slides were incubated in 100 µl
1% BSA/PBS solution with 0.3% Triton X-100, supplied with Alexa Fluor 488
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goat anti-mouse IgG H+L and goat anti-rabbit IgG H+L DyLight 594 for pri-
mary antibody visualization. Hoechst 33258 was added to the solution in 1:500
dilution in order to stain nuclei. Sections were washed in PBS 3 times and sub-
sequently mounted in FluorSave Reagent. Visualization and evaluation of tissue
sections was performed using a Zeiss Axiovert 25 microscope equipped with an
Axiocam-503 color. For characterization of DTCs in the liver, ten view fields were
photographed at 200-fold magnification and the median number of GFP-positive
DTCs and their Ki67 status were determined. Liver micrometastases were defined
as clusters of more than 5 GFP-positive DTCs. For the detection and quantifi-
cation of DTCs and micrometastases in the liver, one entire liver section per
animal was screened. Detected DTCs and micrometastases were photographed
at 200-fold magnification.
3.2.6. RNA-isolation of whole-tissue specimens
For PCR-based analysis of liver tissues, the cryo-preserved half of the respective
extracted organ was used. The tissue specimen was removed from the cryotube
and transferred into a plastic dish. A piece of probe was cut out without allowing
thawing of tissue. The cut section was immediately transferred into a ceramic
mortar which was filled with liquid nitrogen and stored on ice. The tissue was
then disrupted and homogenized into fine powder by grinding with a pestle while
liquid nitrogen was allowed to vaporize completely. In the following, total RNA of
up to 40 mg of tissue homogenizate was isolated using the peqGOLD Total RNA
Kit according to manufacturer’s instructions. Then, isolated RNA was eluted in
40 µl of nuclease-free ddH2O and collected in a 1.5 ml reaction tube. Nucleic acid
concentration was measured using an Infinite 200 PRO spectrophotometer and
the RNA was stored at -80°C.
3.2.7. cDNA synthesis
Complementary DNA (cDNA) was generated from isolated RNA using the Rever-
tAid First Strand cDNA Synthesis Kit according to the manufacturer’s guidelines.
For this process, up to 500 ng of RNA were mixed with 1 µl of oligo(dT)18 primers
and filled up with nuclease-free ddH2O to a total volume of 12.5 µl. Following
mixing, the solution was incubated at 65°C for 5 min to assure optimal anneal-
ing of primers to the template RNA. After cooling on ice, samples were briefly
spinned down and the following components were added to the respective RNA
probe:
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Components per RNA sample
5.0 µl 5x SybR Reaction Buffer
0.5 µl Ribolock RNase Inhibitor (20 U/µl)
2.0 µl 10 mM dNTP Mix
1.0 µl M-MuLV Reverse Transcriptase (200 U/µl)
8.5 µl Total volume
After gentle mixing, probes were incubated at 42°C for 1 h. Finally, the reaction
was stopped by a 5 min incubation step at 70°C. Samples were diluted 1:4 and
kept at -20°C for long-term storage.
3.2.8. Quantitative realtime-polymerase chain reaction
(qRT-PCR)
For the implementation of qRT-PCR, 2.5 µl of synthesized cDNA were pipetted
into a white 96-well microtiter plate, which was stored on ice. Subsequently,
each probe was filled up to a total volume of 10 µl according to the reaction
mixture specified in the table below. The microtiter plate was then sealed with a
translucent foil and the plate centrifuged at 400 g for 2 min. The qRT-PCR was
carried out according to the program listed in the table below applying annealing
temperatures as listed in Chapter 2.8. A melting curve analysis was affiliated
for PCR quality control. All probes were pipetted and measured in duplicates
using a maximum cycle amount of 50 cycles in a Light Cycler 480 II. Template-
free ddH2O was measured as a negative control. The qRT-PCR evaluation was
performed using the proprietary Light Cycler 480 software (Version 1.5) and
Microsoft Excel. The relative gene expression was determined using the 2∆∆-
method and the mean of m β-Actin- and m GAPDH expression as normalization
reference.
Reaction mixture per probe
2.5 µl 1:4 diluted cDNA sample
5.0 µl Light Cycler Sybr Green
I Master
0.1 µM Forward primer
0.1 µM Reverse primer
0.5 µl nuclease free ddH2O
10 µl Total volume
QRT-PCR protocol
1 Denaturing 10 sec 95°C
2 Annealing 20 sec Cf. 2.8
3 Amplification 30 sec 72°C
4 -50 cycles 1-3
5 Final extension
6 Melting curve
7 Cooling
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3.3. Cell biological methods
3.3.1. Cell cultivation
All following cell culturing procedures were conducted under sterile conditions
in a laminar-flow cabinet. Autoclaved material was used and cells were regu-
larly examined with a MycoAlertTM PLUS Mycoplasma Detection Kit to assure
mycoplasma-free conditions.
Thawing cells
In order to take cells into culture after long term storage at -196 °C in liquid ni-
trogen, cryo vials containing the cells in suspension were removed from a nitrogen
tank and prewarmed in a water bath at 37 °C. The cells were then carefully re-
suspended in 5 ml prewarmed medium in a 50 ml centrifuge tube and centrifuged
for 5 min at 400 xg. Subsequently, the cell pellet was resuspended in 10 ml of
the respective cell culture medium (cf. Chapter 2.7.2) and transferred into a
75 cm2 cell culture flask and stored in an incubator at 37 °C, 86% humidity and
5% CO2. The next day, the cell culture medium was aspirated and exchanged for
fresh prewarmed medium. At this step, external factors for cell stimulation were
pipetted into the medium (cf. Chapter 2.7.2).
Cultivation
If not indicated otherwise, all cells were cultivated in 10 ml of their respected
culture medium (cf. Chapter 2.7.2) in 75 cm2 culture flasks at 37 °C, 86%
humidity and 5% CO2. Twice a week, or whenever cultured cells showed a con-
fluence of about 70% - 80%, passaging was performed. For this purpose, the
medium was carefully aspirated, substituted by 5 ml of prewarmed PBS and the
flask gently pivoted. The PBS was aspirated and 5 ml of prewarmed Accutase
were pipetted into the cell culture flask, following 20 min incubation at 37 °C, 86%
humidity and 5% CO2. The cell suspension was subsequently transferred into a
50 ml centrifugation tube containing 5 ml of prewarmed cell culture medium and
spinned down for 5 min at 400 xg. The medium was then aspirated and the
obtained cell pellet resuspended in 10 ml of cell culture medium. The suspension
was filled up with cell culture medium to a total amount of 30 ml, of which 10 ml
were transferred into fresh culture flasks, respectively. If provided, additional
factors for stimulation or maintenance of cell cultures (cf. Chapter 2.7.2) were
pipetted into the medium and the flasks were incubated as described above. To
avoid unintended activation of the M1-4HSC and HHSteC cells in culture, these
cells were treated with particular carefulness and a number of 10 passages was
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not exceeded. All other cell lines were cultured to a maximum passage number
of 15.
Freezing cells
In order to freeze cells for long-term storage, these were washed with PBS and
detached from 75 cm2 culture flasks as described above. After 5 min centrifugation
at 400 xg, the cell pellet was resuspended in prewarmed PBS and again spinned
down. Finally, the pellet was resuspended in 10% sterile DMSO dissolved in FCS
and transferred into a cryo vial. The latter one was then transferred into a cryo
box and stored at -80 °C. After two days, cryo vials were conveyed into liquid
nitrogen.
3.3.2. Determination of vital cell numbers
In order to seed defined amounts of cells and furthermore determine the vital cell
number after a completed experiment, a Neubauer counting chamber was utilized.
Following cell detachment as described above, a proportion of the respective cell
suspension was diluted 1:10 in trypan blue solution. In the following, 10 µl of the
solution were pipetted into the counting chamber. Only unstained cells were then
included into the counting and the number of vital cells per ml was determined,
applying the following formula:
cells
ml
=
vital cells ∗ 104
number of counted squares
3.3.3. Coculture
To examine the impact of the hepatic microenvironment on the proliferation be-
havior of PDEC at different stages of malignant progression, indirect coculture
systems were established and utilized. Representative of PDECs disseminating
and seeding the liver at an early, premalignant stage of PDAC development the
human PDEC line H6c7-kras [183] was used in this study. Dissemination from an
already established malignant tumor was modelled using the malignant PDAC
cell line Panc1 [185]. Different inflammatory conditions in the hepatic microenvi-
ronment were modelled using HSCs at different grades of activation and transdif-
ferentiation. Representative of a physiological liver microenvironment HSC in an
early activation stage, namely the murine cell line M1-4HSC [188], were utilized.
To model an inflamed hepatic microenvironment, activated and transdiffentiated
HMFs were applied in this study. The murine cell line M-HT [182], resulting of
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M1-4HSC cells after 3 weeks of permanent exposure to 1 ng/ml TGF-β1, was
thereby deployed. In order to reproduce key experiments in a human-human co-
culture system, human primary HSCs (HHSteC, cf. Chapter 2.7.1) at different
degrees of transdifferentiation were utilized.
Murine - human coculture system
For indirect cocultivation, hepatic stromal cells and PDECs were seeded sepa-
rately before both cell compartments were combined in order to start the cocul-
ture. Therefore, 2 ∗ 104 H6c7-kras or 1 ∗ 104 Panc1 cells, cultured and detached
as described (cf. Chapter 3.3.1), were seeded into the cavities of 6-well-plates
in 2 ml of their respective medium (cf. Chapter 2.7.2). In parallel, M1-4HSC
or M-HT cells were detached and resuspended in MI-medium free of exogenous
TGF-β1 and Pen/Strep. The cavities of 6-well-plates were filled with 2 ml of MI-
medium and corresponding transwell-inserts with 0.4 µ pores were placed therein.
Then, 5 ∗ 104 M1-4HSC or M-HT cells, suspended in 1.5 ml medium were seeded
into the transwell-inserts, respectively. After overnight incubation at 37 °C, 86%
humidity and 5% CO2, the medium of all wells was aspirated and substituted by
the particular coculture medium (cf. Chapter 2.7.2). Subsequently, the cocul-
ture was started by transferring the transwell-inserts into the corresponding wells
containing PDECs (Figure 3.3). The coculture conditions were maintained for
6 days at 37 °C, 86% humidity and 5% CO2.
Figure 3.3.: Settings for murine-human coculture systems. M1-4HSC (HSC), representative of a
physiological liver microenvironment, or M-HT (HMF), modelling an inflamed liver, were indirectly co-
cultured with premalignant H6c7-kras cells or malignant Panc1 cells for 6 days. HMF were generated by
long-term exposure of HSC to 1 ng/ml TGF-β1. H6c7-kras cells were used to model the dissemination of
PDECs at an early stage of PDAC pathogenesis while Panc1 cells were applied to model PDEC dissemina-
tion from an established PDAC primary tumor. Both compartments were connected by a membrane with
0.4 µm-pores which facilitates mutual influence by soluble factors.
Human - human coculture system
HHSteC are primary HSCs isolated from human liver tissue and expose an ad-
vanced degree of transdifferentiation. To generate a human cell system exhibit-
ing features corresponding to M1-4HSC and M-HT, respectively, human HHSteC
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were cultured as described above (cf. Chapter 3.3.2) and particular factors
were added into the medium upon cell passaging. A previous study reported
that all-trans-retinoic acid (ATRA) reprograms pancreatic stellate cells (PSCs)
to quiescence via retoinic acid receptor beta (RAR-γ)-mediated downregulation
of actomyosin [189]. Accordingly, HHSteC were cultured in 2.5 µM ATRA to
obtain cells with a phenotype corresponding to HSCs with a lower degree of tran-
differentiation. In line with the generation of M-HT cells from M1-4HSC cells
according to Proell et al. [182], HHSteC were weekly stimulated with 1 ng/ml
TGF-β1 in order to promote transdifferentiation. Due to the light sensitivity of
ATRA, all experiments were conducted under the exclusion of light.
HHSteC pretreated with ATRA or TGF-β1 were then cocultured with Panc1
and H6c7-kras cells, respectively, applying culture conditions and cell numbers
corresponding to the above mentioned murin-human coculture system. All co-
culture experiments were conducted with with HHSteC at passage 5-8 to assure
replicable conditions. The coculture setup is depicted in Figure 3.4.
Figure 3.4.: Settings for human-human coculture-systems. HHSteC-HSC were generated by treat-
ment of HHSteC with 2.5 µM all-trans-retinoic acid (ATRA) and used representative of a physiological liver
microenvironment. HHSteC-HMF were produced by permanently exposing HHSteC to 1 ng/ml TGF-β1,
modelling an inflamed liver. HHSteC-HSC and HHSteC-HMF were indirectly cocultured with premalignant
H6c7-kras cells or malignant Panc1 cells for 6 days. H6c7-kras cells were used to model the dissemination
of PDECs at an early stage of PDAC development while Panc1 cells were applied to model PDEC dissemi-
nation from an established PDAC primary tumor. Both compartments were connected by membranes with
0.4 µm-pores which facilitate mutual influence by soluble factors.
3.3.4. Immunocytochemical staining of Ki67
For immunocytochemical stainings of Ki67, H6c7-kras and Panc1 cells were co-
cultured as described in Chapter 3.3.3, while the cells were grown on glass
coverslips, placed on the bottom of the respective well. After completed culture,
transwells were discarded and the coverslips were transferred into the cavities of
12-well-plates, which were filled with 1 ml PBS. After 5 min incubation, coverslips
were kept in 1 ml of a 4.5% paraformaldehyde solution for 10 min at RT. After 3
washing steps for 5 min in PBS, the coverslips were transferred into 0.3% H2O2
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solved in methanol and incubated at -20 °C for 10 min to quench endogenous
peroxidases. After 3 further PBS-washing steps for 5 min, blocking was done
in 4% BSA/PBS for 60 min. Subsequently, 100 µl of mouse anti-human-Ki67
antibody, dissolved 1:250 in 1% BSA/PBS, were applied on the coverslips for 1
h at RT in a humid chamber. After 3 washing steps in PBS for 5 min, the cov-
erslips were incubated on a drop of EnVisionTM System HRP anti-mouse for 30
min at RT. Following 3 further 5 min washing steps in PBS, the immunostain-
ing was visualized with AEC Substrate for 10 min. In the following, coverslips
were repeatedly washed in PBS and a brief hematoxilin staining was affiliated.
Finally, the coverslips were blued under floating tap water for 5 min, dried and
subsequently sealed on microscope slides with Richard-Allan ScientificTM Mount-
ing Medium. Evaluation and quantification of Ki67-stainings were carried out
using an Evos XL Core Cell Imaging System. Therefore, 5 images per probe
were captured at 280-fold magnification and cells staining positive for Ki67 were
marked using Adobe Fireworks CS6. Stained and unstained cells were counted
and the percentage ratio of positively stained cells was calculated before the mean
percentage of Ki67-positive cells of 5 images was determined.
3.3.5. Immunocytofluorescence-staining of α-SMA and desmin
For immunofluorescence detection of α-SMA and desmin in HHSteC, these cells
were detached and grown in accordance with the procedure described in Chapter
3.3.1 and 3.3.3. The coverslips were incubated in 1 ml of PBS in the cavities
of 12-well-plates and fixed applying 1 ml of a 4.5% paraformaldehyde-solution.
Before coverslips were incubated in 1 ml methanol for 10 min at -20 °C, they
were washed 3 times with PBS. Blocking was performed incubating the cover-
slips in 1 ml of 4% BSA/PBS. The blocking solution and all following solutions
contained 0.3% Triton X-100 to induce and maintain the permeabilization of
cell membranes. For incubation of the coverslips in primary antibody solution,
anti-mouse-α-SMA antibody was diluted 1:100 in 1% PBS/BSA and anti-rabbit-
desmin antibody was added in 1:50 dilution. The staining specificity was validated
using isotype control antibodies in corresponding dilutions. The coverslips were
incubated in 100 µl of the prepared primary antibody solution in a humidified
chamber overnight at 4 °C. Following 3 washing steps in PBS for 5 min, the
secondary antibody solution was applied for 1 h at RT in a humidified cham-
ber. This solution consisted of Alexa Fluor 488 goat anti-mouse IgG H+L and
goat anti-rabbit IgG H+L DyLight 594 as well as Hoechst 33258 diluted 1:400,
respectively, in 1% BSA/PBS + 0.3% Triton. The coverslips were subsequently
washed 3 times for 5 min in PBS and mounted on microscope slides in FluorSave
Reagent. Stained cells were evaluated using a BZ-9000 II microscope using the
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proprietary BIOREVO software.
3.3.6. Staining of senescence-associated beta-galactosidase
(SABG)
In order to determine the activity of SABG and visualize the lysomal
compartment in H6c7-kras and Panc1 cells after coculture, the Senescence
β-Galactosidase Staining Kit (Cell Signaling) was utilized according to man-
ufacturer’s instructions. For this purpose, transwell-inserts were removed after
completed coculture and the culture medium was aspirated and replaced by PBS.
After 5 min incubation, cells were fixed for 15 min at RT in a formaldehyde-based
fixative solution. During 2 washing steps in PBS for 5 min, the staining solution,
supplied with the kit was prepared and set to pH 5.9 - 6.1. Fixed cells were in-
cubated in the staining solution overnight in a dry incubator at 37 °C. Cells were
then washed with PBS 3 times for 5 min and covered with 2 ml 70% glycerol
for long-term storage at 4 °C. An Evos XL Core Cell Imaging System (AMG)
was applied for evaluating the stainings. For the quantification of SABG-positive
cells, 5 view fields per probe were photographed at 280-fold magnification. Using
Adobe Fireworks CS6, a horizontal centerline was projected into the obtained
images. Stained and unstained cells along the line were counted and the per-
centage ratio of positively stained cells was calculated. The mean percentage of
SABG-positive cells was then determined from 5 examined images.
3.3.7. Extended coculture and realtime Life Cell Imaging
In order to examine changes in the proliferation behavior of M1-4HSC cocultured
H6c7-kras and Panc1 cells in presence of M1-4HSC or M-HT, the coculture was
prolonged for further 6 days. For this approach, the cell number of H6c7-kras
and Panc1 cells upon initial seeding was halved. Accordingly, 1 ∗ 104 H6c7-kras
cells or 0.5 ∗ 104 Panc1 cells were seeded into the cavities of 6-well-plates whereas
transwell-inserts containing M1-4HSC were prepared in line with the descriptions
in Chapter 3.3.3.
After 6 days of coculture, the transwell-inserts were removed and substituted
by fresh transwell-inserts comprising 5 ∗ 105 M1-4HSC or 5 ∗ 105 M-HT. Latter
ones were seeded and prepared one day before substitution as described in
Chapter 3.3.3. For the duration of coculture, the respective 6-well-plate
was placed in a JuLITM Br Live Cell Analyser and surveilled by using a 4x
objective and maximum digital zoom. PDECs showing a flattened, enlarged
morphology (cf. Chapter 4.3) were thereby particularly focussed. Images were
recorded all 10 min for a total duration of 144 h. After completed coculture,
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the surveillance was stopped and an AVI-Video was rendered and converted
into the mpeg4-format using VideoLAN-software 2.2.4. The initial resolution of
2560 ∗ 1920 pixels was thereby cropped to a resolution of 640 ∗ 480 pixels.
PDECs exhibiting a flattened, enlarged morphology were counted and the ratio
of proliferating versus non-proliferating cells in this population was determined.
Additionally, PDECs were characterized regarding their Ki67-status by im-
munocytochemical stainings performed and quantified after 6 days and 12 days
cocultures according to Chapter 3.3.4. The experimental setting is summarized
and schematically depicted in Figure 3.5.
Figure 3.5.: Experimental setting for an extended coculture system. 1 ∗ 104 H6c7-kras cells or
0.5 ∗ 104 Panc1 cells were cultured in the presence of 5 ∗ 104 M1-4HSC (HSC) for 6 days. Transwells
were substituted after 6 days for transwells with 5 ∗ 104 fresh M1-4HSC (HSC-HSC coculture) or M-HT
(HSC-HMF coculture). M1-4HSC and M-HT used in the second coculture period were prepared one day
prior to application. H6c7-kras and Panc1 cells were observed using a JuLITM Br Live Cell Analyser during
coculture with particular regard to cells exhibiting a flattened and enlarged morphology (cf. Chapter 4.3).
After completion of the first and the second coculture period, cells grown on coverslips were examined for
their Ki67-status via immunocytochemical staining as described in Chapter 3.3.4.
3.3.8. Quantification of soluble factors in cocultures
An indirect coculture system allows mutual influence of two cocultured cell en-
tities via soluble factors. In order to identify and quantify soluble factors se-
questered by PDECs and hepatic stromal cells, supernatants obtained from co-
cultures were examined via Multiplex analysis. Multiplex is a high-throughput
immunoassay combining the principles of enzyme-linked immunosorbent Assay
(ELISA) and flow cytometry, allowing the simultaneous quantification of a va-
riety of different protein and peptide targets from a small probe amount. The
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utilization of a murine-human coculture system thereby facilitates the identifica-
tion of the origin compartment of the particular factor via application of species
specific antibodies.
In this work, the Bio-Plex® Multiplex Immunoassay System was applied. It
makes use of polystyrol beads, which contain different combinations of two flu-
orochromes allowing the discrimination of 500 different bead groups by a green
laser in a flow cytometer. The beads are coated with monoclonal antibodies spe-
cific to a particular protein and peptide which bind the target of interest. After
recognition by biotinylated secondary antibodies, the generated complexes can
be visualized using a streptavidin-phycoerythrin solution which is detected in the
red laser channel of a flow cytometer. In brief, a flow cytometer can recognize the
analyte of interest in the green laser channel while the red laser channel allows
its quantification.
H6c7-kras and Panc1 cells were cultured in the presence of M1-4HSC or M-HT for
6 days as described in Chapter 3.3.3. After completed coculture, supernatants
were removed and transferred into centrifugation tubes in which they were cen-
trifuged for 5 min at 400 xg and stored at -80 °C until further analysis. The
respective blank medium was incubated in parallel and used as control. For the
detection and quantification of protein and peptide targets the Bio-Plex® Pro
Assay was utilized following the manufacturer’s guidelines. Six murine and 27 hu-
man targets were thereby analyzed. Fluorometric measurements were carried out
in a Bio-Plex® 200 reader using the corresponding Bio-Plex® manager software.
Measurements were carried out in the Department of Immunobiology, Research
Center Borstel (Borstel, Germany). Protein values of simultaneously cultured
medium controls were subtracted from protein values of coculture supernatants.
3.3.9. Blocking of soluble factors under coculture conditions
In order to examine the impact of factors analyzed and quantified via Multiplex
analysis on PDEC growth behavior, the signaling of particular factors of interest
was blocked or neutralized under coculture conditions. The blocking agent was
thereby pipetted into the medium of cocultures set up as described in Chapter
3.3.3. First, the respective blocking agent was prediluted in the corresponding
coculture medium and pipetted into the coculture upon gentle shaking of the
culture plate. The procedure was then iterated after 72 h. In case of SDF-1α-
blocking a final concentration of 1 mM blocking agent was applied. IL-8 signaling
was blocked using 2.5 µg/ml of respective antibody while agents for blocking
IL-6 and VEGF signaling were applied at final concentrations of 10 µg/ml. As
a control treatment, corresponding amounts of isotype control antibody were
applied under equal conditions. In case of VEGF neutralization approaches in
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extended cocultures (cf. Chapter 3.3.7), the administration of the blocking
agent was carried out upon start of the second coculture period and repeated
after 72 h while PDECs were observed in a JuLITM Br Live Cell Analyser (cf.
Chapter 3.3.7).
3.3.10. Stimulation with exogenous factors
To investigate the impact of factors identified and quantified in the Multiplex
analysis on PDEC growth behavior, Panc1 cells were stimulated with the respec-
tive protein under monoculture conditions. Therefore, 1 ∗ 104 Panc1 cells were
seeded as described in Chapter 3.3.3 and cultured for 1 week. One day after
seeding, cells were stimulated with the respective factor and again on day 4. Re-
combinant murine (m) IL-6, human (h) IL-6, h IL-8, h SDF-1α and h VEGF
were diluted in culture medium, respectively, and pipetted into the medium of
the cultured cells to reach a final concentration of 10 ng/ml. The corresponding
plates were gently pivoted upon stimulation and subsequently incubated at 37 °C,
86 % humidity and 5% CO2. As a control treatment, Panc1 cells were treated
with corresponding amounts of the respective protein solvent.
3.4. Biochemical methods
3.4.1. Isolation and purification of proteins
To obtain and purify protein lysates from cultured cells the NucleoSpin®
RNA/Protein extraction kit was utilized according to manufacturer’s instruc-
tions. The culture medium was aspirated from the the 6-well-cultivation vessel
and replaced by 2 ml of PBS. After 5 min incubation, the cells were detached
applying 1 ml Accutase for 20 min at 37 °C. The protease reaction was stopped
by transferring the obtained suspension into a 2 ml reaction tube containing 1 ml
PBS and subsequent vortexing. After 5 min centrifugation at 400 xg, the obtained
cell pellet was resuspended in 1 ml PBS and again spinned down 5 min at 400 xg.
The cell pellet was then lysed in 80 - 200 µl 2 x Laemmli buffer corresponding to
the amount of cells. The buffer was supplied with 1 mM sodium orthovanadate to
inhibit the activity of cell endogenous phosphatases. In the following, the lysate
was homogenized via 4 pulses of 1 sec in a sonicator. Completed lysates were
stored at -20 °C.
3.4.2. Determination of protein concentration
The concentration of proteins in a cell lysate was determined applying the DCTM
Protein Assay following the manufacturer’s instructions. The corresponding pho-
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tometric measurement was done using a translucent 96-well flat-bottom plate in
an Infinite® 200 PRO Microplate Reader after 15 min incubation. The total
amount of protein per probe was calculated based on a reference serial dilution
with known concentrations of bovine γ-globulin.
3.4.3. Sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE)
For the vertical separation of proteins in a cell lysate a SDS-PAGE was carried
out. For this procedure, protein lysates containing 5 µg - 15 µg protein in 20 µl -
40 µl volume were generated by dilution of cell lysates with 2 x Laemmli buffer.
The probes were then mixed 1:4 with loading dye and heated for 5 min at 95°C.
After cooling on ice, the samples were loaded onto a polyacrylamide gel prepared
of the compounds listed in the tables below. The protein separation ensued by
applying a voltage of 95 mV until the probes had reached the separation gel and
was then increased to 140 mV until completed segregation.
Separation gel (10 %)
2.5 ml ddH2O
1.5 ml Tris buffer (pH 6.8)
2 ml bis-acrylamide 40 %
22 µl APS 10 % (w/v)
4.4 µl TEMED
Stacking gel
750 µl ddH2O
312.5 µl Tris buffer (pH 6.8)
162.5 µl bis-acrylamide 40 %
6.75 µl APS 10 % (w/v)
1.25 µl TEMED
3.4.4. Protein transfer
After completed SDS-PAGE, the proteins were transferred onto a polyvinylidene
fluoride (PVDF) membrane utilizing the semidry blotting technique. The PVDF
membrane was activated by 1 min incubation in 100% methanol and subsequent
washing in ddH2O. The SDS-gel was placed on the membrane and stacked be-
tween Whatman papers soaked in buffer and arranged as depicted in Figure
3.6.
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Figure 3.6.: Protein transfer setup. The SDS-gel containing the protein lysate separated by protein
weight was transferred onto a PVDF-membrane via the semidry blotting procedure. Therefore, the gel was
placed on the membrane and stacked between whatman papers soaked in either buffer A, buffer B or buffer
C.
After setting up the blotting stack, the transfer was carried out in a blotting
chamber by applying an electric current of 1.25 mA/cm2 for 60 min.
3.4.5. Immunodetection of proteins
After disassembling the blotting chamber, the immunodetection of the proteins
of interest was performed. The PVDF membrane was therefore washed in ddH2O
and incubated in Blotto for 2 h at RT or overnight at 4 °C under gentle pivoting.
Next, specific antibodies diluted according to Chapter 2.9.1 were applied by
incubating the membrane overnight at 4°C in a 50 ml centrifugation tube on a
roll mixer. The next day, membranes were washed 3 times 10 min in TBS-T be-
fore the secondary antibody, prepared according to Chapter 2.9.1, was applied
for 1 h at RT. After 3 further 10 min washing steps in TBS-T, horseradish-
peroxidase (HRP) conjugated secondary antibodies were visualized by 5 min in-
cubation in Clarity ECL substrate at RT. The resulting chemiluminescence signal
was recorded via exposure in a Fusion SL detection system using the Fusion Capt
Software 16.06.
3.4.6. Densitometric quantification of western blot signals
Signals measured in western blot analysis can be measured via semi-quantitative
densitometry allowing conclusions on the amount of a particular protein in a
lysate. The ratio of phosphorylated-ERK (p-ERK) to phosphorylized p38 (p-p38)
was determined using the ImageJ 1.47v software which interprets measured grey
scale signals of protein bands as signal peaks. The area under the curve (AUC)
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of the peaks was calculated. Heat shock protein 90 (HSP90) was detected as a
loading control and the p-ERK or p-p38 signal values divided by the correspond-
ing HSP90 signal value. The normalized p-ERK value was then divided by the
p-p38 value to determine the p-ERK/p-p38 ratio.
3.5. Statistical analysis
For statistical analysis the SigmaPlot Software 12.5 was used. The Shapiro-Wilk
test was applied to test for normal distribution. Parametric data were analyzed by
t-test or one-way repeated measures analysis of variance (one-way RM ANOVA)
and are presented as mean ± standard deviation (SD). Non-parametric data were
analyzed by Kruskal-Wallis one-way ANOVA on ranks test and are represented
as medians with 25% and 75% quartiles in box-whisker plots. The statistical
significance was determined applying the Student-Newman-Keuls test. P-values
≤ 0.05 were regarded as statistically significant and are indicated with an asterisk
(*).
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4. Results
4.1. Proliferative activity of PDAC cells in liver
metastases correlates with the presence of
HSCs or HMFs
It is to date poorly established whether the condition of the hepatic microen-
vironment influences the proliferation and outgrowth of PDAC metastases. To
address the question how the hepatic microenvironment may impact on the out-
growth of metastatic lesions, the well established KPC mouse model was uti-
lized. KPC mice carry pancreas duct specific mutations in the KRAS and TP53
genes which together potently induce PDAC formation and metastatic progres-
sion [176]. FFPE liver tissues of KPC mice were immunohistologically processed
and metastases evaluated considering their proliferation with particular regard
to metastasis size. Staining for cytokeratin-19 (CK-19) was performed to detect
micrometastases (lesion diameter ≤ 200 µm) and macrometastases (lesion diam-
eter > 200 µm) originating from the pancreas duct, while Ki67 was stained in
order to determine their corresponding proliferation status. The condition of the
surrounding tumor stroma was characterized via desmin staining to detect HSCs
and α-SMA staining to visualize HMFs.
Merging of the obtained immunstainings show the occurrence of micrometastases
with a low proliferative activity of PDAC cells (Median score 2 =̂ 10% - 50% Ki67-
positive cells) predominantly in areas with a low ratio of HMF to HSC (Median
α-SMA/Desmin ratio score = 1) (Figure 4.1 A & B, Supplementary Figure
A.1). Concurrently, macrometastases containing a significantly higher amount
of proliferative CK-19-positive cells (Median score 3 =̂ 50% - 100% Ki67-positive
cells; p = 0.016) were mostly detected in liver areas with a high presence of HMF
(Median α-SMA/Desmin ratio score = 3)(Figure 4.1 A & B, Supplementary
Figure A.2). Taken together these results indicate the correlation of stroma
activation and the proliferative activity of PDAC liver metastases. Moreover, the
high abundance of HMFs in the stroma of macrometastases indicate a correlation
of inflammatory processes and metastatic outgrowth.
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Figure 4.1.: Proliferative activity of PDAC cells in liver metastases correlates with the pres-
ence of hepatic stellate cells (HSC) or hepatic myofibroblasts (HMF). Liver sections of mice
harboring advanced PDAC (n=13) were examined for the presence of micrometastases (lesion diameter
≤ 200 µm) and macrometastases (lesion diameter > 200 µm) by staining of cytokeratin-19 (CK-19; to
visualize PDAC cells), Ki67 (to detect proliferating cells), α-SMA (for detection of HMF) and desmin (for
detection of HSC). A) Representative images show the overlay of CK-19, Ki67, desmin and α-SMA stain-
ings obtained by costainings of serial sections. B) Scoring of Ki67 and determination of the α-SMA/desmin
score in micro- and macrometastases. Data represent median values with quartiles (Q0,75 as upper, Q0.25
as lower deviation) of 7 micro- and 9 macrometastases. * = p <0.05.
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4.2. Aged livers exhibit enhanced inflammation and
outgrowth of PDAC metastases
The correlation of the desmoplastic reaction and metastatic growth pointed out
in 4.1 raised the question if PDAC cells were attracted by the activated, HMFs-
rich stroma or if the tumor cells themselves induced the observed inflammation.
Hence, an in vivo model exhibiting different hepatic conditions regarding the
inflammation status was utilized to elucidate whether a persisting liver inflam-
mation fosters the outgrowth of PDAC cells to metastasis.
Aging represents one of the few ensured risc factors for PDAC development.
Accordingly, the median age of patients upon PDAC diagnosis is 71 years [2].
Aging wash shown to promote inflammatory processes in the liver which in turn
cause remodelling of the hepatic microenvironment, including HSC activation
[103, 177, 190, 191]. Thus, aging was chosen as a clinically relevant inflammation-
causing trigger to study the impact of liver inflammation on PDAC metastases
formation.
For this purpose, wild type-C57BL/6 mice of different age were injected ortho-
topically with 3 ∗ 104 KPC mouse derived R254 PDAC cells and surveilled for
2 and 4 weeks, respectively [184]. Upon inoculation, mice were either 8 weeks
or 52 weeks of age, the latter being equivalent to 65 human years and therefore
approximately corresponding to the median age of PDAC patients at the time of
diagnosis. Before sacrifice, in vivo imaging was performed to measure primary
and secondary tumor growth before pancreata and livers were extracted and an-
alyzed via immunhistological and PCR-based methods.
Two weeks after tumor cell injection both groups showed a similar extend of pri-
mary tumor growth in the pancreas. While 8 weeks old mice exposed a median
tumor volume of 7.2 mm3, 52 weeks old mice exhibited pancreatic tumors with
a similarly low median volume of 6.0 mm3 as determined via ultrasound imaging
(Figure 4.2 A, B & C). The ultrasound analysis did not show the occurrence
of tumorous lesions in the liver. Subsequently, sonographic measurements were
validated via bioluminescence quantification in a NightOwl imaging system. The
whole-animal bioluminescence in vivo analysis yielded comparable results show-
ing similarly small tumors in young and old mice (83.6 av. ph/s in young mice
versus 106.1 av. ph/s in aged mice)(Figure 4.3 A). Again, no animal showed
a distinct bioluminescence signal in the hepatic region (Figure 4.3 B). In con-
trol animals which either received abdominal surgery or were left untreated no
tumorous tissue was detectable via both imaging modalities (data not shown).
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Figure 4.2.: Sonographic tumor detection in young and aged mice 2 weeks post-injection. Two
weeks after injection of R254 cells, mice were examined considering primary tumor growth via ultrasound
imaging with a resolution of 30 µm (A). Data represent the median values with quartiles (Q0,75 as upper,
Q0.25 as lower deviation) of 20 animals/group. Representative ultrasound images of PDAC tissue (outlined
in red) within the pancreas (B) and corresponding 3-dimensional recapitulation of the tumor (C) are
depicted. wks = weeks
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Figure 4.3.: Tumor detection in young and aged mice 2 weeks post-injection via biolumi-
nescence measurement. Two weeks after injection of R254 cells, 8 weeks and 52 weeks old mice were
examined for tumor growth via bioluminescence imaging (A). Animals were placed in a NightOwl in vivo
imaging system and bioluminescence signals were measured for 300s. Data represent the median values
with quartiles (Q0,75 as upper, Q0.25 as lower deviation) of 20 animals/group. Representative images of
two mice, respectively, show bioluminescence signals within the abdomen (B) representing tumorous tissue.
wks = weeks; cps = counts per second.
Since metastatic lesions were neither detected by ultrasound nor bioluminescence
imaging, immunofluorescence stainings of GFP were performed in liver sections
of 8 weeks old mice and 52 weeks old mice. Whereas livers of young and
old mice did not expose GFP positive metastatic lesions, single disseminated
PDAC cells were detectable in liver tissues of both groups. In line with the
observed minor primary tumor growth, both groups exhibited similarly low
numbers of GFP positive DTCs in the liver (0.4 DTCs per view field in young
mice versus 0.5 DTCs per view field in aged mice)(Figure 4.4 A & B).
Interestingly, DTCs detected in livers of aged mice showed a significantly higher
percentage of Ki67-positive DTCs. Livers of 52 weeks old mice exposed 62.1 %
Ki67-positive DTCs whereas in livers of 8 weeks old mice only 23.2 % of DTCs
were Ki67-positive (p = 0.001)(Figure 4.4 C & D).
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Figure 4.4.: Immunofluorescence detection of PDAC cells in young and aged mice 2 weeks
post-injection. Following in vivo imaging, animals were sacrificed and pancreata as well as livers were
resected and analyzed via immunofluorescence staining of GFP (to detect GFP-positive R254 cells) and
Ki67 (to detect proliferating cells). Whole liver sections were photographed at 200-fold magnification and
the median number of DTCs per view field in whole liver sections was determined (A) as well as their
corresponding Ki67 status (C). Data represent the median values with quartiles (Q0,75 as upper, Q0.25 as
lower deviation) or mean ± SD of 10 animals/group. * = p <0.05. Representative images of GFP positive
DTCs in livers of 8 weeks and 52 weeks are depicted in (B) at 200-fold magnification. In (D) GFP-positive
DTCs in livers of 8 weeks and 52 weeks after Ki-67 staining are shown at 400-fold magnification. DTCs
are encircled in white, respectively.
Next, liver tissues of 8 weeks and 52 weeks old mice obtained two weeks after
injection of R254 PDAC cells were characterized with respect to their inflamma-
tory status. Due to the low abundance of DTCs in livers of young and old mice, it
was assumed that these had a negligible impact on the hepatic microenvironment
at this time point and that potential inflammatory alterations can be considered
as aging-related. For the characterization of liver tissues, total-RNA of mouse
livers was isolated and transcribed into cDNA before qRT-PCR-analysis was
performed to quantify the expression of HSC and HMF-related genes as well as
inflammation-related genes.
The qRT-PCR based analysis revealed a slightly elevated aSMA/desmin ratio of
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17.7 % in livers of 52 weeks old mice (1,655) compared to livers of 8 weeks old
animals (1,406)(Figure 4.5 A). However, livers of young and old mice exposed
similar expression levels of collagen-1A1 (col-1A1; 0,0227 in 8 weeks old mice
versus 0,0205 in 52 weeks old mice)(Figure 4.5 B).
Figure 4.5.: qRT-PCR based characterization of HSC and HMF-related genes 2 weeks post-
injection. Two weeks after injection of R254 cells, 8 weeks and 52 weeks old mice underwent hepatectomy
and snap-frozen liver tissue specimens were subjected to gene expression analysis via qRT-PCR. The ratio
of the relative gene expression of α-SMA and desmin was calculated (A) and the relative gene expression of
collagen-1 (Col1A1) was determined (B). GAPDH and β-actin were used as housekeeping-controls. Data
represent the median values with quartiles (Q0,75 as upper, Q0.25 as lower deviation) of 10 animals/group.
Furthermore, the gene expression of a variety of cytokines, involved in activation
of HSCs as well as inflammation was examined. Whereas no differences in
relative gene expression were detected for the pro-inflammatory cytokines
interleukin-6 (IL-6; 0.965e4 in 8 weeks old mice versus 0.717e4 in 52 weeks old
mice)(Figure 4.6 A) as well as tumor necrosis factor-α (TNF-α; 0.00236 versus
0.00258)(Figure 4.6 B), livers of 52 weeks old mice exhibited higher mRNA
levels of fibroblast growth factor-2 (FGF-2; 2.18e4 versus 3.53e4)(Figure 4.6 C),
IL-1β (0.0532 versus 0.0926)(Figure 4.6 D) and keratinocyte chemoattractant
(KC; 0.00623 versus 0.0178)(Figure 4.6 E) than livers of 8 weeks old mice.
Furthermore, higher mRNA levels of TGF-β1 were detected in livers of 52 weeks
old mice (0.104 in livers of 8 weeks old mice versus 0.128 in livers of 52 weeks old
mice)(Figure 4.6 F). Of note, livers of aged mice showed a significant, 1.7-fold
increase in the relative gene expression of VEGF-A compared to livers of young
mice (0.0374 versus 0.0211; p = 0.009)(Figure 4.6 G). By way contrast, a higher
relative gene expression of macrophage inflammatory protein-2 (MIP-2)(0.0275
in 8 weeks old mice versus 0.00450 in 52 weeks old mice)(Figure 4.6 H) and
lipopolysaccharide-induced CXC chemokine (LIX)(0.103 versus 0.00545)(Figure
4.6 I), two murine functional homologues to human IL-8, was observed in livers
of young mice.
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Figure 4.6.: qRT-PCR based determination of inflammatory cytokines in liver tissues 2 weeks
post-injection. Two weeks after injection of R254 cells, 8 weeks and 52 weeks old mice underwent
hepatectomy and snap-frozen tissues were subjected to gene expression analysis via qRT-PCR. The relative
gene expression of the proinflammatory cytokines IL-6 (A), TNF-α (B), FGF2 (C), IL-1β (D) and KC (E)
was detected. Furthermore, relative gene expression levels of TGF-β (F), VEGF-A (G) MIP-2 (H) as well
as LIX (I) were measured. GAPDH and β-actin were used as housekeeping-controls. Data represent the
median values with quartiles (Q0,75 as upper, Q0.25 as lower deviation) of 10 animals/group. * = p <0.05.
Overall these data show a differential expression pattern of inflammatory cy-
tokines in livers of young and aged mice. Importantly, most of the genes which
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were upregulated in aged livers are known to be involved in the transdifferenti-
ation of HSCs into HMFs, namely IL-1β [192, 193], FGF2 [194], TGF-β1 [195]
and VEGF [196].
To follow the metastatic progression of PDAC in an age-related context for a
longer period, corresponding parameters regarding primary and secondary tumor
growth were examined in young and old mice four weeks after inoculation of
R254 cells.
Animals sacrificed 4 weeks after tumor cell inoculation showed detectable,
but not significant differences in primary tumor growth. Ultrasound imaging
showed a median tumor size of 35,8 mm3 in 8 weeks old mice while 52 weeks
old mice exhibited a median tumor size of 86,5 mm3 (Figure 4.7 A, B & C).
Subsequent bioluminescence signal quantification showed corresponding results
and a visible but not significant increase of primary tumor growth in aged mice
compared to young mice (295,455 ph/s in 52 weeks old mice versus 173,880
ph/s in 8 weeks old mice)(Figure 4.8 A & B). By way of contrast, mice 8
weeks and 52 weeks of age presented distinct differences concerning metastatic
outgrowth. Aged livers exhibited a significantly higher median number of
DTCs per view field compared to livers of young mice (4 DTCs per view field
in livers of 52 weeks old mice versus 2.1 DTCs per view field in livers of 8
weeks old mice; p < 0.001)(Figure 4.9 A). The proliferation rate of detected
DTCs in livers of both groups was comparable (54% Ki67-positive cells in 8
weeks old mice versus 52% Ki67-positve cells in 52 weeks old mice)(Figure 4.9
B). However, micrometastases defined as clusters of more than 5 DTCs were
exclusively found in livers of aged mice (0 micrometastasis per liver in young
mice versus 3 micrometastasis per liver in aged mice; p = 0.001) (Figure 4.9 C).
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Figure 4.7.: Sonographic tumor detection in young and aged mice 4 weeks post-injection. Four
weeks after injection of R254 cells, mice were examined for primary tumor growth via ultrasound imaging
with a resolution of 30 µm (A). Data represent the median values with quartiles (Q0,75 as upper, Q0.25
as lower deviation) of 10 animals/group. Representative ultrasound images of tumorous tissue (outlined in
red) within the pancreas (B) and corresponding 3-dimensional recapitulation of the tumor (C) are depicted.
wks = weeks
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Figure 4.8.: Tumor detection in young and aged mice 4 weeks post-injection via biolumi-
nescence measurement. Four weeks after injection of R254 cells, 8 weeks and 52 weeks old mice were
examined for tumor growth via bioluminescence imaging (A). Animals were placed in a NightOwl in vivo
imaging system and bioluminescence signals were measured for 300s. Data represent the median values
with quartiles (Q0,75 as upper, Q0.25 as lower deviation) of 10 animals/group. Representative images of
two mice, respectively, show bioluminescence signals within the abdomen (B) representing tumorous tissue.
wks = weeks; cps = counts per second.
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Figure 4.9.: Immunofluorescence detection of PDAC cells in young and aged mice 4 weeks
post-injection. Following in vivo imaging, animals were sacrificed and pancreata as well as livers were
resected and analyzed via immunofluorescence staining of GFP (to detect GFP-positive R254 cells) and
Ki67 (to detect proliferating cells). Whole liver sections were photographed at 400-fold magnification
and the median number of DTCs per view field in whole liver sections was determined (A) as well as
their corresponding Ki67 status (B). C) shows the quantification of micrometastases, defined as clusters
of 5 or more GFP-positive R254 cells as well as representative images of GFP-positive R254 cells and
micrometastases (encircled in white) at 200-fold magnification. Data represent median values with quartiles
(Q0,75 as upper, Q0.25 as lower deviation) or mean ± SD of 10 animals/group. * = p <0.05.
Taken together, the results shown in this chapter demonstrate a marked impact
of aging-related inflammation on the metastatic progression of PDAC. Whereas
young and aged mice exposed visible but not significant differences in primary
PDAC growth, distinct effects could be observed in the hepatic microenvironment
and with respect to micrometastases. Two weeks after orthotopical injection of
R254 cells, a higher state of inflammation and level of HMFs-related genes were
detected in livers of 52 weeks old mice concomitantly with a higher number of
Ki67-positive DTCs compared to 8 weeks old mice. Accordingly, significantly
higher amounts of GFP-positive DTCs and micrometastases were detected in
livers of 52 weeks old mice four weeks after PDAC cell inoculation.
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4.3. The presence of HSC promotes the enrichment
of PDECs with a quiescence-associated
phenotype (QAP)
To further unravel the mechanisms by which HSCs and their transdifferentiated
inflammatory counterpart HMFs impact on growth behavior of disseminated
PDECs in different steps of malignant progression, an indirect coculture system
was applied. In this setting, premalignant H6c7-kras or malignant Panc1 PDECs
were cultivated in the presence of either M1-4HSC cells (HSC) or M-HT cells
(HMF) for 6 days. HSC (Figure 4.10 A & C) were transdifferentiated to
HMF (Figure 4.10 B & C) via administration of exogenous TGF-β1 which
allowed the examination of HSC at different grades of activation with the
same genetic background [182]. HSC were utilized to model a physiologic liver
microenvironment while HMF were used representative for an inflamed hepatic
microenvironment.
Figure 4.10.: The hepatic stromal cell lines M1-4HSC and M-HT. A) M1-4HSC (HSC) grown
on plastic expose a characteristic stellate cell morphology. B) After 3 weeks of continuous administration
of recombinant TGF-β1, M1-4HSC (HSC) acquired a spindle-shaped morphology which is a hallmark of
myofibroblasts, the generated cell line is termed M-HT (HMF)[182]. Depicted are representative phase
contrast images of both cell lines in monoculture. In (C) representative western blots of HSC and HMF
lysates are depicted which show a lower ratio of desmin to α-smooth muscle actin (α-SMA) in HMF in
accordance with the initial description of the cell system [182]. Heat shock protein-90 (HSP90) was used
as loading control.
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The coculture of H6c7-kras and Panc1 cells with HSC and HMF, respectively,
exposed a differential impact of HSC and HMF on growth of PDECs. Both,
H6c7-kras and Panc1 cells exhibited markedly decreased vital cell numbers
after 6d coculture with HSC compared to HMF coculture (9.65*104 versus
15.18*104 for H6c7-kras; p < 0.05 and 15.75*104 versus 28.37*104 for Panc1
cells; p = 0.01)(Figure 4.11 A)*.
Figure 4.11.: PDECs exhibit a reduced proliferative activity in the presence of HSC compared
to HMF coculture. H6c7-kras and Panc1 cells were cocultured with HSC or HMF. After 6 days, vital
cell numbers (A) and percentage of Ki67-positive cells (B) were determined. Depicted data represent the
mean values ± SD of at least 5 independent experiments. * = p <0.05. C) shows representative images of
Ki67 immunostainings in H6c7-kras and Panc1 cells after respective coculture in 200-fold magnification.
In line with their vital cell count, HSC cocultured H6c7-kras and Panc1 cells
showed a significantly lower amount of Ki67-positive cells than HMF cocultured
*Vital cell counts for H6c7-kras and Panc1 cocultures with HSC or HMF were previously
shown in the own Master’s thesis [180] and the Master’s thesis of Maren Pein [181] and validated
in independent experiments.
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PDECs (15.9% versus 42.9% Ki67-positive cells for H6c7-kras; p < 0.001 and
19.2% versus 49.8% Ki67-positive cells for Panc1; p = 0.001)(Figure 4.11 B &
C). This indicates that the observed differences in PDEC vital cell count were a
result of stroma-mediated alterations in PDEC proliferation behavior.
The monitoring of both PDEC lines after Ki67 immunostainings at 400-fold
magnification revealed that predominantly HSC coculture conditions led to the
emergence of a high number of Ki67-negative PDECs with a flattened, enlarged
cytoplasm and nucleus (Figure 4.12 A).
Figure 4.12.: HSC coculture fosters the manifestation of a QAP in PDECs. H6c7-kras and
Panc1 cells were cocultured with HSC or HMF for 6 days, respectively. A) Representative images of Ki67
stainings in H6c7-kras and Panc1 cells after HSC coculture conditions shown at 400-fold magnification
(encircled: PDECs exhibiting flattened enlarged morphology). B) Representative western blots showing
the abundance of total and phosphorylated Erk (Erk/p-Erk) and p38 (p38/p-p38) as well as p21. Hsp90
was used as loading control. Data of densitometric analysis of the ratio of p-Erk and p-p38 expression are
presented as mean ± SD of 4 independent experiments. Data represent the median values with quartiles
(Q0,75 as upper, Q0.25 as lower deviation) of 5 independent experiments. * = p <0.05.
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Since these observed morphologic features were previously described to be asso-
ciated with either cellular quiescence, cellular dormancy and cellular senescence
[125, 136, 197], a deepened characterization of proliferation-associated features
of PDECs under the influence of HSC or HMF was conducted. Western blot
analysis of PDEC lysates obtained after coculture showed a lower ratio of p-ERK
to p-p38 after HSC coculture compared to HMF coculture which was weakly
pronounced in H6c7-kras cells (1.1 after HSC coculture versus 1.3 after HMF
coculture) and significantly pronounced in Panc1 cells (5.4 after HSC coculture
versus 15.5 after HMF coculture)(Figure 4.12 B). Accordingly, protein levels of
the cell cycle inhibitor p21 were found to be weakly higher in HSC cocultivated
H6c7-kras cells and markedly elevated in Panc1 cells compared to HMF cocul-
tured PDECs (Figure 4.12 B). Moreover HSC and HMF cocultured H6c7-kras
and Panc1 cells were analyzed with regard to the activity of the senescence
marker SABG. Both PDEC lines exhibited distinctly and significantly higher
SABG-activity after HSC coculture compared to HMF cocultured H6c7-kras and
Panc1 cells (69.2% versus 30.2% SABG-positive H6c7-kras cells; p < 0.05 and
45.3% versus 12.3% SABG-positive Panc1 cells; p = 0.013)(Figure 4.13 A & B).
Figure 4.13.: PDECs exhibit enhanced senescence-associated β-galactosidase (SABG) acivity
in the presence of HSC compared to HMF coculture. H6c7-kras and Panc1 cells were cocultured
with HSC or HMF. After 6 days, SABG activity was measured (A). Depicted data represent the mean
values ± SD of at least 5 independent experiments. * = p <0.05. B) shows representative images of SABG
stainings in H6c7-kras and Panc1 cells after respective coculture in 200-fold magnification.
Overall, these results show a significant impact of HSC and HMF on the pro-
liferation features of premalignant and malignant PDECs. Compared to HMF
coculture conditions, the presence of HSC led to a marked proliferation reduction
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in H6c7-kras and Panc1 cells. This manifested by the emergence of features which
are associated with quiescence, dormancy and senescence like Ki67 negativity, a
flattened and enlarged morphology, a low p-ERK/p-p38 ratio and an increase
in p21 and SABG-activity. This manifestation of growth arrest in PDECs is
hereafter referred to as quiescence-associated phenotype (QAP).
4.4. Human HSCs foster QAP emergence in
PDECs similar to murine HSC
A variety of chemokines and cytokines show a species-specific efficacy and
may hence not cross-react in a mouse-human coculture system. Therefore, a
human-human coculture system was established to validate key findings from
mouse-human coculture systems.
This approach aimed at coculturing H6c7-kras and Panc1 cells with human
hepatic stromal cells equivalent to HSC and HMF. After a first comparative
analysis of different available human HSCs with particular regard to their acti-
vation status and transdifferentiability, commercially obtainable HHSteC cells
were selected for further experiments. Since HHSteC cells appeared to exhibit
an advanced state of transdifferentiation, characterized by a spindle shaped
morphology, weak expression of collagen-1A1, α-SMA and desmin, pretreatments
with different factors were carried out to obtain characteristics corresponding to
HSC and HMF. To generate HHSteCs with an HSC like phenotype (HHSteC-
HSC), cells were cultured in medium containing 2.5 µl all-trans-retinoic acid
(ATRA) while an HMF-like phenotype (HHSteC-HMF) was generated applying
medium with 1 ng/ml TGF-β1 for two weeks, respectively. Afterwards, cells
were characterized via immunofluorescence stainings and western blot analysis.
Immunofluorescence stainings revealed a distinctly lower ratio of α-SMA to
desmin in HHSteC-HSC compared to HHSteC-HMF (Figure 4.14 A). Direct
comparison of untreated HHSteC cells with HHSteC-HSC and HHSteC-HMF
showed highest levels of collagen-1A1 and α-SMA in HHSteC-HMF while the
highest level of desmin was found in HHSteC-HSC (Figure 4.14 B). Overall
these results indicate the successful generation of human HSCs with phenotypes
corresponding to murine HSC and HMF.
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Figure 4.14.: Generation of HSC and HMF like phenotypes in HHSteC. In order to generate
human hepatic stromal cells with characteristics equivalent to HSC and HMF, HHSteC were pretreated
with medium containing either 2.5 µl all-trans-retinoic acid (ATRA) and 1 ng/ml TGF-β1 for 2 weeks,
respectively. Cells were characterized via immunofluorescence stainings of α-SMA and desmin (A) and
detection of collagen-1A1, α-SMA and desmin via western blot (B) HSP90 was used as loading control.
Representative results of 4 respective independent experiments are shown, immunofluorescence stainings
are depicted in 400-fold magnification.
In line with the preceding chapter, HHSteC-HSC and HHSteC-HMF were set in
coculture with H6c7-kras and Panc1 cells for 6 days, respectively. HHSteC-HSC
coculture resulted in a lower vital cell number of H6c7-kras and Panc1 cells
than the corresponding HHSteC-HMF coculture (1.96-fold increase in vital
cells in H6c7-kras and 1.48-fold increase in Panc1 cells)(Figure 4.15 A).
Accordingly, a significantly lower percentage of Ki67-positive PDECs was found
after HHSteC-HSC coculture conditions (31,8% versus 51,0% Ki67-positive cells
in H6c7-kras (p=0.004) and 33.2% versus 62.5% Ki67-positive cells in Panc1
(p=0.016))(Figure 4.15 B). Furthermore, H6c7-kras cells and Panc1 cells co-
cultured with HHSteC-HSC showed a markedly higher number of SABG-positive
cells than HHSteC-HMF cocultured PDECs (48.6% versus 40.2% SABG-positive
H6c7-kras cells (p=0.039) and 35.6% versus 16.2% SABG-positive Panc1
cells)(Figure 4.15 C). Taken together, these results show differential effects
of human HSCs and HMFs on proliferation thereby validating key findings
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obtained in the HSC/HMF coculture system. Moreover, an induction of QAP in
H6c7-kras and Panc1 cells by human HSCs, similar to the QAP promoting effect
of HSC could be observed.
Figure 4.15.: HHSteC-HSC induce QAP in H6c7-kras and Panc1 cells. HHSteC were pretreated
with medium containing either 2.5 µl all-trans-retinoic acid (ATRA) or 1 ng/ml TGF-β1 and set in coculture
with either H6c7-kras or Panc1 cells for 6 days. Vital cell numbers were determined (A) as well as the
percentage of Ki67-positive cells after immunostainings (B). Moreover, H6c7-kras and Panc1 cells were
examined for their SABG-activity (C). Data represent the mean values ± SD of 4 independent experiments.
* = p <0.05.
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4.5. The presence of HMF reverts QAP in PDECs
Recent studies suggest that during early carcinogenesis PDECs may disseminate
and seed the liver, even before a primary tumor is fully established [88, 89, 117]. It
is, however, assumed that the accumulation of several genetic alterations or envi-
ronmental stimuli is mandatory for successful metastatic outgrowth [89, 117, 119].
Thus, the prevalent condition in the microenvironment DTCs are facing may
represent a crucial factor for their fate and determine if they either persist in a
resting, non-proliferative state or alternatively start to divide and form metasta-
sis [71]. In the preceding chapters it was emphasized that HSC potently induced
a state of growth arrest in premalignant and malignant PDECs. On the oppo-
site, the presence of HMF led to a marked acceleration of PDEC proliferation.
To elucidate if HMF, modelling an inflamed hepatic stroma, may revert HSC-
driven QAP induction and reactivate proliferation in growth arrested PDECs, an
extended coculture system was established.
In this setting, QAP was induced in H6c7-kras and Panc1 cells by 6 days of HSC
coculture, before HSC were substituted for either newly seeded HSC (HSC-HSC
coculture) or HMF (HSC-HMF coculture) and cocultured in their presence for
further 6 days. During coculture, H6c7-kras and Panc1 cells showing a flattened,
enlarged morphology of QAP were particularly surveilled via realtime Life Cell
Imaging. Since HSC- and HMF-mediated effects were more pronounced in Panc1
cells, experiments were first conducted with this cell line.
After extended HSC coculture, the vast majority of Panc1 cells exhibiting a
QAP morphology showed no signs of cytokinesis, indicating that the permanent
presence of HSC fostered not only the induction, but also the maintenance
of QAP in Panc1 cells (Figure 4.16 A). In the rare case of Panc1 cells
reacquiring proliferative capacity in the presence of HSC, these cell divisions
occurred notably slower or were directly followed by cell death (Figure 4.16 A,
Supplementary Video 1(HSC-HSC)).
By way of contrast, the presence of HMF led to a high number of proliferating
Panc1 cells despite persisting QAP morphology (Figure 4.16 A, Supplemen-
tary Video 2 (HSC-HMF)). While only 19 % of Panc1 cells with a QAP
morphology proliferated after HSC-HSC-coculture, a significantly higher amount
of 70 % Panc1 cells with QAP morphology regained proliferative capacity
after HSC-HMF coculture (p=0.008)(Figure 4.16 B). Accordingly, HSC-HMF
coculture resulted in a significantly higher number of Ki67-positive Panc1 cells
with morphologic features of QAP (27.5 % Ki67-positive Panc1 cells with QAP
morphology after HSC-HSC-coculture versus 41.5 % Ki67-positive Panc1 cells
with QAP morphology after HSC-HMF coculture; p=0.047)(Figure 4.16 C &
D)
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Figure 4.16.: The quiescence-associated phenotype (QAP) of Panc1 cells can be reversed in
the presence of HMF. Panc1 cells were cocultured with HSC for 6 days. Subsequently, coculture was
extended with freshly seeded HMF (HSC-HMF). During the second period of coculture, Panc1 cells were
surveilled via realtime Life Cell Imaging with particular focus on cells with morphologic features of QAP.
A) shows representative images of Panc1 cells during respective coculture in 400-fold magnification after
0 hours (h), 72 hours and 144 hours. Encircled in white are non- or unsuccessfully dividing Panc1 cells with
QAP morphology, while Panc1 cells with QAP morphology successfully undergoing cytokinesis are encircled
in black. After completed coculture, the number of dividing (B) as well as the percentage of Ki67-positive
(C) Panc1 cells with QAP morphology was determined. Data represent the median values with quartiles
(Q0,75 as upper, Q0.25 as lower deviation) or mean ± SD of 3-5 independent experiments * = p <0.05.
Representative images of Ki67 stainings in Panc1 cells after HSC-HSC- or HSC-HMF coculture, obtained in
400-fold magnification are depicted in (D) with Ki67-negative Panc1 cells with QAP morphology encircled
in white and Ki67-positive Panc1 cells with QAP morphology encircled in black.
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Furthermore, Panc1 cells which were surveilled via realtime Life Cell Imaging
were examined for their SABG-activity after coculture extended in presence of
HMF. Interestingly, Panc1 cells which still exhibited morphologic features of
QAP but evidently fulfilled successful cytokinesis during HSC-HMF coculture
stained positive for SABG (Figure 4.17).
Figure 4.17.: Panc1 cells with QAP morphology maintain their SABG-activity after HMF-
mediated proliferation. Panc1 cells were cocultured with HSC for 6 days. Subsequently, coculture
was extended with either freshly seeded HSC (HSC-HSC) or HMF (HSC-HMF). During the second period
of coculture, Panc1 cells were surveilled via realtime Life Cell Imaging with particular focus on cells with
morphologic features of QAP (left). An SABG-staining in corresponding observed cells was affiliated (right).
Depicted are representative phase contrast (PC) images of Panc1 cells with QAP morhology after HSC-
HMF coculture in 400-fold magnification. Panc1 cells with QAP morphology which underwent successful
division are encircled in black.
In summary, these results show an HSC-driven induction of QAP as well as
an HMF-mediated QAP reversion in Panc1 cells. The fact that HSC-induced
growth arrest can be reversed by HMF suggests that the observed QAP can be
interpreted as tumor cell dormancy. Furthermore, these results indicate that the
condition of the hepatic microenvironment determines the dormancy status of
disseminated PDECs. However, the preservation of QAP features like flattened,
enlarged morphology as well as persistent SABG-positivity despite proliferative
activity indicate that HMF revert the QAP of Panc1 cells only partially.
To validate if the above mentioned effects of hepatic stromal cells on maintenance
and reversion of QAP noticed in Panc1 cells are equally observable in premalig-
nant cells, corresponding extended coculture experiments were conducted with
H6c7-kras cells.
In line with the effects observed in Panc1 cells, the extended presence of HSC
resulted in the maintenance of QAP in cocultured H6c7-kras cells. Only a mi-
nority of 17.4 % H6c7-kras cells exhibiting morphologic features of QAP regained
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proliferative activity after HSC-HSC coculture (Figure 4.18 A).
Figure 4.18.: H6c7-kras cells maintain a QAP after extended coculture. H6c7-kras cells were
cocultured with HSC for 6 days. Subsequently, coculture was extended with either freshly seeded HSC
(HSC-HSC) or HMF (HSC-HMF). During the second period of coculture, H6c7-kras cells were surveilled
with a realtime Life Cell Imaging device with particular focus on cells with morphologic features of QAP.
After completed coculture, the number of dividing (A) as well as the percentage of Ki67-positive (B) H6c7-
kras cells with QAP morphology was determined. Data represent the median values with quartiles (Q0,75 as
upper, Q0.25 as lower deviation) or mean ± SD of 5 independent experiments * = p <0.05. Representative
images of Ki67-stainings in H6c7-kras cells after HSC-HSC or HSC-HMF coculture are depicted in C
with Ki67-positive cells exposing QAP morphology encircled in black. C shows representative images of
H6c7-kras cell after SABG stainings carried out after HSC-HSC or HSC-HMF coculture.
However, in contrast to the effect observed in Panc1 cells, HMF had a minor
impact on cell division in H6c7-kras cells. While 41.5% Panc1 cells with QAP
morphology regained proliferative activity, only 25.9% of the observed H6c7-kras
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cells with QAP morphology showed proliferative activity after HSC-HMF cocul-
ture (Figure 4.18 A). Interestingly, subsequent Ki67 stainings showed a visible
though not statistically relevant increase in Ki67-positive cells with QAP mor-
phology after HSC-HMF coculture (26.7% Ki67-positive cells with QAP morphol-
ogy versus 44.1% Ki67-positive cells with QAP morphology)(Figure 4.18 B &
C). This points to an HMF-driven proliferation induction in H6c7-kras cells with
QAP morphology on the one hand which does not lead to a successful cytokinesis
on the other hand.
Similar to observations from Panc1 cells, H6c7-kras cells stained positive for
SABG after HSC-HSC as well as HSC-HMF coculture (Figure 4.18 D).
Overall, the extended cocultures of Panc1 cells and H6c7-kras cells with HSC or
HMF indicate a significant role of the hepatic microenvironment on maintenance
and reversion of dormancy in PDECs. The attendance of HMF represents a
potent stimulus in dormancy reversion and outgrowth of Panc1 cells whereas this
effect is markedly less pronounced in H6c7-kras cells.
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4.6. Identification of factors involved in hepatic
stroma-mediated effects on PDECs growth
behavior.
To identify factors involved in the stroma-mediated growth behavior of PDECs,
supernatants of HSC or HMF cocultures were analyzed for the abundance of
soluble inflammatory mediators by Multiplex assay. Therefore, Panc1 cells
showing the most pronounced effects under coculture conditions were incubated
in the presence of HSC or HMF for 6 days before supernatants were harvested
and soluble factors of murine and human origin were quantified. Under 27 human
and 6 murine cytokines, factors differentially released under HSC coculture or
HMF coculture were identified.
Factors showing a considerably higher abundance in supernatants of HSC
cocultured Panc1 cells were murine (m) IL-6 (1000.4 pg/ml under HSC versus
124.8 pg/ml under HMF coculture; p=0.005)(Figure 4.19 A) and human
(h) IL-8 (244.8 pg/ml under HSC coculture versus 192.5 pg/ml under HMF
coculture)(Figure 4.19 B). Furthermore, higher levels of m IL-12 were detected
in Panc1 supernatants after HSC coculture compared to HMF coculture (34.0
pg/ml under HSC coculture versus 13.0 pg/ml under HMF coculture)(Figure
4.19 C). The higher abundance of m IL-6, h IL-8 and m IL-12 in Panc1-HSC
coculture supernatants indicates that these factors may possess QAP promoting
potential.
In contrast, protein levels of m VEGF (722.4 pg/ml under HSC coculture versus
1049.8 pg/ml under HMF coculture)(Figure 4.19 D), h VEGF (348.8 pg/ml
under HSC coculture versus 594.2 pg/ml under HMF coculture)(Figure 4.19 E)
and h SDF-1α (1761.1 pg/ml under HSC coculture versus 2739.1 pg/ml under
HMF coculture; p=0.012)(Figure 4.19 F) were detected at higher levels in
supernatants of Panc1 cells cocultured with HMF compared to HSC suggesting
that these factors might be responsible for increased proliferation and QAP
reversal under these conditions.
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Figure 4.19.: Identification of factors involved in hepatic stroma-mediated effects on PDECs
growth behavior. Supernatants of Panc1 cells cocultured either in the presence of HSC or HMF for 6
days were analyzed by Multiplex analysis. Murine (m) Interleukin-6 (IL-6) (A), human (h) IL-8 (B) and
m IL-12 (C) were found at higher levels under HSC coculture compared to HMF coculture. M VEGF (D),
h VEGF (E) and h SDF-1α (F) were detected at higher levels in supernatants of HMF cocultures. Data
are presented as mean concentration (in pg/ml) ± SD 3 - 5 independent experiments * = p <0.05.
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4.7. IL-6 is not an inducer of QAP in PDECs
Up to this point, it could be emphasized, that the presence of HSC induces the
emergence of QAP in PDECs, while HMF coculture conditions promote prolifera-
tion of PDECs (cf. Chapter 3.3 & 3.5). Factors with either a higher release in
Panc1/HSC cocultures or Panc1/HMF cocultures were thereby identified. Hence,
the next step was to evaluate a causal involvement of soluble factors with a dif-
ferential release under the respective coculture conditions in the mediation of the
observed differences in PDEC growth behavior. Since the most pronounced dif-
ferential stroma-mediated effects were determined in Panc1 cells, corresponding
blocking and induction experiments were conducted in this cell line.
First, candidate cytokines with a possible relevance in QAP induction were ex-
amined. Murine IL-6 showed the plainest release in Panc1/HSC cocultures. The
role of IL-6 in PDAC progression is to date insufficiently elucidated. A senes-
cence promoting and tumor suppressing effect has been reported for IL-6, while
other studies support a tumor promoting role of IL-6 [136, 198]. IL-6 can fulfill
its function in two different fashions: classic cis-signaling or trans-signaling. IL-6
cis-signaling works through binding of soluble IL-6 to a membrane-anchored IL-6
receptor (IL-6R) on the cell surface. This complex formation causes the recruit-
ment and homodimerization of gp130, which exerts signal transduction via the
JAK/STAT and RAS/MAPK-pathways [199]. While the occurrence of IL-6R is
limited to lymphocyte lineages, neutrophils, hepatocytes and monocytes, gp130
is expressed ubiquitously [200]. Cells lacking IL-6R are hence receptive to IL-6
via IL6-trans-signaling, exerting its function via a soluble IL-6R (sIL-6R)[200].
The sIL-6R emerges by translation of a differentially spliced IL-6R mRNA or
cleavage of IL-6R on the cell surface by ADAM17 and is released into the inter-
cellular space [201]. Here it can interact with IL-6 and the formed complex may
bind to gp130 and exert the above mentioned effects. While IL-6 cis-signaling
exclusively functions intraspecifically, IL-6 trans-signaling may also be initiated
species-overlapping [200].
To identify a possible role of IL-6 in HSC-driven induction of QAP, IL-6 sig-
naling was blocked under HSC coculture conditions. Both, cis- and trans-
signaling modes were thereby examined. First, the clinically approved antibody
Tocilizumab was utilized. Tocilizumab is a h IL-6R-antagonist and thus blocks
cis- and trans-signaling of IL-6. As a control treatment, 10 mg/ml Rituximab, a
humanized monoclonal anti-CD20 antibody of the IgG1κ subclass was applied.
Panc1 cells were cocultured with HSC for 6 days and concurrently treated with
10 mg/ml of Tocilizumab and Rituximab, respectively.
The treatment of Panc1/HSC cocultures with Tocilizumab led to a visible, but
insignificant increase of vital Panc1 cells of 20.6% (3.2∗104 vital Panc1 cells
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after Rituximab treatment versus 3.9∗104 vital Panc1 cells after Tocilizumab
treatment)(Figure 4.20 A), which, moreover, did not induce QAP features
in Panc1 cells (data not shown). To examine effects of IL-6 trans-signaling
blockade, the fusion protein sgp130Fc was utilized. The sgp130Fc protein
unites the extracellular unit of gp130 fused to the Fc domain of a human IgG1
antibody and blocks IL-6 trans-signaling without affecting IL-6 cis-signaling
[200]. As a control, the corresponding IgG1-Fc-domain (control-Fc) was utilized.
The blockade of IL-6 trans-signaling under HSC coculture conditions had
no clear effect on the vital cell count of Panc1 cells (11.75∗104 vital Panc1
cells after control-Fc treatment versus 9.6∗104 vital Panc1 cells after gp130Fc
treatment)(Figure 4.20 B), underlining a minor role of classic IL-6 signaling in
HSC-mediated QAP induction in Panc1 cells.
Figure 4.20.: IL-6 is not important for HSC-mediated QAP in Panc1 cells. Panc1 cells were
indirectly cocultured with HSC for 6 days. Upon start of culture and again after 3 days, cocultures were
treated with 10 µg/ml of IL-6 signaling blocking or agents. After 6 days, vital cells were counted. A)
Vital cell numbers of Panc1 cells upon HSC coculture and application of a Rituximab control or IL-6R
antagonist Tocilizumab. B) Vital cell numbers of Panc1 cells upon HSC coculture and application of
a Ctrl-Fc-antibody or IL-6 trans-signaling blocking sgp130Fc. Values are depicted as mean ± SD of 4
independent experiments.
In order to substantiate these findings, monocultured Panc1 cells were treated
with 10 ng/ml recombinant (r) human (h) IL-6 (r h IL-6) and compared to un-
treated cells. Since murine (m) IL-6 exhibits a negligible affinity towards the
human IL-6R, r m IL-6 was utilized as a control. In comparison to untreated
Panc1 cells and Panc1 cells exposed to r m IL-6, treatment with r h IL-6 led to
a clear but not significant increase of vital cells (4.2∗104 vital Panc1 cells after
untreated monoculture versus 7.9∗104 vital Panc1 cells after r h IL-6-treatment
versus 3.8∗104 vital Panc1 cells after r m IL-6 treatment)(Figure 4.21). This
indicates a proliferation-inducing effect of h IL-6.
In summary, these results exclude murine and human IL-6 alone as crucial fac-
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tors in HSC-driven proliferation inhibition and hence promote the view that these
proteins are not causally involved in QAP induction in Panc1 cells.
Figure 4.21.: Human IL-6 increases cell growth of Panc1 cells. Panc1 cells were monocultivated
for 6 days. Cells were either left untreated (unstim.) or treated with 10 ng/ml IL-6 signaling inducing
agents upon start of culture and again after 3 days. Depicted is the vital cell count of monocultivated
Panc1 cells, either left untreated or stimulated with recombinant (r) murine (m) IL-6 (r m IL-6) or r human
IL-6 (r h IL-6). Values are depicted as mean ± SD of 4 independent experiments.
4.8. IL-8 is important for HSC-mediated QAP in
PDECs
Next, a possible involvement of h IL-8, also known as CXCL8, in HSC-mediated
QAP induction was verified. A differential release of h IL-8 of 244.8 pg/ml un-
der HSC coculture versus 192.5 pg/ml under HMF coculture was measured (cf.
Chapter 3.6). IL-8 has already been reported to prevent tumor cell prolifer-
ation and to exhibit senescence-inducing potency [136]. Therefore, in line with
IL-6 blocking experiments, h IL-8 was blocked under HSC coculture conditions
and QAP features of Panc1 cells were examined. For this approach, Panc1 cells
were cocultured with HSC for 6 days, while IL-8 signaling was compromised by
application of 2.5 µg/ml neutralizing human CXCL8/IL-8 antibody. As a control,
corresponding concentrations of monoclonal mouse IgG1-antibody were utilized.
The neutralization of h IL-8 under HSC coculture resulted in an increase of vital
Panc1 cells by 31% compared to control treated cells (19.37∗104 Panc1 cells after
h IL-8 blockade versus 13.33∗104 vital Panc1 cells after control treatment)(Figure
4.22 A).
Since the blockade of h IL-8 exposed a marked increase in vital Panc1 cells, fur-
ther proliferation-associated features were examined in Panc1 cells after h IL-8
blockade to examine a potential QAP promoting role of IL-8. In line with the
elevated vital cell count, SABG stainings showed that h IL-8 blockade led to a
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significant decrease in SABG-positive Panc1 cells by 35% (26.7% SABG-positive
Panc1 cells after h IL-8 blockade versus 40.9% SABG-positive Panc1 cells after
control treatment; p = 0.008)(Figure 4.22 B). Accordingly, the p-ERK/p-p38
ratio of HSC cocultured Panc1 cells was clearly increased after h IL8 blockade,
compared to HSC cocultured cells treated with control antibodies (p-ERK/p-p38
ratio = 0.84 in Panc1 cells after control treatment versus p-ERK/p-p38 ratio = 1.1
in Panc1 cells after h IL-8-blockade)(Figure 4.22 C).
Figure 4.22.: IL-8 is important for HSC-mediated QAP in PDECs. Panc1 cells were indi-
rectly cocultured with HSC and either treated with control IgG (2.5 µg/ml) or an anti-IL-8 antibody
(2.5 µg/ml)(A-C). After 6 days, vital cell numbers (A) and the percentage of SABG-positive cells (B)
were determined. C) shows representative western blots of phosphorylated-ERK (p-ERK) and ERK as
well as phosphorylated-p38 (p-p38) and p38. Furthermore, the corresponding p-ERK/p-p38 ratio, deter-
mined via densitometric quantification is depicted. HSP90 was used as loading control. Values are presented
as mean ± SD of 4 independent experiments. * = p <0.05.
To further substantiate these findings, monocultured Panc1 cells were stimulated
with r h IL-8. In accordance with the blockade of IL-8 under HSC coculture con-
ditions, the stimulation of Panc1 cells with r h IL-8 resulted in a mild decrease of
vital cells by 14.9% (6.7∗104 vital Panc1 cells after stimulation with recombinant
h IL-8 versus 7.7∗104 vital Panc1 cells after control treatment)(Figure 4.23).
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Figure 4.23.: Human IL-8 decreases cell growth of Panc1 cells. Panc1 cells were monocultivated
for 6 days and either left untreated (unstim.) or treated with 10 ng/ml recombinant human IL-8 (r h IL-8)
upon start of culture and again after 3 days. Depicted are mean vital cell counts ± SD of 4 independent
experiments.
In summary, blockade of IL-8 showed an increase in vital cell number and
p-ERK/p-p38-ratio in line with a significantly decreased SABG-activity of HSC
cocultured Panc1 cells. Taken together with the reduced vital cell count de-
termined after stimulation with r h IL-8, these results identify IL-8 as a QAP
promoting factor in Panc1 cells.
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4.9. SDF-1α is not a proliferation promoting factor
under HMF coculture.
HMF coculture of H6c7-kras and Panc1 cells led to a higher proliferation and the
absence of QAP features, compared to HSC cocultured PDECs (cf. Chapter
3.3). Accordingly, factors associated with proliferation and cell growth were de-
tected in higher abundance in Panc1/HMF coculture compared to Panc1/HSC
coculture. Hence, the next step was to investigate whether these cytokines with
elevated release under Panc1/HMF coculture were causally responsible for the
observed accelerated proliferation of Panc1 cells under these conditions.
The most striking and significant differences between Panc1/HSC and
Panc1/HMF cocultures concerning cytokine release were found for h SDF-1α
(1761.1 pg/ml under HSC coculture versus 2739.1 pg/ml under HMF coculture;
p=0.012)(cf. Chapter 3.6). Hence, corresponding loss and gain of function
experiments were conducted to validate the significance of h SDF-1α in HMF-
driven proliferation of PDECs. SDF-1α preferably binds to the receptor CXCR4
(SDF-1α receptor) on the cell surface and induces signaling via G-protein re-
cruitment and activation [202]. In order to block SDF1-α signaling, the clinically
approved CXCR4-receptor antagonist AMD3100 (Plerixafor) was applied under
HMF coculture conditions. Panc1 cells were cultured in the presence of HMF for
6 days. Upon start of the coculture and again on day 4, coculture medium was
supplied with 1 µM AMD3100 [203]. As a control treatment, DMSO was added
to Panc1/HMF cocultures in corresponding amounts. After 6 days, Panc1 cells
were examined for proliferation-associated features. The blockade of CXCR4 sig-
naling led to a minor increase in vital Panc1 cell numbers by 20% (25.9∗104 vital
Panc1 cells under HMF coculture and DMSO application versus 32.6∗104 vital
Panc1 cells under HMF coculture and AMD3100 application)(Figure 4.24 A),
indicating that CXCR4 signaling is not involved in HMF-driven proliferation of
Panc1 cells.
To validate this finding, recombinant (r) h SDF-1α was added to monocultured
Panc1 cells. This resulted in a nearly unaltered number of vital Panc1 cells
(7.5∗104 vital cells in untreated Panc1 monocultures versus 6.5∗104 vital Panc1
cells after r h SDF-1α application)(Figure 4.24 B).
In summary, these results show a negligible impact of h SDF-1α on proliferation
of Panc1 cells under HMF coculture.
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Figure 4.24.: SDF-1α is not a proliferation promoting factor under HMF coculture. A) Panc1
cells were indirectly cocultured with HMF and either treated with DMSO or 1 µM AMD3100 upon start
and again on day 4 of coculture. After 6 days, vital cell numbers were determined. B) Panc1 cells were
monocultured and either left untreated or treated with 10 ng/ml recombinant human SDF-1α (r h SDF-1α
upon start and again on day 4 of coculture and the vital cell number was measured. Data represent the
median values with quartiles (Q0,75 as upper, Q0.25 as lower deviation) or mean ± SD of 4 independent
experiments.
4.10. HMF promote proliferation in Panc1 cells via
VEGF.
Beyond SDF-1α, both, murine and human VEGF isoforms were found in higher
concentrations in Panc1/HMF coculture supernatants (722.4 pg/ml under HSC
coculture versus 1049.8 pg/ml under HMF coculture for m VEGF and 348.8
pg/ml under HSC coculture versus 594.2 pg/ml under HMF coculture for
h VEGF). Furthermore, in the utilized age-related syngenic mouse model VEGF
expression correlated with mouse-age and metastatic outgrowth (cf. Chapter
3.2). Moreover, VEGF has already been shown to foster the onset of colorectal
cancer cells [204]. Thus, VEGF was adjudged as likely mediator of HMF-driven
PDEC proliferation and corresponding blocking experiments were conducted.
VEGF was first described as a crucial molecule in angiogenesis [205]. Cur-
rently the VEGF family is composed of five structurally related factors:
VEGF-A,VEGF-B,VEGF-C,VEGF-D and placenta growth factor (PGF), which
all excert their effects by binding to receptor tyrosine kinases (RTK) [205]. In
order to verify a possible proliferation inducing role of VEGF under HMF cocul-
ture, Panc1 cells were cocultured with HMF and either 10 µg/ml VEGF blocking
antibodies or control antibodies were added into the medium. In a first approach,
the h VEGF-A neutralizing antibody Bevacizumab was utilized to block VEGF
signaling in Panc1/HMF cocultures. As a control, the anti-CD20 antibody Rit-
uximab was applied under equal conditions. Bevacizumab application had no
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impact on vital cell count of Panc1 cells under HMF coculture (14.8∗104 vital
Panc1 cells after Bevacizumab application versus 14.0∗104 vital Panc1 cells after
control treatment)(Figure 4.25 A).
Figure 4.25.: VEGF is a proliferation promoting factor under HMF coculture. Panc1 cells
were indirectly cocultured with HMF and either treated with 10 µg/ml Bevacizumab (A) or Aflibercept
(B-D) upon start and again on day 4 of coculture. Rituximab, applied in corresponding conditions, was
used as respective istotype control-antibody (A-D). After 6 days, vital cell numbers after VEGF blockade
via Bevacizumab (A) or Aflibercept (B) and respective control treatment were determined. Furthermore,
the number of Ki67-positive Panc1 cells after Aflibercept treatment versus control treatment was calcu-
lated (C). D) shows representative western blots of phosphorylated-ERK (p-ERK) and ERK as well as
phosphorylated-p38 (p-p38) and p-38. Moreover, the corresponding p-ERK/p-p38 ratio, determined via
densitometric quantification is depicted. HSP90 was used as loading control. Data represent the median val-
ues with quartiles (Q0,75 as upper, Q0.25 as lower deviation) or mean ± SD of 3-5 independent experiments
* = p <0.05. experiments.
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This either indicates a neglectable role of h VEGF-A in HMF-mediated prolif-
eration acceleration or that the blockade of h VEGF alone is not sufficient to
completely prohibit HMF-mediated VEGF signaling since m VEGF is not af-
fected by Bevacizumab [206]. Hence, Aflibercept, an antibody that targets not
only VEGF-A but also VEGF-B of human as well as murine origin was applied
to neutralize VEGF in Panc1/HMF cocultures.
In contrast to treatment with Bevacizumab, application of Aflibercept led to
a significant decrease of Panc1 cell growth and proliferation under HMF influ-
ence by 41.5% compared to control treatment (8.2∗104 vital Panc1 cells after
Aflibercept-application versus 14.0∗104 vital Panc1 cells after control treatment;
p = 0.035)(Figure 4.25 B). In line with this finding, a marked and significant
reduction of Ki67-positive Panc1 cells by 33% was observed (62.5% Ki67-positive
Panc1 cells after control treatment versus 41.4% Ki67-positive Panc1 cells after
application of Aflibercept; p = 0.030)(Figure 4.25 C). Finally, a corresponding
lower p-ERK/p-p38 ratio after Aflibercept treatment was determined (p-ERK/p-
p38 ratio = 1.60 after HMF-Rituximab control treatment versus p-ERK/p-p38
ratio = 1.38 after HMF-Aflibercept treatment)(Figure 4.25 D).
To examine the impact of exogenous VEGF on Panc1 cells, monocultured Panc1
cells were stimulated with r h VEGF-A. Contrary to the negligible impact of Be-
vacizumab blockade under HMF coculture, administration of exogenous VEGF-A
resulted in a visible increase in vital Panc1 cells (7.9∗104 vital Panc1 cells after
stimulation with recombinant h VEGF versus 11.6∗104 vital Panc1 cells after con-
trol treatment)(Figure 4.26). This indicates a proliferation promoting impact
of VEGF-A on Panc1 cells.
Figure 4.26.: VEGF-A promotes Panc1 cell growth. Panc1 cells were monocultivated for 6 days
and either left untreated (unstim.) or treated with 10 ng/ml recombinant human VEGF-A (r h VEGF)
upon start of culture and again after 3 days. Depicted are mean vital cell counts ± SD of 4 independent
experiments.
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Taken together, these results emphasize a crucial role of VEGF in HMF-driven
acceleration of proliferation in Panc1 cells.
4.11. VEGF-neutralization reverts HSC-mediated
QAP in Panc1 cells.
In a previous chapter it was shown that the presence of HMF reverts HSC-driven
induction of QAP (cf. Chapter 3.5). Since VEGF was identified as factor by
which HMF induce proliferation in Panc1 cells (cf. Chapter 4.10), the ques-
tion arose whether VEGF may also be causally involved in HMF-mediated QAP
reversion of Panc1 cells. In accordance with corresponding extended coculture
experiments (cf. Chapter 3.5), Panc1 cells were therefore first cultured in pres-
ence of HSC for 6 days before coculture conditions were changed to HMF for
further 6 days during which 10 µg/ml Aflibercept were applied in order to block
VEGF-signaling, while Rituximab was used as an isotype control.
The determination of vital Panc1 cells after HSC-HMF coculture exhibited a mild
decrease of vital cells by 14% after VEGF blockade via Aflibercept (65.3∗104 vital
Panc1 cells after HSC-HMF coculture and Rituximab application versus 56.1∗104
vital Panc1 cells after HSC-HMF coculture and Aflibercept application)(Figure
4.27 A). In addition, Aflibercept treatment under HMF coculture conditions fol-
lowing HSC coculture resulted in a clear and significant reduction of Ki67-positive
Panc1 cells by 23% (50.0% Ki67-positive Panc1 cells after Rituximab treatment
versus 38.4% Ki67-positive cells after Aflibercept application under respective
HSC-HMF coculture conditions)(Figure 4.27 B). Realtime Life Cell Imaging
with particular focus on cells showing morphologic features of QAP, however, de-
tected equal amounts of successful proliferations in Panc1 cells exhibiting QAP
morphology after HSC-HMF coculture irrespective of the applied antibody treat-
ment (36.7% proliferating Panc1 cells with QAP morphology after HSC-HMF
coculture and Rituximab treatment versus 43.0% proliferating Panc1 cells with
QAP morphology after HSC-HMF coculture and Aflibercept treatment)(Figure
4.27 C). By way of contrast, the decrease of the p-ERK/p-p38 ratio by 22.4%
indicates a striking effect of VEGF neutralization on the reversal of QAP in
Panc1 cells (1.318 after HSC-HMF coculture and Rituximab application versus
1.023 after HSC-HMF coculture and Aflibercept application)(Figure 4.27 D).
Taken together, whereas Aflibercept treatment under HSC-HMF coculture did
not impact on the number of dividing Panc1 cells with QAP morphology within
the time of observation, the decreased vital cell number, amount of Ki67-positive
cells and diminished p-ERK/p-P38 ratio as compared to control treatment, point
to a distinct role of VEGF in HMF-mediated dormancy reversion of growth ar-
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rested Panc1 cells.
Figure 4.27.: VEGF neutralization reverts HSC-mediated QAP in Panc1 cells. Panc1 cells
were indirectly cocultured with HSC for 6 days. Subsequently, coculture was extended with freshly seeded
HMF (HSC-HMF). During the second period of coculture, cocultures were either treated with 10 µg/ml
Aflibercept upon start and again on day 4. Rituximab, applied in corresponding concentrations, was
used as respective isotype control antibody. The vital cell number was determined (A) as well as the
number of Ki67-positive cells (B). During Aflibercept or Rituximab treatment, Panc1 cells were surveilled
via realtime Life Cell Imaging with particular focus on cells showing morphologic features of QAP and
successful proliferations were quantified (C). Furthermore, phosphorylated (p)-ERK and ERK as well as
phosphorylated (p)p-38 and p-38 were detected via western blot analysis and the p-ERK/p-p38 ratio was
determined via densitometric measurement (D). HSP90 was used as loading control. Data represent the
mean ± SD of 3-5 independent experiments * = p <0.05.
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5. Discussion
5.1. Inflammatory conditions in the hepatic
microenvironment foster the outgrowth of
disseminated PDECs in the liver
The first aim of this study was to gain a better image of PDAC liver metastases
at different stages of progression and detect possible coherences with the
prevalent conditions in the respective microenvironment. Due to their plasticity
and particular involvement in different inflammatory processes in the liver, HSCs
and their transdifferentiated counterpart HMF were detected representative of
the inflammatory status of the hepatic microenvironment. Liver metastases
were identified in FFPE liver tissues of KPC mice via immunohistochemistry
and characterized with regard to their size, proliferation status as well as
α-SMA/desmin ratio in the direct surrounding representative for HSC and HMF
abundance. This initial screening unveiled the emergence of micrometastases
with a low amount of proliferating tumor cells in unobtrusive, HSCs-rich
microenvironments whereas macrometastases with a significantly higher amount
of proliferating tumor cells were mostly detected in HMFs-rich areas (cf. Figure
4.1). These findings imply that the condition of the microenvironment deter-
mines the growth behavior of PDAC metastasis and support the view that HMFs
generate a growth permissive microenvironment for PDAC metastasis in the
liver. Supporting this view, Aiello et al. recently observed that the development
of liver metastases is associated with dynamic changes in the microenvironment
and that HMFs represent an essential component of this process [207]. Using
the KPC-related PKCY mouse model (Pdx1-Cre; Kras LSL-G12D/+; P53fl/+;
Rosa26 LSL-YFP/+ [89]), they showed how the amount of α-SMA positive
HMFs in the stroma of PDAC liver metastases increased with advancing lesion
size. HMFs thereby appeared in direct contact to metastatic lesions as early as
these were 6-7 cells in scale. Accompanying growth, secondary lesions acquired
a morphology and fibrotic degree similar to primary PDAC lesions. However,
in contrast to the results presented in this thesis, in their study the observed
changes in α-SMA positive cells in the microenvironment did not correlate with
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the proliferation status of metastatic lesions. In a further study, applying a
model of experimental metastasis based on intrasplenic injection of KPC mouse
derived PDAC cells Nielsen et al. showed that the deposition of ECM molecules,
mainly periostin, by HMFs promoted the progression of PDAC metastases in
the liver [208]. Both studies accordingly emphasized that HMFs emerged early
around DTCs after their engraftment, supporting the view that the high number
of HMFs detected in proximity to proliferating macrometastases of KPC mice
arose concomitantly with lesion growth. Importantly, in line with the study at
hand, both reports promote the view that stroma activation and inflammatory
processes in the liver generate a metastatic niche that fosters the outgrowth of
PDAC metastases. However, neither of the two studies nor the applied KPC
mouse model allowed conclusions regarding a potential metastasis promoting
effect of inflammatory alterations in the liver devoid of disseminated PDAC cells.
It was therefore sought to examine the behavior of malignant PDECs that
encounter a physiological, HSCs-rich liver versus an inflamed liver exposing
a higher abundance of HMFs. A syngeneic mouse model utilizing aging as
inflammatory trigger allowed a clearer distinction of a physiological versus an
inflamed hepatic microenvironment. C57BL/6J mice, either 8 weeks or 52 weeks
of age, were orthotopically injected with KPC mouse-derived R254 PDAC cells.
Two weeks and four weeks after injection, 10 animals per group were sacrificed,
respectively, and pancreatic tumor growth and metastatic burden were examined.
Indeed, higher age was associated with elevated growth of disseminated PDAC
cells in the liver. Whereas primary tumors of 8 weeks and 52 weeks old mice were
comparably small two weeks after tumor cell injection (cf. Figure 4.2 & 4.3),
older mice presented with a significantly higher number of Ki67-positive DTCs
in the liver (cf. Figure 4.4). Concordantly, four weeks after injection, primary
tumors were visibly but not statistically enlarged in 52 weeks old mice, whereas
only these mice harbored micrometastases (cf. Figure 4.9), indicating that
proliferating DTCs observed after two weeks indeed progressed to metastatic
lesions. Moreover, to detect aging-related inflammatory alterations in the liver,
the expression of various pro-inflammatory cytokines was measured. Indeed,
most of the genes found upregulated in 52 weeks old mice represented factors
which are reported to expose a higher expression in HMFs than HSCs or to be
involved in HSC-activation (cf. Figure 4.5)[192–196]. Accordingly, a slightly
higher α-SMA/desmin-ratio could be detected in livers of these mice, indicating
an elevated amount of HMFs in aged livers which supports the view that aging
is a stimulus for HSC activation (cf. Figure 4.6). These observations strongly
promote the view that inflammatory processes in the liver and the concomitant
emergence of HMFs occurring prior to metastatic spread provide a more growth
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permissive microenvironment for malignant PDECs that encounter the organ.
Supporting these results, an experimental study of breast cancer recently showed
increased seeding and proliferation of DTCs in the pulmonary microenvironment
after lungs were challenged with injury stimuli which caused the emergence
of myofibroblasts and concomitantly enhanced deposition of collagen-1 and
fibronectin [209]. Concordantly, more recent studies provided compelling
evidence for the involvement of HMFs in processes preceding metastatic spread
of PDAC and showed their role in the establishment of a pre-metastatic niche.
In experiments conducted by Costa-Silva et al., HMFs deposed fibronectin in
the hepatic microenvironment prior to DTC engraftment. Bone-marrow derived
macrophages and granulocytes accumulated in fibronectin-rich areas and in turn
provided a favorable niche for PDAC liver metastasis formation. In their model,
the emergence of HMFs was promoted by tumor derived exosomes containing
migration inhibitory factor-1 (MIF-1). Injected exosomes were incorporated by
Kupffer cells which in turn activated quiescent HSCs in a TGF-β1 dependent
fashion [110]. Studies by Gru¨nwald et al. showed corresponding results and found
that HMFs attracted neutrophils via release of SDF-1α [111]. Furthermore, this
study emphasizes the role of tissue inhibitor of metalloproteinases-1 (TIMP-1)
which is also a prognostic factor for PDAC patient survival and was shown to
activate HSCs via CD63 signaling [111, 210]. Both, MIF-1 bearing exosomes and
TIMP-1, rendered livers more susceptible to DTC engraftment and specifically
directed PDECs to the liver, indicating that HMFs may also be effective in
processes promoting DTC homing [110, 111, 210, 211]. Homing in the context of
cancer describes the phenomenon that cells of certain tumor entities specifically
seed in particular target organs [212]. Interestingly, in the experiments conducted
in this work, the proliferation state of detected DTCs was altered whereas the
number of DTCs in the liver was comparable in young and aged mice two weeks
after PDAC cell injection (cf. Figure 4.4). This observation indicates that
aging-related inflammation in the liver has a minor impact on the homing of
disseminated PDECs to the organ but rather determines their survival and
growth in the hepatic microenvironment in the earliest steps of metastasis. In
contrast, a higher amount of DTCs was observed in livers of aged mice four
weeks after injection of R254 cells compared to livers of young mice (cf. Figure
4.9), indicating that homing processes may have played a more important role
at this time point. However, it has to be taken into consideration that primary
tumors of old mice were visibly larger than PDAC tumors of younger animals
four weeks after tumor cell injection although this effect was not statistically
significant. The size of a primary tumor was shown to correlate with the number
of CTCs in the circulation and also with the amount of DTCs in secondary
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organs [213]. It would therefore be reasonable to detect CTCs in the blood of
young and old mice which was also sampled within experiments conducted in
this work. This approach would allow to exclude that differences in the amount
of DTCs observed four weeks post injection are due to larger primary tumors
determined in 52 weeks old mice.
Of note, the pre-metastatic niche is defined as metastasis promoting alterations
in a secondary environment devoid of tumor cells that are elicited by factors that
derive from primary lesions [214]. In the above mentioned studies, MIF-1 con-
taining exosomes and TIMP-1 which were shown to cause the activation of HSCs
originated from PDAC cells or corresponding pre-conditioned culture media and
can hence be regarded as tumor derived factors [110, 111, 210]. In contrast,
differences in the conditions of the hepatic microenvironment as exposed in the
syngeneic mouse model applied here were most likely provoked by aging-related
inflammatory processes indicating that the dominance of HSC or HMF prevalent
in a hepatic microenvironment vastly devoid of primary tumor derived factors
may already determine the permissiveness for growth of disseminated PDECs
in the liver. Accordingly, while tumor derived factors like TIMP-1 and MIF-1
containing exosomes form a pre-metastatic niche that promotes attraction of
PDECs to the liver, aging may represent a tumor cell-independent promoter for
conditions corresponding to a pre-metastatic niche in the liver by providing a
proliferation and survival conductive microenvironment in dependence of HMF.
Aging is a systemic process, therefore causing inflammation not only in the
liver but also in other organs and tissues of the body including the pancreas
[177, 215, 216]. Hence, it was assumed that aging-related inflammation also
significantly impacts on primary tumor growth. Surprisingly, in the aging-
related syngeneic mouse model utilized here, primary tumors were comparably
small two weeks after tumor cell inoculation whereas significant distinctions
concerning DTC proliferation in the liver were already detectable at this time
point (cf. Figure 4.2 & 4.4). Furthermore, four weeks after tumor cell
injection, aging-associated differences in tumor growth detected livers were more
pronounced than distinctions of tumor size in the pancreas (cf. Figure 4.7
& 4.9). This indicates that in the utilized model inflammaging did not affect
tumor growth in all organs to the same extend and has a higher impact on
secondary tumor growth in the liver than on primary tumor growth. It can
also be hypothesized that aging represents a particular trigger for inflammatory
processes and tumor cell proliferation in the hepatic microenvironment. To
conclude whether aging-associated inflammatory alterations impact stronger on
metastatic outgrowth in the liver than in other organs, further studies should
aim to examine DTC proliferation in e.g. the lungs which are also a common
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target of PDAC metastasis [92]. Similar to pancreata and livers, lungs were
extracted from corresponding animals from the aging-related syngeneic mouse
model and will be subject of further immunohistological analysis.
Due to the inaccessibility of tissue samples from PDAC patients in general
and in particular in the early clinical course of the disease, the examination of
PDAC metastases at different stages of progression demands the utilization of
sophisticated animal models. For the initial screening of metastatic lesions and
inflammation in the corresponding microenvironment the KPC mouse model
was chosen as it represents a well-established PDAC model which recapitulates
the human disease process. KPC mice expose metastatic spread via the portal
circulation and predominantly to the liver [176, 217, 218]. Various studies
aiming at elucidating processes of metastatic progression in PDAC are based
on xenograft approaches comprising the application of human cancer cells into
immunodeficient host animals [219]. While a great advantage of these models
lies in the facilitated identification of tumor cells via human specific antibodies,
the validity of findings obtained from such model systems may be questioned
owed to species specific restrictions in the efficacy of potentially relevant factors
[220]. Furthermore, xenograft models generally demand the injection of high
numbers of tumor cells or the utilization of immunedeficient mice whereas an
intact immune response is one of the crucial determinants for the inefficiency
of metastasis so that its significance may not be neglected [221]. However, the
KPC-model also revealed certain limitations which exacerbated the evaluation
of experimental metastases. Due to the lack of unambiguous markers for PDAC
cells, their detection can solely be carried out by immunohistological staining
of cytokeratins. In the present study, CK-19 was utilized as marker to detect
DTCs in mouse livers which is, however, also present in bile duct tissue [222].
This circumstance aggravated the identification of metastasis and rendered the
evaluation of metastases via HE staining mandatory. Particularly single DTCs
and DTC clusters were due to their minor size only detectable in one or two serial
sections. However, 4 serial sections were necessary for staining of the complete
marker set and thorough characterization. Hence, morphologically ambiguous
potential micrometastases were excluded from the analysis to prevent false
positive evaluations. Of note, the examined liver tissue specimens were extracted
after PDAC primary tumor growth was well advanced. Matched primary tumors
which were also immunohistologically examined, occupied the majority of the
KPC mouse pancreas and showed a high degree of dedifferentiation (data not
shown). Consequently, micrometastases were only rarely found and conclusions
regarding early events in the malignant progression of PDAC were hard to draw.
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Moreover, some micrometastases exposed particularly high proliferation despite
the presence of desmin in the surrounding microenvironment, indicating certain
heterogeneity and a potential role of further intrinsic and extrinsic cues that
determine metastasis proliferation. The aging-related syngeneic mouse model
used in this study helped overcoming most of these issues and allowed a more
detailed analysis of early occurring events in metastases formation. Importantly,
injected R254 cells were supplied with GFP and Luciferase reporter constructs
[184]. This facilitated the surveillance of primary and secondary tumor growth
with non-invasive imaging modalities and the distinct identification of dissemi-
nated PDAC cells in the FFPE liver via GFP-Tag antibodies. Moreover, utilized
C57/Bl6 mice possess an intact adaptive immune system with various immune
cell subsets [223]. Since R254 PDAC cells expose the same genetic background, a
natural immune response in the vicinity of primary and disseminated R254 cells
can be expected. The syngeneic mouse model system allowed the examination
of metastasis formation processes in the earliest steps of metastatic spread.
However, targeted injection of R254 PDAC cells into the pancreas head rendered
abdominal surgery mandatory. Hence, it is possible that differential regulation
of inflammation-associated genes was a result of an aging-related response to
surgery itself. Elevated levels of IL-1, IL-6, TNF-α and VEGF have been
detected after major abdominal surgery in the peripheral blood of mice and
men [224–227]. Although these levels commonly decrease in the days after
surgery, it may well be that the decline of pro-inflammatory mediators proceeds
notably slower in elder patients and accordingly in older mice [228]. The longer
persistence of pro-inflammatory cytokines in the circulation could accordingly
represent a HSC-activating stimulus. Likewise this option involves significant
clinical relevance since also the curative treatment of PDAC comprises severe
surgical intervention. Interestingly, the observed gene expression profile of
pro-inflammatory cytokines in livers of old mice is partially in line with previous
reports which showed that several cytokines associated with inflammation expose
a dynamic expression pattern altering with proceeding age of mice. Foremost the
observed higher expression of IL-1β in livers of aged mice was in accordance with
findings of previous studies identifying higher levels of IL-1β in aged C57BL/6J
mice in comparison to younger individuals [190, 191]. Moreover, elevated levels
of TGF-β1 were previously detected in livers of 24 months old animals compared
to younger mice similar to the results presented here [191]. Importantly, a further
study confirmed the finding that livers of young mice exhibit higher levels of the
functional murine IL-8 homologue MIP-1. Guo et al. found a more than 2.5
times higher level of MIP-1 in 24 months old mice than 6 months old mice [229].
This accordance with previous observations from unoperated mice indicates that
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the differential gene expression level of pro-inflammatory cytokines in 8 weeks
versus 52 weeks old animals may indeed be due to aging-related processes. To
further validate the relevance of an aging-related response to surgical processes
in the utilized model a higher amount of young and old animals which solely
undergo sham surgery will be included in future studies.
Importantly, although most of the factors found upregulated in livers of 52
weeks old mice are reported to be highly expressed in HMFs or involved in the
activation of HSCs, it cannot be ruled out that the observed aging-related effects
on DTC proliferation are also caused by other cell entities apart from HSCs or
HMFs. For example, macrophages which were shown to play a crucial role in
the initial and final steps of metastatic niche formation in PDAC are reported
to release various of the here detected pro- and anti-inflammatory cytokines
e.g. IL-1β, IL-6, FGF, TGF-β and VEGF [110, 208, 230]. Furthermore, it
is reported that HSCs and HMFs differentially impact on other cell entities
e.g. T-lymphocytes and neutrophils [105]. It would therefore be reasonable to
examine the role of further hepatic stromal cell entities in the applied models.
For example, the detection of neutrophils via Ly6G staining or macrophages via
F4/80 staining in livers of young and old mice could clarify a potential impact
of these cell entities on the proliferation of disseminated PDECs [231][186]).
Combined, the mentioned studies and the results presented here outline a rough
picture of how HMFs as a characteristic of inflammatory conditions in the hepatic
microenvironment contribute to engraftment and outgrowth of disseminated
PDECs and support the view that HMFs are involved in the early steps of
metastatic outgrowth of PDAC liver metastases. HMFs are critically involved in
events that precede DTC engraftment in the liver as they support the attraction
of CTCs to the liver specifically [110, 111, 210]. These studies demonstrate
that HMFs participate in establishing and maintaining growth permissive
conditions after engraftment of disseminated PDECs. The results presented here
promote the view that aging may be regarded as an additional process for HMFs
emergence which supports the proliferation of disseminated PDECs in the liver
despite tumor derived cues, thereby further fuelling metastatic growth. Hence,
the data presented here deliver a further explanation how elevated age increases
the risk to develop metastatic PDAC.
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5.2. A physiological hepatic microenvironment
hampers outgrowth of PDAC liver metastasis
by promoting dormancy in disseminated
PDECs.
Whereas several previous studies and the results obtained from the mouse
models applied in this thesis accordingly report a PDAC metastasis promoting
effect of inflammatory conditions in the liver, to date no study examined if
physiological conditions in the hepatic microenvironment may act to hamper
the engraftment and onset of PDAC metastasis in the liver. The observation
that micrometastases with a significantly lower amount of Ki67-positive tumor
cells were located in areas with a low α-SMA/desmin ratio (cf. Figure 4.1),
allows the conclusion that the predominance of HSC in the microenvironment
may diminish the likelihood of metastatic outgrowth of disseminated PDECs.
Furthermore, the minor degree of DTC proliferation detected in younger mice
compared to old mice two weeks after tumor cell injection (cf. Figure 4.4)
was accompanied by higher expression levels of the pro-inflammatory mediators
MIP-1 and LIX (cf. Figure 4.6), which is most likely due to stromal cells
with a higher presence in the less inflamed hepatic microenvironment of young
mice. Since HSCs are a crucial component of a physiological microenvironment,
this correlation may accordingly represent a further indication that a high
abundance of HSCs represents hostile conditions for disseminated PDEC and
hampers their outgrowth to overt metastases in contrast to HMF which are a
characteristic of an inflamed liver. However, the applied mouse model systems
did not allow conclusions regarding a potential direct proliferation inhibiting
effect of HSCs on PDECs by e.g. paracrine signaling. The utilization of an
indirect coculture system allowed investigations on the proliferation of PDECs
and underlying mechanisms in dependence of HSC or HMF in a system devoid
of other hepatic stromal cells. Furthermore, using H6c7-kras and Panc1 cells the
behavior of PDECs at different stages of malignant progression was examined
[180, 181, 232]. Representative for disseminated PDECs encountering a phys-
iological hepatic microenvironment, H6c7-kras and Panc1 cells were cocultured
with the murine cell line M1-4HSC (HSC) or human HHSteC pretreated with
ATRA (HHSteC-HSC). Modelling the dissemination of PDECs that face an
inflamed hepatic microenvironment, H6c7-kras and Panc1 cells were cultured in
the presence of the murine cell line M-HT (HMF) or human HHSteC pre-treated
with TGF-β1 (HHSteC-HMF). Indeed, the presence of HSC resulted in a
significantly lower number of vital cells and Ki67-positive cells in both PDEC
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lines compared to HMF cocultured H6c7-kras and Panc1 cells (cf. Figure 4.11).
Similar results were obtained when comparing HHSteC-HSC and HHSteC-HMF
cocultured H6c7-kras and Panc1 cells (cf. Figure 4.15). Interestingly, unlike
HMF coculture, HSC coculture resulted in the emergence of Ki67-negative cells
with a flattened, enlarged morphology. These features of growth arrested cells
were validated by further analysis which showed that HSC coculture led to a
higher p-ERK/p-p38 ratio, concomitantly with a higher level of the cell cycle
inhibitor p21 and a significantly greater SABG-activity than in HMF cocultured
PDECs. Accordingly, a corresponding QAP in H6c7-kras and Panc1 cells was
obtained in the presence of HHSteC-HSC but not HHSteC-HMF coculture.
These results unveil a distinct impact of HSCs and HMFs on the proliferation of
disseminated PDECs and, moreover, show a growth arrest promoting effect of
HSCs. This is a remarkable finding, since there are only a few indications in the
literature that describe a proliferation inhibiting effect of isolated fibroblastoid
cells, like a pioneering experimental study from 1966 in which normal fibroblasts
inhibited the growth of polyoma-transformed baby hamster kidney cells [233].
Importantly, in experiments conducted in this work the observed QAP of pre-
malignant and malignant PDECs was reversed when exchanging the coculture
from HSC to HMF after 6 days. A majority of H6c7-kras and Panc1 cells with a
QAP-morphology was Ki67-positive after HMF coculture. Accordingly, realtime
Life Cell Imaging showed that PDECs with a QAP-morphology reacquired
their proliferative capacity in the presence of HMF which hardly occurred in
HSC-HSC cocultures. Latter effect was more pronounced in Panc1 than in
H6c7-kras cells. These findings identified QAP as a reversible state of growth
arrest and that its manifestation is dependent on the presence of HSC or HMF
in the microenvironment. Hence, QAP can be regarded as an expression of
cellular dormancy in PDECs. To this end, this work contributes to the issue
which factors may induce and restrain cellular dormancy in metastases. It
has already been proposed that factors of a physiological tissue may promote
metastatic dormancy [119]. However, to date only a few of such stimuli were
identified. Interestingly, several of these stimuli can be related to fibroblasts at
different stages of activation. For instance, Kobayashi et al. found a phenotype
similar to the HSC-driven QAP of PDECs in prostate cancer cells in dependence
on the osteal microenvironment [169]. In their study, bone morphogenetic
protein-7 (BMP-7), a member of the TGF-β protein family activated p38 and
p21, resulting in the induction of growth arrest and a high SABG-activity in
PC3 prostate cancer cells. BMP-7 was shown to be released from fibroblasts
and osteoblasts from the bone stroma. Deprivation of BMP-7 reversed the
dormant phenotype and reinduced proliferation of PC3 cells in vitro and in
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vivo. Bragado et al. found that lungs which comprise lower amounts of TGF-β
II promote homing and outgrowth of breast cancer cells [171]. In PDAC, the
clinical significance of dormancy processes, in particular in metastatic processes,
has been regarded as circumstantial due to the short time span from diagnosis
of PDAC to the decease of the patient to metastatic disease. Accordingly, only
few environmental dependent signaling cues crucial for dormancy processes in
PDAC cells were so far identified. Using a model of reversible PDAC, Lin et al.
demonstrated that dormant cancer cells contribute to residual disease in PDAC
in a MYC dependent fashion. Pancreas specific expression of MYC resulted in
the formation of PDAC and sporadic metastasis formation in the liver. While
ablation of MYC resulted in apoptosis of the majority of PDAC cells, few cells
persisted in pancreas and liver in a growth arrested state and could be reinduced
to proliferate after re-expression of the MYC oncogene [166]. Interestingly, in
their experiments residual dormant tumor cells were always detected in close
proximity to or entirely embedded in the fibrotic stroma of pancreata and livers.
They consequently hypothesized that signaling cues from the microenvironment
represent an essential component of dormancy processes [234]. The observation
that H6c7-kras and Panc1 cells are driven into cellular dormancy by HSC and
subsequently reacquire proliferative capacity mediated by HMF support these
findings and indicate that the condition of the microenvironment – physiologic
tissue homoestasis versus inflamed state – determines if and when PDECs may
outgrow to metastases. Further evidence for this hypothesis was previously
brought forward by experimental models of breast cancer metastasis. Barkan
et al. provoked fibrosis of the lungs via adenoviral vectors expressing active
TGF-β1. The subsequent deposition of collagen-1A1 induced dormant breast
cancer cells to form proliferative metastatic lesions via β1-integrin signaling
[173, 174]. More recently, DeCock et al. described how inflammation promotes
the escape from growth arrest of dormant breast cancer cells in the lung. The
group generated dormant cells via in vivo passaging and in vitro expansion
of slow-cycling mammary carcinoma cells. Inflammatory conditions in the
pulmonary microenvironment were induced by challenging BALB/c mice with
lipopolysaccharide and reinduced proliferation in dormant cancer cells in a
neutrophil dependent fashion [235]. These results may also to some extend apply
for PDAC metastases as these also occur in the lung. However, since PDECs
most commonly spread to the liver, inflammatory processes in this organ may
be more significant for PDAC and other cancer entities exposing predominant
spread to the liver. To this end, the reversion of QAP in PDECs in presence
of HMF may deliver corresponding evidence for a dormancy restrictive impact
provided by inflammatory conditions in the liver.
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However, it has to be emphasized that H6c7-kras and Panc1 cells did not regain
proliferative activity in presence of HMF to a same extend, indicating differences
in premalignant and malignant PDECs concerning the ability to leave the
state of dormancy (cf. Figure 4.16 & 4.18). This supports the hypothesis
that beyond environmental cues, cell intrinsic traits e.g. acquired mutations,
genetic stability and epigenetic configuration critically determine the fate of
disseminated PDEC in the secondary environment. Several reports showed that
distant metastases derive from a unique subclone of the primary tumor and that
most of the mutations prevalent in metastases correspond to genetic alterations
in the primary context [87, 236, 237]. Hence, the mutational pattern a potential
DTC exposes by the time of dissociation from the primary context is likely to
be the most important determinant for its capacity to colonize the liver. With
respect to PDAC-associated mutations, H6c7-kras cells harbor only a mutation
in the KRAS oncogene while Panc1 cells among others carry a mutation in TP53
which emerges later in clonal evolution of PDAC [38]. Hence, differences in the
mutational status of TP53 may harbor the explanation for the different prolif-
eration behavior of H6c7-kras and Panc1 cells with QAP traits in presence of
HMFs. This hypothesis is supported by findings from corresponding experiments
conducted in the TP53 wildtype PDAC cell line Colo357 which was isolated from
a PDAC lymph node metastasis [238]. In line with findings from H6c7-kras cells,
Colo357 cells with HSC-mediated QAP-morphology did not regain proliferative
activity but exposed a higher amount of Ki67-positive cells after HSC-HMF
coculture compared to HSC-HSC coculture (data not shown). The utilization of
H6c7-kras and Panc1 cells may allow conclusions which mutations are necessary
to survive and proliferate in the hepatic microenvironment. It was previously
shown that a mutation in KRAS is sufficient for PDECs to induce survival
pathways which may foster their persistence in unfavorable conditions. For
instance, oncogenic KRAS activates the kinase Mirk/Dyrk1B in growth arrested
PDECs [239]. A 7-fold increase of Mirk was detected in PDAC cells which were
arrested in the G0-phase and was shown to lower intracellular levels of noxious
ROS (reactive oxygen species)[240]. This mechanism is of particular interest for
the applied setting since the utilized cell line HSC is reported to expose and
release higher amounts of ROS than HMF [182]. Further reports show that
survival mechanisms of dormant cancer cells do not necessarily rely on oncogenic
drivers. With autocrine IGF1/AKT signaling, a survival pathway for dormant
PDECs independent of KRAS and MYC was lately identified [241]. Accordingly,
both, premalignant PDECs carrying only a KRAS mutation, as well as further
transformed PDECs which also acquired mutations in TP53 may survive in the
hepatic microenvironment. Moreover, the observation that a distinct amount of
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H6c7-kras cells were Ki67-positive after extended coculture with HMF indicates
that these cells might harbor the capacity to regain proliferative activity when
further extending HMF coculture. Consequently, it can be concluded that
the outgrowth of both, KRAS mutated as well as KRAS and TP53 mutated
disseminated PDECs in the liver is potentially possible. Importantly, however,
in the studies performed by Rhim et al., the number of CTC derived from
PanIN lesions was significantly lower than the amount of CTCs that descended
from established PDAC tumors [89]. Furthermore, due to various rate limiting
steps in metastasis, only a very low percentage of DTCs successfully outgrows
to a macroscopical lesion [242]. Adding the observation that only 25.9 %
of H6c7-kras cells with QAP-morphology proliferated in presence of HMFs
(cf. Figure 4.18), it may be concluded that PDECs which disseminate prior
to establishment of PDAC primary tumor have a significantly lower chance to
colonize the liver than PDAC cells that fully underwent malignant transfor-
mation. This view is supported by further results from the Rhim study which
showed that DTCs derived from PanIN mice did not form overt metastasis in
the hepatic microenvironment [89]. Importantly, however, the data shown in
this thesis promote the view that inflammatory conditions in the liver may
significantly enhance the chance of metastasis formation by premalignant PDECs.
The observation that subpopulation of both PDEC lines maintained their
proliferative capacity despite the acquisition of growth arrest and re-entered the
cell cycle in presence of HMFs led to the view that QAP can be regarded as
a manifestation of cellular dormancy. However, SABG-activity is a feature of
QAP that was present in a high percentage of HSC cocultured H6c7-kras and
Panc1 cells (cf. Figure 4.17 & 4.18). It must therefore be argued that the
state of growth arrest described by QAP could also represent a form of reversible
senescence. To date, SABG is regarded as the only valid marker for senescence.
However, the inclusion of further markers is recommended to detect senescent
cells more specifically [243]. DNA microarray analysis predicted DEC1 and
decoy receptor 2 as potential novel markers for senescent cells [243]. However,
in stainings both markers failed to unambiguously identify a subpopulation of
H6c7-kras and Panc1 cells exposing features of QAP (data not shown) indicating
that DEC1 and decoy receptor 2 are not adequate markers for senescent PDECs.
It can be argued that the markers applied here are not sufficient to describe
senescent cells. To this end, cells with QAP do not expose phenotypical features
apart from SABG activity that would represent a detectable distinction to a
state of cellular dormancy. Therefore, a senescence phenotype may represent a
feature or a subpopulation of dormant cells. Stainings of SABG in liver tissue
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resected from the applied mouse models could be performed to identify the role
of such a subpopulation in vivo.
Most of the own findings discussed in this chapter were generated in an
indirect in vitro coculture which was used in order to model a physiological
or an inflamed hepatic microenvironment. Self-evidently, an in vitro coculture
model system is not sufficient to recapitulate the complexity of the human
disease. However, it represents one of the few options to identify a mutual
influence of two cell compartments in an isolated fashion. The MI1-4HSC/M-HT
(HSC/HMF) cell system was utilized, as it represents HSCs at different degrees
of transdifferentiation with the same genetic background [182]. However,
studies with HSCs in vitro comprise certain general limitations since HSCs
are easily activated and transdifferentiated upon isolation. Accordingly, most
described immortalized HSCs lines expose an advanced stage of activation
indicated by increased expression of α-SMA [244]. Activated HSCs differ from
quiescent HSCs by enhanced proliferation and migratory potential as well as
unbalanced ECM deposition [245]. HSC which were applied in this study also
show increased amounts of α-SMA (cf. Figure 4.1)[182]. However, HSC but
not HMF concomitantly expose high amounts of the intermediate filament
desmin (cf. Figure 4.1) which is regarded as the “gold standard” for HSC
characterization. Their phenotype may hence be considered as an early stage
of activation and transdifferentiation. Accordingly, HSC had to be treated
carefully and not be cultivated for more than ten passages to maintain a constant
phenotype. Other often utilized cell lines with an HSCs-like phenotype e.g.
LX-2 cells expose a more transdifferentiated profile (data not shown) and were
hence not utilized in the study at hand. An in vitro cell system that fully
recapitulates the traits of quiescent HSCs has yet to be established and would
represent an interesting extension for further studies. However, HHSteC-HSC
which were generated by treating HHSteC with ATRA may come close to such
a phenotype, since ATRA has proven as a compound that reprograms activated
HSCs to quiescent HSCs [189]. Importantly, when using the HSC/HMF system
to examine the impact of different cell lineages on the proliferation of tumor
cells in a comparative manner, potential differences in the proliferation or FCS
uptake of the stromal cells have to be taken into consideration. Accordingly,
it could be argued that the diminished proliferative activity of H6c7-kras and
Panc1 cells after HSC coculture compared to HMF coculture could be based
on a higher proliferation and FCS consumption of HSC compared to HMF.
However, vital cell numbers of HSC and HMF isolated after completed coculture
were principally comparable whereas growth of H6c7-kras and Panc1 cells was
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unaltered in media with different FCS amounts (data not shown). Hence, it can
be assumed that the differences of PDEC growth under HSC or HMF coculture
were indeed due to soluble factors derived of respective hepatic stromal cells
and not owed to differences in the proliferation of HSC and HMF. Of note,
key findings from HSC/HMF coculture experiments were validated in a second
coculture system comprising only human cells. HHSteC-HSC and HHSteC-HMF
exposed phenotypes comparable to their respective murine counterpart HSC
and HMF (cf. Figure 4.14) and showed a comparable differential impact on
H6c7-kras and Panc1 cells (cf. Figure 4.15). Hence, albeit its limitations
the HSC/HMF system represents a useful tool to backup findings from in vivo
models and to determine underlying mechanisms by which these hepatic stromal
cells impact on the proliferation of disseminated PDECs.
A further important issue in the context of proliferation is the validity of Ki67
as a proliferation marker. Ki67-positivity is regarded as strictly associated with
proliferation since nuclear Ki67 is detectable in cells during all active phases of
the cell cycle and absent in resting cells [246]. Therefore, Ki67 is a widely applied
marker which is also used in clinical routine. However, cells that entered the
cell cycle but became growth arrested in phases apart from G0 may also stain
positive for Ki67. Accordingly, Ki67 stainings may have stained PDECs which
were actually captured in growth arrest. This would explain the emergence of
Ki67-positive H6c7-kras and Panc1 cells after HSC-HSC coculture. Thus, other
methods to unambiguously discriminate proliferative and non-proliferative cells
could be included in further studies. As such, BrdU-labeling or carboxyfluores-
cein succinimidyl ester (CFSE) stainings could be deployed.
Taken together, the results discussed so far clearly indicate that inflammatory
conditions in hepatic microenvironment, characterized by the presence of HMFs,
represent growth permissive conditions for PDEC that encounter the liver.
HSC as integral component of a physiological microenvironment may act to the
restrain the progression of disseminated PDECs to overt metastases by inhibiting
their proliferation. Accordingly, the conditions of the hepatic microenvironment
can be regarded as a dynamic factor determining the likelihood of metastatic
outgrowth in the liver and may represent a switch from a dormancy permissive
to a dormancy restrictive microenvironment.
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5.3. Growth arrest and progression of disseminated
PDECs is determined by proinflammatory
mediators.
Remodelling of the hepatic microenvironment within inflammatory processes
in the liver is accompanied by altered release of various chemokines, cytokines
and growth factors [247]. Accordingly, distinct alterations were found when
comparing the expression of inflammatory mediators in livers of 8 weeks and
52 weeks old mice (cf. Figure 4.6). Furthermore, the indirect coculture of
PDECs with HSC or HMF facilitated the identification of soluble factors of a
physiological or inflamed hepatic microenvironment which may act to promote
or to revert QAP in PDECs.
First, stroma derived factors potentially involved in the induction of dormancy in
PDECs were examined. A significantly higher concentration of m IL-6 was found
in supernatants of Panc1 cells which were cocultured with HSC in comparison
to Panc1 cells cocultured with HMF (cf. Figure 4.19). The circumstance
that only IL-6 of murine origin was detected in higher amounts indicates that
IL-6 derived from the HSC compartment. Due to these findings and previous
studies which showed a quiescence and senescence promoting effect of IL-6
[136], it was suggested that HSC-mediated IL-6 signaling may be responsible
for the observed QAP induction in Panc1 cells under HSC coculture. However,
neither the blockade of the IL-6 receptor via Tocilizumab nor the inhibition of
IL-6 trans-signaling via sgp130fc impacted on the vital cell count of Panc1 cells
under HSC coculture (cf. Figure 4.20) or affected the morphology of Panc1
cells regarding a potential QAP emergence to a visible extent (data not shown).
Concomitantly, h IL-6 stimulated Panc1 cells showed an increased vital cell
number compared with control stimulated cells (cf. Figure 4.21). These data
validated previous experiments conducted in the workgroup with H6c7-kras cells
[181] and indicate that IL-6 signaling is not causally involved in stroma-mediated
QAP promotion in both, H6c7-kras and Panc1 cells. M IL-6 was exclusively
detected in coculture supernatants while monocultured HSC and HMF did
not release detectable amounts of this cytokine. Hence, the measured levels of
m IL-6 were probably a consequence of the vice versa communication of HSC
or HMF with Panc1 cells. In contrast to m IL-6, which shows no affinity to h
IL-6R, the human isoform of IL-6 binds both, the m IL-6R and h IL-6R [200].
Accordingly, the elevated release of m IL-6 may have represented a secondary
effect initiated by Panc1 cells. IL-6 was reported to be a major component
of the SASP [136, 152]. It is hence possible that Panc1 cells which acquired
a QAP elicited senescence-associated signaling in HSC which manifested in
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a distinct SASP and subsequent elevated IL-6 release. Accordingly, HSC
exposed an increased SABG-activity after coculture with Panc1 cells (data not
shown). It could not be clarified, whether the application of Tocilizumab or
sgp130fc fully neutralized IL 6 signaling which should be validated in further
experiments. However, IL-6 showed no aging-related differential gene expression
in the livers of C57Bl/J6 mice (cf. Figure 4.6) indicating that this molecule
also plays a minor role in stroma-mediated differences in DTC proliferation
between young and old mice in the applied mouse model. A previous study
showed increased levels of IL-6 in livers of 18 months old C57Bl6/J mice
compared to 6 months old animals which indicates that altered IL-6 signaling
may rather emerge at advanced age as an expression of an aging-related SASP
[152, 190]. Furthermore, IL-6 is considered one of the main signaling pathways
that mediate chronic morbidity in aging patients [248]. In line with the growth
promoting effect of h IL-6 on Panc1 cells shown in this study, several reports
provided evidence that IL-6 fosters the development of PDAC in the primary
and secondary context [198, 249]. These data promote the view that IL-6
signaling may have a proliferation promoting impact and plays a minor role
in HSCs-mediated dormancy induction and maintenance in disseminated PDECs.
A more significant role in the maintenance of QAP can be accredited to IL-8.
In in vitro coculture experiments, IL-8 was detected at higher levels in super-
natants of HSC cocultured Panc1 than supernatants obtained from Panc1/HMF
coculture (cf. Figure 4.19). In order to examine the role of IL-8 signaling in
cellular dormancy of PDECs, h IL-8 was blocked in Panc1 cells following an
approach similar to the blockade of IL-6 signaling. However, in contrast to the
blockade of IL-6, the neutralization of IL-8 via monoclonal anti IL-8 antibodies
resulted in a clear increase of vital cell Panc1 cells after 6 days of HSC coculture
(cf. Figure 4.22). Moreover, the neutralization of h IL-8 resulted in a visibly
elevated p-ERK/p-p38 ratio in HSC cocultured Panc1 cells accompanied by
a significant decrease of SABG activity and a decreased number of cells with
a QAP-morphology (cf. Figure 4.22). These findings indicate that IL-8 is
a critical mediator of HSC-mediated dormancy of PDECs. IL-8 signaling was
reported to be altered in various cancer entities [250]. However, the role of
IL-8 signaling on tumor promotion is discussed controversially. Several studies
recognize IL-8 as a tumor promoting molecule as it among other functions
exposes potent pro-angiogenic potential and shows a marked upregulation in
chronic inflammation [251–253]. Accordingly, some reports showed a direct
impact of IL-8 on the proliferation of tumor cells of different cancer entities
including PDAC [254–257]. By way of contrast, other studies report that IL-8
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signaling dictates growth arrest in PDAC upon inflammation-mediated OIS
[136, 258]. The circumstance that IL-8 was shown to increase both, ERK as
well as p38 signaling, leads to the assumption that the functions and effects
of IL-8 signaling are context dependent [259]. HSCs and HMFs both are
among the cell entities which are known to release IL-8 (Weiskirchen & Tacke
2014). Importantly, IL-8 has also been shown to promote cancer stem cell-like
properties in PDAC cells. The administration of recombinant h IL-8 resulted in
the formation of mammaspheres in Capan-1 cells [260]. In a further study, the
blockade of IL-8 signaling increased the effectiveness of AC (cyclophosphamide,
doxorubicin) chemotherapy [261]. Accordingly, previous reports from the work
group showed that H6c7-kras and Panc1 cells acquire stem cell features under
HSC coculture including enhanced colony formation ability and clonogenicity
as well as the induction of stem cell markers nanog and nestin [232]. Hence,
it is possible that IL-8 works to induce stemness in disseminated PDECs in
dependence on the hepatic microenvironment. A recent study supports this
hypothesis and unveiled a link between IL-8 and cellular dormancy. In a 3d
coculture, MDA breast cancer cells and Panc1 cells engulfed mesenchymal
stromal cells (MSCs) and acquired various features of dormancy and cancer
stemness, respectively. After engulfment of MSCs, MDA cells exposed a strong
upregulation of pro-inflammatory mediators including IL-8 and IL-6 among
other molecules which are reported to be part of the SASP [262].
So far, only functional homologues of h IL-8 but no sequence identical homologues
of h IL-8 were identified in mice [263]. Since HSC and HMF are murine cell
lines, the detected and neutralized IL-8 could only originate from Panc1 cells.
Hence, elevated IL-8 release by Panc1 cells under HSC coculture is probably
dependent on another HSC-derived factor which remains to be identified. This
factor may induce an IL-8 feedback loop in Panc1 cells which manifests in QAP.
Accordingly, the neutralization of IL-8 may hamper this feedback loop and allow
the induction of proliferation in Panc1 cells with a QAP. It is hence possible that
the absence of IL-8 fostered the proliferation of PDAC cells, which may harbor
an explanation for the observed reversion of QAP under HMF coculture. Since
the presence of HHSteC-HSC resulted in QAP in Panc1 cells similar to HSC
coculture conditions further experiments should aim to neutralize IL-8 in the
human-human coculture system. Importantly, young C57Bl/6J mice exposed
higher expression levels of the murine chemokines MIP-2 and LIX (cf. Figure
4.6) which are recognized as functional homologues of IL-8 [263]. The higher
expression of these cytokines correlated with a lower proliferation of disseminated
PDECs. Like IL-8, MIP-2 and LIX fulfill their effect by binding to the CXCR1/2
receptor complex [263]. A knockdown of CXCR1/CXCR2 in PDECs in the
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applied in vitro and in vivo systems would therefore help to further validate the
role of IL-8 as a QAP promoting factor.
The applied system also allowed identifying candidate cytokines by which an
inflamed hepatic microenvironment, and therefore HMFs, may promote reversion
of dormancy in disseminated PDECs. Molecules detected in significantly higher
levels in Panc1/HMF cocultures than Panc1/HSC cocultures were h SDF-1α,
h VEGF and m VEGF (cf. Figure 4.19). As a first step to test a potential
involvement of these factors in the reversion of dormancy, their impact on
the proliferation of Panc1 cells in dependence on the microenvironment was
examined. For this approach, the respective cytokine of interest was blocked
under Panc1/HMF coculture conditions or monocultured Panc1 cells were ex-
posed to the respective recombinant protein. Human SDF-1α exposed the most
distinct differential release between Panc1/HSC and Panc1/HMF cocultures
(cf. Figure 4.19). Furthermore, a proliferation promoting effect of SDF-1α
released by CAFs had previously been reported [264]. However, blockade of
SDF-1α signaling via the CXCR4 antagonist AMD3100 did not affect the vital
cell count of Panc1 cells to a visible extent (cf. Figure 4.24). Alternatively to
CXCR4 signaling, SDF1-α may also work by binding CXCR7 [265]. However,
stimulation of Panc1 cells with r h SDF-1α had a similar minor impact on the
vital cell number of Panc1 cells, implying a negligible role of SDF-1α in the
HMF-mediated proliferation induction. The SDF-1α/CXCR4 axis is mostly
known for its involvement in chemotactic processes [266]. SDF-1α attracts
CXCR4 expressing cells and is as such involved in processes promoting cell
trafficking of stem and progenitor cells e.g. hemato- and lymphopoietic cells to
their corresponding target organs. Furthermore, SDF1-α was shown to promote
the formation of a pre-metastatic niche in PDAC via neutrophil attraction
[111, 210]. It can thus be assumed that SDF-1α may impact Panc1 cells in
cellular processes apart from proliferation which were not particularly addressed
in the applied indirect coculture system. However, SDF-α expression could be
examined in the aging-related syngeneic mouse model to validate the observed
minor impact of inflammaging on homing of disseminated PDECs to the liver.
A differential cytokine release between Panc1/HSC and Panc1/HMF cocultures
was also detected for VEGF. Of note, in case of VEGF, however, both the
human and the murine homologue of the cytokine were detected at higher levels
in Panc1/HMF coculture supernatants compared to supernatants obtained from
Panc1/HSC coculture (cf. Figure 4.19). Moreover, VEGF-A showed the most
striking differential gene expression between livers of 8 weeks and livers of 52
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weeks animals (cf. Figure 4.6). Consequently, VEGF-signaling was blocked
under HMF coculture conditions using different antibodies which are also applied
in clinical routine. The neutralisation of VEGF-A via Bevacizumab had no
visible impact on the vital cell count of Panc1 cells compared to Panc1 cells
which were treated with the control antibody Rituximab (cf. Figure 4.25). By
way of contrast, the stimulation with recombinant h VEGF-A resulted in a clear
increase of vital Panc1 cells (cf. Figure 4.26). This validated a proliferation
promoting effect of VEGF-A on Panc1 cells and indicated that the neutralization
of h VEGF-A alone was not sufficient to entirely compromise VEGF-signaling.
In contrast, the consequent neutralization of VEGF-A and VEGF-B of murine
and human origin via Aflibercept led to a significant decrease of vital Panc1
cells under HMF coculture and number of Ki67-positive cells accompanied by
a diminished p-ERK/p-p38 ratio (cf. Figure 4.25). Since these observations
clearly pointed to the involvement of VEGF in the HMF-mediated proliferation
induction, it was also examined if the blockade of VEGF may restrain the
observed HMF-mediated dormancy reversal of Panc1 cells. The administration
of Aflibercept under HMF coculture following HSC coculture decreased the
number of vital and proliferative Panc1 cells as well as the p-ERK/p-p38 ratio
(cf. Figure 4.27). Together, these results identify VEGF as a crucial factor
in the HMF-mediated promotion of proliferation. Furthermore, they imply
that HMF revert dormancy of Panc1 cells in a VEGF dependent manner.
A significant role of VEGF signaling in escape of tumor dormancy is well
appreciated. However, this effect is mostly based on the role of VEGF as a
pro-angiogenic factor as which it was first described [267]. VEGF supports
the pro-angiogenic switch which is necessary for growing tumors to overcome
insufficient blood and nutrient supply and concerns the phenomenon of tumor
mass dormancy [118]. Due to this function, VEGF plays a fundamental role
in various cancer entities and is a common target of chemotherapy approaches
[268]. However, to date all clinical phase-III trials which included anti-VEGF
treatment showed no survival benefit in PDAC patients which is also believed
to be due to the profound tumor stroma and the observation that tumors
expose a strong hypovascularity [219, 269]. In this context, recent studies
indicate that the pro-angiogenic switch is dispensable for the progression from
micrometastases to macrometastases in PDAC [207]. However, VEGF was shown
to directly accelerate the growth of different PDAC cells [270]. Furthermore,
it was reported that the inhibition of VEGF induces cellular senescence in
colorectal cancer cells [204]. Yet, a direct dormancy reverting effect of VEGF on
tumor cells has not been shown. Of note, in a study by Tang et al. the enzyme
15-lipoxygenase-2 induced dormancy in prostate cancer cells which correlated
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with a diminished VEGF-A expression [271]. In line with the results presented
in the study at hand, HMFs were reported to expose higher levels of VEGF
than HSCs [106]. Accordingly, VEGF-signaling is also critically involved in
inflammatory and fibrotic processes [272]. Furthermore, the observation that
h VEGF and m VEGF were similarly elevated in HMF cocultures compared to
HSC cocultures (cf. Figure 4.19) indicates that VEGF was indeed released by
HMFs in the coculture setting. Concomitantly, the observation that livers of 52
weeks old mice exposed significantly higher expression levels of VEGF-A then
livers 8 weeks old animals (cf. Figure 4.6) represents a further strong indicator
that VEGF may promote growth of disseminated PDECs in vivo. Importantly,
failing clinical phase III trials testing the effect of Bevacizumab or Aflibercept as
Gemcitabine additives were conducted in advanced stage, metastasized PDAC
patients [273, 274]. Therefore, anti-VEGF therapy aiming at preventing the
outgrowth of PDAC metastases might represent a more promising approach for
the treatment of early stage PDAC patients. This motivates further endeavors
seeking to identify novel mechanisms for earlier detection of PDAC.
Some cytokines, e.g. IL-6 expose species specific efficacy [275]. Hence, results
from an in vitro coculture system based on cell lines of two different species
as given in the applied HSC/HMF coculture system have to be regarded with
care. Concomitantly, this coculture system harbors a crucial advantage as it
enables the identification of a cytokine’s respective origin compartment. To fully
examine the mutual impact of stroma and tumors cells via soluble factors, the
role of cytokines has to be validated in a one-species coculture system. The
established HHSteC coculture system allows this approach and will be used for
further corresponding studies. Moreover, this system could be used to conduct a
further Luminex assay. This would represent a feasible way to validate factors
that may be effective in induction and reversion of dormancy. Furthermore,
stromal cells and tumor cells may also communicate via direct contact apart
from soluble factors. A feasible way to examine the straight impact of HSCs
and HMFs on PDECs would be a direct coculture system. Such a system could
recapitulate the architectural traits of the liver and would be an interesting
approach for future studies. In some blocking strategies applied in this work, the
validation of the blockade of respective factors failed. Hence, the full inhibition
of chemokines and cytokines is not ensured to a similar extend in all experiments.
This may comprise the explanation why no differences in the reversion of QAP
in Panc1 were observed in realtime Life Cell Imaging upon Aflibercept and
Rituximab treatment during respective HMF coculture (cf. Figure 4.27). How-
ever, importantly, the role of factors like VEGF and IL-8 could be validated in
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the syngeneic mouse model, promoting the validity of the applied in vitro system.
Taken together, the murine/human and human/human coculture system in com-
bination with the applied mouse models identified conditions and factors as well as
underlying mechanisms by which the hepatic microenvironment may promote or
revert dormancy in disseminated premalignant and malignant PDECs. The data
presented in this thesis promote the hypothesis that the hepatic microenviron-
ment and the disseminated PDEC itself represent dynamic and variable systems.
Their condition and interplay determine the fate of the disseminated PDEC and
their likelihood to progress to overt metastasis in the liver (Figure 5.1).
Figure 5.1.: Model of how the condition of the hepatic microenvironment determines the
growth behavior of disseminated PDECs. A physiological microenvironment, characterized by high
abundance of HSCs, prevents the outgrowth of disseminated pancreatic ductal epithelial cells (PDECs)
to overt metastases. HSCs induce and maintain a quiescence-associated phenotype (QAP) in PDECs that
encounter the organ, manifesting in Ki67-negativity, low phosphorylated (p)-ERK/p-p38 ratio, accompanied
by high levels of p21 and senescence-associated β-galactosidase (SABG) acitivity. This QAP is induced and
maintained via IL-8. Aging processes, lifestyle factors or therapy promote inflammation and the emergence
of HMFs in the hepatic microenvironment. As a consequence, disseminated PDECs escape dormancy in
dependence on VEGF released by HMFs. In this fashion, an inflamed hepatic microenvironment promotes
the progression of PDAC metastasis.
Analogous to Stephen Paget’s theory, the disseminated PDEC can be regarded as
a dynamic seed. The mutations PDECs acquired by the time of spreading to the
liver determine its plasticity as well as its ability to survive and proliferate in the
secondary microenvironment. Whereas both, premalignant and malignant dis-
seminated PDECs can persist in the liver in a dormant state, cells with mutated
TP53 may harbor a markedly higher capability to outgrow to overt metastases.
114
DISCUSSION
This further promotes the view that PDECs which disseminate lately during
PDAC pathogenesis may form metastasis notably faster. The hepatic microenvi-
roment can be seen as a dynamic soil. A physiological microenvironment may act
to restrain the progression of disseminated DTCs to overt metastasis and hence
represent a dormancy permissive microenvironment. The results presented here
indicate that IL-8 which is elevated in an HSCs-rich, physiological microenviron-
ment embodies a factor which acts to induce and maintain a state of dormancy
in disseminated PDECs. In contrast, inflammatory conditions in the liver, mani-
festing in the emergence of HMFs, may represent a switch to a rather dormancy
restrictive microenvironment and promote the growth of disseminated PDECs
that encounter the liver or persist in the organ in a growth arrested state. These
alterations may be triggered by aging processes and lifestyle factors like smoking
and alcoholic abuse, but potentially also by therapy procedures like abdominal
surgery or chemotherapy. Therefore, the data presented here may comprise an
explanation for the emergence of metastases in patients even after R0 resection
[7]. Based on the findings from this thesis, VEGF represents a potential factor
by which HMFs promote the escape from dormancy in disseminated PDECs. Al-
together this thesis shows a marked impact of the hepatic microenvironment on
the proliferation behavior of disseminated premalignant and malignant PDECs.
Furthermore, they promote the view that dormancy processes play a crucial role
in PDAC metastasis. The results from this study encourage undertakings aim-
ing at early diagnosis and prevention of metastasis in PDAC to eradicate this
devastating disease.
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6. Outlook
This study showed for the first time how aging-related inflammatory alterations
in the liver promote growth of dormant disseminated PDECs. It thereby pro-
vides the foundation for further studies on the impact of inflammatory processes
on PDAC metastasis formation. The applied syngeneic mouse model can be used
to validate the role of the factors IL-8 and VEGF in induction and reversion
of dormancy in disseminated PDECs in vivo. A feasible way to test a PDAC
proliferation promoting role of VEGF on disseminated PDECs would be to in-
traperitoneally inject VEGF neutralizing Aflibercept in 8 weeks and 52 two weeks
old mice. This could be performed two weeks after orthotopic injection of R254
cells, a time point at which metastatic lesions are still relatively small. Four
weeks after tumor cell injection, primary and secondary tumor growth can be
examined as well as the regulation of inflammation-associated genes in the liver,
further organs and systemically. In a similar approach, a dormancy promoting
effect of IL-8 could be validated. For this purpose, antibodies recognizing IL-8 or
its murine homologues can be deployed to block tumor cell and stroma-mediated
IL-8 signaling, respectively. Furthermore, the syngeneic model can be extended
for a premalignant PDEC line in order to examine the role of mutated TP53 in
disseminated PDECs in vivo in dependence on different conditions in the hepatic
microenvironment. Regarding PDAC relevant mutations, the KC mouse derived
cell line 8182 harbors only a KRAS mutation but beyond that possesses the same
detection modalities as the R254 cell line [184]. Accordingly, differences between
premalignant and malignant PDECs concerning stroma-mediated QAP reversion
detected in vitro could be validated in an in vivo setting.
The results from this thesis promote the view that a physiological tissue home-
ostasis restrains the outgrowth of disseminated PDECs. This view is in line
with studies concerning primary PDAC [276, 277]. Sherman et al. showed how
treatment with the vitamin D receptor (VDR) ligand calcipotriol reduced inflam-
mation and fibrosis in the PDAC stroma as well as growth of primary PDAC. It
would be interesting to examine if corresponding effects can be obtained in the
hepatic microenvironment in the context of liver metastasis.
The presence of HSC resulted in enhanced SABG activity in H6c7-kras and Panc1
cells. However, additional markers failed to further characterize and identify
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senescence in the applied PDEC lines. The characterization of senescent PDAC
cells, especially in vivo, may represent a worthwhile approach, since senescent
PDECs may embody a particularly hazardous cell subpopulation due to their
SASP. The SASP of senescent cells stimulates cells in the surrounding, causing
an immunotolerant milieu via recruitment of immunosuppressive myeloid cells
[278]. Furthermore, the SASP is reported to stimulate senescent fibroblasts to
pro-inflammatory cells [152]. A further fibrotic remodelling of the microenviron-
ment can be the consequent result which may attract or promote the outgrowth
of further DTCs. Studies on therapy induced senescence showed the emergence
and significance of such a phenotype in lymphoma cells [279]. A promising ap-
proach to further characterize potentially senescent cells are peculiarities in their
metabolism which will be examined in further studies in the group of inflamma-
tory carcinogenesis.
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1.1. Development of primary PDAC. A normal pancreas duct develops to PDAC
via stepwise progression of pancreatic intraepithelial neoplastia (PanIN) lesions.
PanIN progression is accompanied by the frequent accumulation of mutations.
Upper panel: Hematoxilin eosin (HE) stainings of pancreas sections (adapted
from Han and Hoff, 2013). Lower panel: The four most common driver mutations
of PDAC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2. The invasion-metastasis cascade of malignant carcinoma. A primary tu-
mor forms (1) and cells from this tumor invade the local tissue (2). Some cells
manage to intravasate into newly formed blood vessels and to survive as circu-
lating tumor cell (CTC) in the blood circulation (3). At the distant organ, some
cells adhere to the endothelial surface and extravasate into the organ (4). Dis-
seminated tumor cells (DTCs) form a micrometastasis which later on outgrows
to an overt and clinically detectable metastasis (5). . . . . . . . . . . . . . . . . . 6
1.3. The invasion-metastasis cascade in PDAC. Pancreatic ductal epithelial
cells (PDECs) first invade the surrounding connective tissue. PDECs may de-
rive from an established primary tumor or, as more recent reports suggest,
also from precancerous lesions like PanIN [89, 90]. In this case, epithelial-to-
mesenchymal transition may precede the complete acquisition of PDAC hall-
mark mutations. After intravasation, premalignant PDECs from PanIN lesions
or malignant PDAC cells may similarly be found in the circulation as circulating
PDECs. After reaching the liver, disseminated PDECs are confronted with con-
ditions of the secondary foreign microenvironment that may determine if these
cells may go into apoptosis, become growth arrested or outgrow to overt metastases. 10
1.4. The activation of hepatic stellate cells (HSCs). HSCs are located in the
space of Disse and represent a quiescent cell population. Upon activation stimuli
like e.g. inflammation or injury, HSCs cease their lipid storing function and trans-
differentiate into hepatic myofibroblasts (HMFs). Latter ones release a plethora
of extracellular matrix molecules and determine the architecture of the liver
(adapted from [109]). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.5. Working hypothesis. HSCs are a characteristic of a physiological liver whereas
an inflamed liver is characterized by higher amounts of HMFs. It was recently
reported that besides malignant PDAC cells, also premalignant PDECs may
disseminate to the liver [89]. It was hence hypothesized that the condition of
the liver – physiological versus inflamed – determines the likelihood of succesfull
outgrowth of dissemintated PDECs from PanINs or PDAC to overt metastases. . 19
3.1. Experimental setup for the characterization of liver metastases in an
endogenous PDAC mouse model . . . . . . . . . . . . . . . . . . . . . . . . 37
3.2. Experimental setup for the analysis of pancreatic and hepatic tumor
growth in an age-related syngeneic PDAC mouse model. . . . . . . . . . 40
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3.3. Settings for murine-human coculture systems. M1-4HSC (HSC), repre-
sentative of a physiological liver microenvironment, or M-HT (HMF), modelling
an inflamed liver, were indirectly cocultured with premalignant H6c7-kras cells
or malignant Panc1 cells for 6 days. HMF were generated by long-term exposure
of HSC to 1 ng/ml TGF-β1. H6c7-kras cells were used to model the dissem-
ination of PDECs at an early stage of PDAC pathogenesis while Panc1 cells
were applied to model PDEC dissemination from an established PDAC primary
tumor. Both compartments were connected by a membrane with 0.4 µm-pores
which facilitates mutual influence by soluble factors. . . . . . . . . . . . . . . . . 47
3.4. Settings for human-human coculture-systems. HHSteC-HSC were gener-
ated by treatment of HHSteC with 2.5 µM all-trans-retinoic acid (ATRA) and
used representative of a physiological liver microenvironment. HHSteC-HMF
were produced by permanently exposing HHSteC to 1 ng/ml TGF-β1, modelling
an inflamed liver. HHSteC-HSC and HHSteC-HMF were indirectly cocultured
with premalignant H6c7-kras cells or malignant Panc1 cells for 6 days. H6c7-kras
cells were used to model the dissemination of PDECs at an early stage of PDAC
development while Panc1 cells were applied to model PDEC dissemination from
an established PDAC primary tumor. Both compartments were connected by
membranes with 0.4 µm-pores which facilitate mutual influence by soluble factors. 48
3.5. Experimental setting for an extended coculture system. 1 ∗ 104 H6c7-
kras cells or 0.5∗104 Panc1 cells were cultured in the presence of 5∗104 M1-4HSC
(HSC) for 6 days. Transwells were substituted after 6 days for transwells with
5 ∗ 104 fresh M1-4HSC (HSC-HSC coculture) or M-HT (HSC-HMF coculture).
M1-4HSC and M-HT used in the second coculture period were prepared one day
prior to application. H6c7-kras and Panc1 cells were observed using a JuLITM Br
Live Cell Analyser during coculture with particular regard to cells exhibiting a
flattened and enlarged morphology (cf. Chapter 4.3). After completion of the
first and the second coculture period, cells grown on coverslips were examined
for their Ki67-status via immunocytochemical staining as described in Chapter
3.3.4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.6. Protein transfer setup. The SDS-gel containing the protein lysate separated
by protein weight was transferred onto a PVDF-membrane via the semidry blot-
ting procedure. Therefore, the gel was placed on the membrane and stacked
between whatman papers soaked in either buffer A, buffer B or buffer C. . . . . 55
4.1. Proliferative activity of PDAC cells in liver metastases correlates with
the presence of hepatic stellate cells (HSC) or hepatic myofibroblasts
(HMF). Liver sections of mice harboring advanced PDAC (n=13) were ex-
amined for the presence of micrometastases (lesion diameter ≤ 200 µm) and
macrometastases (lesion diameter > 200 µm) by staining of cytokeratin-19 (CK-
19; to visualize PDAC cells), Ki67 (to detect proliferating cells), α-SMA (for
detection of HMF) and desmin (for detection of HSC). A) Representative im-
ages show the overlay of CK-19, Ki67, desmin and α-SMA stainings obtained
by costainings of serial sections. B) Scoring of Ki67 and determination of the
α-SMA/desmin score in micro- and macrometastases. Data represent median
values with quartiles (Q0,75 as upper, Q0.25 as lower deviation) of 7 micro- and
9 macrometastases. * = p <0.05. . . . . . . . . . . . . . . . . . . . . . . . . . . 58
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4.2. Sonographic tumor detection in young and aged mice 2 weeks post-
injection. Two weeks after injection of R254 cells, mice were examined consider-
ing primary tumor growth via ultrasound imaging with a resolution of 30 µm (A).
Data represent the median values with quartiles (Q0,75 as upper, Q0.25 as lower
deviation) of 20 animals/group. Representative ultrasound images of PDAC tis-
sue (outlined in red) within the pancreas (B) and corresponding 3-dimensional
recapitulation of the tumor (C) are depicted. wks = weeks . . . . . . . . . . . . 60
4.3. Tumor detection in young and aged mice 2 weeks post-injection via
bioluminescence measurement. Two weeks after injection of R254 cells, 8
weeks and 52 weeks old mice were examined for tumor growth via biolumines-
cence imaging (A). Animals were placed in a NightOwl in vivo imaging sys-
tem and bioluminescence signals were measured for 300s. Data represent the
median values with quartiles (Q0,75 as upper, Q0.25 as lower deviation) of 20
animals/group. Representative images of two mice, respectively, show biolumi-
nescence signals within the abdomen (B) representing tumorous tissue. wks =
weeks; cps = counts per second. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
4.4. Immunofluorescence detection of PDAC cells in young and aged mice
2 weeks post-injection. Following in vivo imaging, animals were sacrificed
and pancreata as well as livers were resected and analyzed via immunofluores-
cence staining of GFP (to detect GFP-positive R254 cells) and Ki67 (to detect
proliferating cells). Whole liver sections were photographed at 200-fold magnifi-
cation and the median number of DTCs per view field in whole liver sections was
determined (A) as well as their corresponding Ki67 status (C). Data represent
the median values with quartiles (Q0,75 as upper, Q0.25 as lower deviation) or
mean ± SD of 10 animals/group. * = p <0.05. Representative images of GFP
positive DTCs in livers of 8 weeks and 52 weeks are depicted in (B) at 200-fold
magnification. In (D) GFP-positive DTCs in livers of 8 weeks and 52 weeks after
Ki-67 staining are shown at 400-fold magnification. DTCs are encircled in white,
respectively. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
4.5. qRT-PCR based characterization of HSC and HMF-related genes 2
weeks post-injection. Two weeks after injection of R254 cells, 8 weeks and 52
weeks old mice underwent hepatectomy and snap-frozen liver tissue specimens
were subjected to gene expression analysis via qRT-PCR. The ratio of the relative
gene expression of α-SMA and desmin was calculated (A) and the relative gene
expression of collagen-1 (Col1A1) was determined (B). GAPDH and β-actin were
used as housekeeping-controls. Data represent the median values with quartiles
(Q0,75 as upper, Q0.25 as lower deviation) of 10 animals/group. . . . . . . . . . . 63
4.6. qRT-PCR based determination of inflammatory cytokines in liver tis-
sues 2 weeks post-injection. Two weeks after injection of R254 cells, 8 weeks
and 52 weeks old mice underwent hepatectomy and snap-frozen tissues were sub-
jected to gene expression analysis via qRT-PCR. The relative gene expression of
the proinflammatory cytokines IL-6 (A), TNF-α (B), FGF2 (C), IL-1β (D) and
KC (E) was detected. Furthermore, relative gene expression levels of TGF-β
(F), VEGF-A (G) MIP-2 (H) as well as LIX (I) were measured. GAPDH and
β-actin were used as housekeeping-controls. Data represent the median values
with quartiles (Q0,75 as upper, Q0.25 as lower deviation) of 10 animals/group.
* = p <0.05. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
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4.7. Sonographic tumor detection in young and aged mice 4 weeks post-
injection. Four weeks after injection of R254 cells, mice were examined for
primary tumor growth via ultrasound imaging with a resolution of 30 µm (A).
Data represent the median values with quartiles (Q0,75 as upper, Q0.25 as lower
deviation) of 10 animals/group. Representative ultrasound images of tumorous
tissue (outlined in red) within the pancreas (B) and corresponding 3-dimensional
recapitulation of the tumor (C) are depicted. wks = weeks . . . . . . . . . . . . 66
4.8. Tumor detection in young and aged mice 4 weeks post-injection via
bioluminescence measurement. Four weeks after injection of R254 cells, 8
weeks and 52 weeks old mice were examined for tumor growth via biolumines-
cence imaging (A). Animals were placed in a NightOwl in vivo imaging sys-
tem and bioluminescence signals were measured for 300s. Data represent the
median values with quartiles (Q0,75 as upper, Q0.25 as lower deviation) of 10
animals/group. Representative images of two mice, respectively, show biolumi-
nescence signals within the abdomen (B) representing tumorous tissue. wks =
weeks; cps = counts per second. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
4.9. Immunofluorescence detection of PDAC cells in young and aged mice
4 weeks post-injection. Following in vivo imaging, animals were sacrificed
and pancreata as well as livers were resected and analyzed via immunofluores-
cence staining of GFP (to detect GFP-positive R254 cells) and Ki67 (to detect
proliferating cells). Whole liver sections were photographed at 400-fold magni-
fication and the median number of DTCs per view field in whole liver sections
was determined (A) as well as their corresponding Ki67 status (B). C) shows
the quantification of micrometastases, defined as clusters of 5 or more GFP-
positive R254 cells as well as representative images of GFP-positive R254 cells
and micrometastases (encircled in white) at 200-fold magnification. Data repre-
sent median values with quartiles (Q0,75 as upper, Q0.25 as lower deviation) or
mean ± SD of 10 animals/group. * = p <0.05. . . . . . . . . . . . . . . . . . . . 68
4.10. The hepatic stromal cell lines M1-4HSC and M-HT. A) M1-4HSC (HSC)
grown on plastic expose a characteristic stellate cell morphology. B) After 3
weeks of continuous administration of recombinant TGF-β1, M1-4HSC (HSC)
acquired a spindle-shaped morphology which is a hallmark of myofibroblasts,
the generated cell line is termed M-HT (HMF)[182]. Depicted are representative
phase contrast images of both cell lines in monoculture. In (C) representative
western blots of HSC and HMF lysates are depicted which show a lower ratio
of desmin to α-smooth muscle actin (α-SMA) in HMF in accordance with the
initial description of the cell system [182]. Heat shock protein-90 (HSP90) was
used as loading control. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4.11. PDECs exhibit a reduced proliferative activity in the presence of HSC
compared to HMF coculture. H6c7-kras and Panc1 cells were cocultured
with HSC or HMF. After 6 days, vital cell numbers (A) and percentage of Ki67-
positive cells (B) were determined. Depicted data represent the mean values ±
SD of at least 5 independent experiments. * = p <0.05. C) shows representative
images of Ki67 immunostainings in H6c7-kras and Panc1 cells after respective
coculture in 200-fold magnification. . . . . . . . . . . . . . . . . . . . . . . . . . . 70
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4.12. HSC coculture fosters the manifestation of a QAP in PDECs. H6c7-kras
and Panc1 cells were cocultured with HSC or HMF for 6 days, respectively. A)
Representative images of Ki67 stainings in H6c7-kras and Panc1 cells after HSC
coculture conditions shown at 400-fold magnification (encircled: PDECs exhibit-
ing flattened enlarged morphology). B) Representative western blots showing the
abundance of total and phosphorylated Erk (Erk/p-Erk) and p38 (p38/p-p38) as
well as p21. Hsp90 was used as loading control. Data of densitometric analysis
of the ratio of p-Erk and p-p38 expression are presented as mean ± SD of 4 in-
dependent experiments. Data represent the median values with quartiles (Q0,75
as upper, Q0.25 as lower deviation) of 5 independent experiments. * = p <0.05. . 71
4.13. PDECs exhibit enhanced senescence-associated β-galactosidase
(SABG) acivity in the presence of HSC compared to HMF coculture.
H6c7-kras and Panc1 cells were cocultured with HSC or HMF. After 6 days,
SABG activity was measured (A). Depicted data represent the mean values ±
SD of at least 5 independent experiments. * = p <0.05. B) shows representative
images of SABG stainings in H6c7-kras and Panc1 cells after respective coculture
in 200-fold magnification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.14. Generation of HSC and HMF like phenotypes in HHSteC. In order
to generate human hepatic stromal cells with characteristics equivalent to HSC
and HMF, HHSteC were pretreated with medium containing either 2.5 µl all-
trans-retinoic acid (ATRA) and 1 ng/ml TGF-β1 for 2 weeks, respectively. Cells
were characterized via immunofluorescence stainings of α-SMA and desmin (A)
and detection of collagen-1A1, α-SMA and desmin via western blot (B) HSP90
was used as loading control. Representative results of 4 respective independent
experiments are shown, immunofluorescence stainings are depicted in 400-fold
magnification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
4.15. HHSteC-HSC induce QAP in H6c7-kras and Panc1 cells. HHSteC were
pretreated with medium containing either 2.5 µl all-trans-retinoic acid (ATRA)
or 1 ng/ml TGF-β1 and set in coculture with either H6c7-kras or Panc1 cells
for 6 days. Vital cell numbers were determined (A) as well as the percentage of
Ki67-positive cells after immunostainings (B). Moreover, H6c7-kras and Panc1
cells were examined for their SABG-activity (C). Data represent the mean values
± SD of 4 independent experiments. * = p <0.05. . . . . . . . . . . . . . . . . . 75
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4.16. The quiescence-associated phenotype (QAP) of Panc1 cells can be re-
versed in the presence of HMF. Panc1 cells were cocultured with HSC for
6 days. Subsequently, coculture was extended with freshly seeded HMF (HSC-
HMF). During the second period of coculture, Panc1 cells were surveilled via
realtime Life Cell Imaging with particular focus on cells with morphologic fea-
tures of QAP. A) shows representative images of Panc1 cells during respective
coculture in 400-fold magnification after 0 hours (h), 72 hours and 144 hours.
Encircled in white are non- or unsuccessfully dividing Panc1 cells with QAP
morphology, while Panc1 cells with QAP morphology successfully undergoing
cytokinesis are encircled in black. After completed coculture, the number of di-
viding (B) as well as the percentage of Ki67-positive (C) Panc1 cells with QAP
morphology was determined. Data represent the median values with quartiles
(Q0,75 as upper, Q0.25 as lower deviation) or mean ± SD of 3-5 independent
experiments * = p <0.05. Representative images of Ki67 stainings in Panc1 cells
after HSC-HSC- or HSC-HMF coculture, obtained in 400-fold magnification are
depicted in (D) with Ki67-negative Panc1 cells with QAP morphology encircled
in white and Ki67-positive Panc1 cells with QAP morphology encircled in black. 77
4.17. Panc1 cells with QAP morphology maintain their SABG-activity after
HMF-mediated proliferation. Panc1 cells were cocultured with HSC for 6
days. Subsequently, coculture was extended with either freshly seeded HSC
(HSC-HSC) or HMF (HSC-HMF). During the second period of coculture, Panc1
cells were surveilled via realtime Life Cell Imaging with particular focus on cells
with morphologic features of QAP (left). An SABG-staining in corresponding
observed cells was affiliated (right). Depicted are representative phase contrast
(PC) images of Panc1 cells with QAP morhology after HSC-HMF coculture in
400-fold magnification. Panc1 cells with QAP morphology which underwent
successful division are encircled in black. . . . . . . . . . . . . . . . . . . . . . . . 78
4.18. H6c7-kras cells maintain a QAP after extended coculture. H6c7-kras
cells were cocultured with HSC for 6 days. Subsequently, coculture was extended
with either freshly seeded HSC (HSC-HSC) or HMF (HSC-HMF). During the sec-
ond period of coculture, H6c7-kras cells were surveilled with a realtime Life Cell
Imaging device with particular focus on cells with morphologic features of QAP.
After completed coculture, the number of dividing (A) as well as the percent-
age of Ki67-positive (B) H6c7-kras cells with QAP morphology was determined.
Data represent the median values with quartiles (Q0,75 as upper, Q0.25 as lower
deviation) or mean ± SD of 5 independent experiments * = p <0.05. Represen-
tative images of Ki67-stainings in H6c7-kras cells after HSC-HSC or HSC-HMF
coculture are depicted in C with Ki67-positive cells exposing QAP morphology
encircled in black. C shows representative images of H6c7-kras cell after SABG
stainings carried out after HSC-HSC or HSC-HMF coculture. . . . . . . . . . . . 79
4.19. Identification of factors involved in hepatic stroma-mediated effects
on PDECs growth behavior. Supernatants of Panc1 cells cocultured either
in the presence of HSC or HMF for 6 days were analyzed by Multiplex analysis.
Murine (m) Interleukin-6 (IL-6) (A), human (h) IL-8 (B) and m IL-12 (C)
were found at higher levels under HSC coculture compared to HMF coculture.
M VEGF (D), h VEGF (E) and h SDF-1α (F) were detected at higher levels
in supernatants of HMF cocultures. Data are presented as mean concentration
(in pg/ml) ± SD 3 - 5 independent experiments * = p <0.05. . . . . . . . . . . . 82
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4.20. IL-6 is not important for HSC-mediated QAP in Panc1 cells. Panc1
cells were indirectly cocultured with HSC for 6 days. Upon start of culture
and again after 3 days, cocultures were treated with 10 µg/ml of IL-6 signaling
blocking or agents. After 6 days, vital cells were counted. A) Vital cell numbers
of Panc1 cells upon HSC coculture and application of a Rituximab control or
IL-6R antagonist Tocilizumab. B) Vital cell numbers of Panc1 cells upon HSC
coculture and application of a Ctrl-Fc-antibody or IL-6 trans-signaling blocking
sgp130Fc. Values are depicted as mean ± SD of 4 independent experiments. . . . 84
4.21. Human IL-6 increases cell growth of Panc1 cells. Panc1 cells were
monocultivated for 6 days. Cells were either left untreated (unstim.) or treated
with 10 ng/ml IL-6 signaling inducing agents upon start of culture and again af-
ter 3 days. Depicted is the vital cell count of monocultivated Panc1 cells, either
left untreated or stimulated with recombinant (r) murine (m) IL-6 (r m IL-6) or
r human IL-6 (r h IL-6). Values are depicted as mean ± SD of 4 independent
experiments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
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A.1.2. Realtime Life Cell Imaging videos
Supplementary Video 1 and 2 are provided on a CD supplied with this work.
A.1.3. Supplementary Video 1
Panc1 cells remain non-dividing during prolonged HSC-coculture. After
6 days coculture with HSC, coculture of Panc1 cells was prolonged for further 6
days in the presence of fresh HSC (HSC-HSC). Growth behavior was monitored by
real-time microscopy particularly focusing on cells with QAP-associated enlarged
and flattened morphology. Cells with flattened and enlarged QAP morphology
remaining non-dividing are encircled in red. The representative video covers 144
hours of coculture recorded at 200-fold magnification.
A.1.4. Supplementary Video 2
HSC-mediated QAP in Panc1 cells is reversed in the presence of HMF.
After 6 days coculture with HSC, coculture of Panc1 cells was prolonged for fur-
ther 6 days in the presence of fresh HMF (HSC-HMF). Growth behavior was
monitored by real-time microscopy particularly focusing on cells with the QAP-
associated flattened morphology. Cells with enlarged, flattened morphology re-
gaining proliferative activity are encircled in black. The representative video
covers 144 hours of coculture recorded at 200-fold magnification.
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